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Abstract 
Mesenchymal Stem Cells (MSC’s) have shown promise as a cell based therapy for 
myocardial repair.  However, MSC’s have a finite replicative lifespan and lose 
proliferative and differentiation capacity during expansion in vitro.  Therefore, 
understanding the molecular mechanisms that regulate ageing and senescence of 
MSC’s should enhance our ability to use these cells in cell based approaches and 
give insight into mechanisms of tissue ageing. 
We established MSC cultures from the sternal bone marrow of eight donors 
undergoing coronary artery bypass surgery.  After thirty population doublings 
(nine passages) MSC’s displayed morphological abnormalities, expression of 
senescence associated β galactosidase, telomere erosion and decreased 
adipogenic and osteogenic differentiation capacity.  Using serial analysis of gene 
expression (SAGE) we identified 243 known genes differentially expressed 
between MSC’s at passages two and nine.  Analysis of known direct interactions 
between genes revealed a regulatory signaling network centered on down 
regulation of the transcription factor, activator protein 1 (AP 1).  Transcriptional 
changes in MSC’s at passage nine included genes associated with inflammation, 
regulation of cell cycle, metabolism and extracellular matrix re modelling.  The 
validation studies corroborated the SAGE results and eighteen genes were 
identified as differentially expressed in late passage MSC’s from multiple donors.  
Furthermore, caveolin 1, cyclin D1, tissue plasminogen activator and 
olfactomedin like 3 were able to discriminate MSC’s of different culture age. 
In addition, we show evidence that the p38 MAPK signalling pathway contributes 
to the decline in proliferation and differentiation of MSC’s during expansion and 
is critical for the maintenance of genomic stability.  The results provide further 
evidence that MSC’s senesce prematurely in response to undefined culture 
stresses.  Our studies have provided novel markers that identify MSC ageing in 
vitro and suggest that identifying factors that activate p38 MAPK signalling 
should enhance our ability to use MSC’s in cell based therapies. 3 
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1  Introduction 
Ischaemic heart disease (IHD) is a major health and economic burden on society 
in the United Kingdom (UK).  The disease is common and results in 146,000 heart 
attacks, 68,000 new cases of heart failure (HF) and 96,000 deaths each year.  
One million people in the UK have HF and based on current trends a further 
500,000 will suffer from the condition by 2015 (www.heartstats.org).  The 
rapidly increasing prevalence can be attributed to both ageing of the population 
and improvements in the treatment and survival of patients following myocardial 
infarction (MI) (1;2).  Despite improvements in management, 40% of patients 
with HF die within a year of diagnosis and novel therapeutic approaches that 
replace cardiomyocytes and enhance myocardial repair are required. 
Encouraging results in animal models has led researchers to evaluate the 
potential of adult progenitor and stem cells in clinical trials.  At present, there 
is huge expectation from patients and the medical community that cellular 
therapy may be an effective adjunct to conventional medical and surgical 
treatments for IHD.  Favourable results using bone marrow mono nuclear cells 
(BM MNC’s) has encouraged researchers to identify cells within this population 
that confer the most benefit and mesenchymal stem cells (MSC’s) have shown 
the most promise in animal studies to date.  This has encouraged the use of 
MSC’s in clinical trials for the treatment of osteogenesis imperfecta (3), 
metabolic disorders (4), BM failure after chemotherapy (5), graft versus host 
disease (6;7), stroke (8) and MI (9;10).  Since MSC’s are present at low frequency 
in the BM, significant expansion is required in vitro in order to generate 
sufficient cells for these approaches.  The expansion process itself induces rapid 
ageing of MSC’s and loss of their stem cell properties as shown by a decline in 
proliferative and differentiation capacity in vitro (11;12).  Furthermore, with 
prolonged culture MSC’s show increased susceptibility to genetic events that 
lead to transformation and although usage appears safe the possibility of cancer 
formation remains a major concern in clinical trials (13;14). 
MSC’s are most extensively studied and characterised in BM samples from young, 
healthy donors and not those with conditions such as IHD.  The characteristics of 
MSC’s in these patients and suitability for autologous use remain largely 
unknown.  With links emerging between ageing and a decline in stem cell Malcolm B Will 2010    Chapter 1, 15 
function, impaired tissue homeostasis and the onset of age related diseases it 
seems crucial that basic research is carried out on MSC’s from patient groups 
that may benefit the most from these therapies.  Gene expression profiling 
should enhance our understanding of the molecular pathways that contribute to 
ageing and senescence of MSC’s and serial analysis of gene expression (SAGE) 
offers the potential to identify novel genes and molecular mechanisms that 
regulate this process in vitro.  Improved understanding of stem cell ageing 
should not only enhance the efficiency of cell based therapies but also increase 
knowledge of tissue ageing and cancer and this may be of importance.   
1.1 Mesenchymal Stem Cells 
The bone marrow stroma functions to create a unique micro environment that 
regulates the proliferation, differentiation and maturation of HSC’s.  The 
cellular composition has been well documented and includes reticular cells, 
adipocytes, osteoblasts, endothelial cells, smooth muscle cells and 
macrophages.  The existence of stem cells within the bone marrow stroma was 
first described over twenty years ago although most researchers have focused on 
their haematopoietic counterparts (15).  The term ‘Mesenchymal Stem Cell’ 
(MSC) was introduced in 1991 (16) and eight years later it was demonstrated that 
MSC’s had the capacity for multi lineage differentiation (17).  The interest 
generated by this report and the potential application of MSC’s for the 
treatment of human diseases has made this one of the most intensely researched 
areas in the last decade. 
1.1.1 Isolation and Characterisation of Mesenchymal Stem Cells 
MSC’s were first identified and primarily characterised in vitro.  Friedenstein et 
al recognised that bone marrow stromal cells adhered to plastic and formed 
colonies almost forty years ago (18).  This was referred to as the colony forming 
unit fibroblast (CFU F) assay.  MSC’s are still derived using the same methods 
today although an additional density gradient separation step using either 
Percoll or Ficoll is performed to separate the MNC fraction (17;19).  After plating 
in basal media containing serum, MSC’s display fibroblast like (spindle shaped) 
morphology and expand rapidy to confluence over fourteen days.  Although first 
described in adult bone marrow, it is has been demonstrated that MSC’s exist in Malcolm B Will 2010    Chapter 1, 16 
almost all organs and tissues of mice (20) and in support MSC’s have been 
isolated from human tissues including periosteum (21), trabecular bone (22), 
adipose tissue (23), synovium (24), skeletal muscle (25), heart (26), lung (27), 
teeth (28), placenta (29), amniotic fluid (30) and umbilical cord blood (31).  For 
the purposes of this research, MSC’s were isolated from the sternal BM of 
patients undergoing coronary artery bypass surgery (CABG). 
Despite the method used to isolate MSC’s, there is unequivocal evidence that 
cultures are heterogeneous consisting of cells of different size, proliferative and 
differentiation potential (19;32).  Although the plastic adherence technique is 
entirely suitable for this research, there have been attempts to identify markers 
that can isolate homogenous populations of MSC’s.  At present, human MSC’s are 
recognised by the absence of haematopoietic and endothelial surface markers 
including CD11b, CD14, CD31, CD34 and CD45 and the high expression of non 
specific markers including CD73 (ecto 5’ nucleotidase and recognised by the 
monoclonal antibodies SH3 and SH4), CD90 (Thy1) and CD105 (Endoglin and 
recognised by the monoclonal antibody SH2) (17;33).  However, none of these 
markers uniquely identify MSC’s  and variable expression is often demonstrated 
depending on the source of cells and culture methods used.  There have been 
attempts to identify surface markers that alone or in combination achieve higher 
levels of enrichment of MSC’s when compared to cultures established by plastic 
adherence.  One of the most encouraging reports was by Gronthos et al using 
magnetic selection of BM MNC’s expressing the markers Stro 1 and CD106 
(vascular adhesion molecule 1, VCAM1) (34).  This combination identified a small 
population of MSC’s (1.4% of the Stro 1 positive fraction) with a CFU F incidence 
of 1 in 2 and was effective in isolating 90% of the CFU F’s from the BM MNC 
fraction.  At the clonal level, Stro 1/CD106 positive MSC’s showed enhanced 
proliferation and differentiation capacity and expressed telomerase which was 
not detectable in MSC’s isolated by plastic adherence.  MSC’s with similar 
properties have been described by other researchers when selecting for cells 
expressing the stem cell markers CD133 and SSEA4 (stage specific embryonic 
antigen 4).  Tondreau et al showed that CD133 positive cells generated adherent 
MSC like cultures and expressed the pluripotency marker Oct 4 (Octamer 4) 
which is found at high levels on undifferentiated embryonic stem cells (ESC’s) 
(35).  Gang et al found that SSEA4 could select for MSC’s with enhanced 
differentiation capacity in comparison to unselected cells (36).  At the clonal Malcolm B Will 2010    Chapter 1, 17 
level, almost 80% of MSC’s underwent adipogenic, osteogenic and chondrogenic 
differentiation in comparison to 30% of clones in MSC’s isolated by plastic 
adherence. 
In addition to cell morphology and surface marker expression, functional studies 
remain the gold standard to assess MSC characteristics in vitro.  The ability to 
differentiate into bone, fat and cartilage is a defining property described by 
multiple laboratories (17;19;37 39).  As mentioned already, MSC’s analysed by 
clonal assays are heterogenous, with individual cells capable of variable 
expansion and differentiation capacity (19;32).  These studies also demonstrate 
that very few clones have multilineage differentiation capacity and most are 
restricted to one or two differentiation pathways.  Furthermore, with increasing 
passage the number of multipotent clones decrease and most become restricted 
to a single differentiation pathway.  Studies suggest the typical default pathway 
is towards osteogenesis and the this can be induced using media containing b 
glycerol phosphate, ascorbic acid, dexamethasone and serum (11;19;37;40).  
When MSC’s are cultured as a monolayer in media containing these supplements, 
an osteoblast like morphology develops and an increase in alkaline phosphatase 
activity and deposition of calcium rich extracellular matrix can be detected 
using Von Kossa and Alizarin Red respectively.  A smaller proportion of clones 
undergo adipogenesis when grown as a monolayer in media containing 
isobutylmethylxanthine (19).  MSC’s change morphology and large lipid filled 
vacuoles accumulate in the cytoplasm that stain positive using the dye, Oil Red 
O.  Very few clones have the capacity to undergo chondrogenic differentiation 
and specific culture conditions are required to intiate this process (19).  MSC’s 
are pelleted by centrifugation and cultured in serum free nutrient media 
containing TGF β, most commonly the β3 isoform.  MSC’s synthesise 
glycosaminoglycans and the pattern of chondroitin sulphate deposition changes 
in a way similar to that of maturing human articular cartilage (39).  Synthesis of 
other cartilage related proteins such as aggrecan, decorin, type II collagen and 
chondroadherin can also be detected. 
In addition to the standard lineages, human MSC’s have been shown to 
differentiate into other cell types in vitro including cardiomyocytes (41), 
endothelial cells (42;43) and neural cells (44).  However, at present these are 
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characterise the cells were not robust and functional assays were not always 
performed.  In these studies, cell differentiation was confirmed by the detection 
of lineage specific transcripts and doubt has arisen over the validity of this 
approach because similar transcripts have been identified in undifferentiated 
MSC’s at the single cell and colony level (45 47).  The findings infer that MSC 
cultures contain both multi potent primitive cells and committed cells with 
restricted lineage potential.  Therefore, the detection of lineage specific 
transcripts alone appears inadequate to confirm that MSC’s acquire the 
functional properties of cells that highly express these transcripts.  It has been 
demonstrated that MSC’s co cultured with cardiomyocytes express cardiac 
specific genes although exhibit the electrophysiological properties of stromal 
cells and not cardiomyocytes (48).  Future studies will need to perform rigourous 
functional assessment of differentiated MSC’s before these alternative 
differentiation pathways can be considered as defining properties of these cells. 
Relative to their in vitro characteristics, the in vivo behaviour of MSC’s remains 
poorly understood.  Unlike HSC’s and ESC’s that are defined by their ability to 
reconstitute haematopoiesis or generate teratomas in vivo, similar assays to 
charactertise MSC’s are not widely performed.  The best described method 
involves loading human MSC’s onto fibronectin coated hydroxyapatite cubes and 
implanting the cubles subcutaneously into immune deficient mice (49).  Bone 
and cartilage formation and to a lesser extent fat have been demonstrated on 
explanted cubes and labelled cells confirmed that those implanted had 
undergone differentiation rather than infiltration of the cubes with host cells.  
Site specific or intravenous delivery of MSC’s in animal models has provided 
additional evidence that the cells can migrate to areas of tissue injury and 
differentiate in vivo.  However, the majority of cells administered intravenously 
become entrapped in the pulmonary circulation (50) and the absolute numbers 
that reach the target tissue and engraft appears low and at levels insufficient to 
explain the beneficial effects seen on tissue function (51;52).  It has been 
increasingly recognised that the beneficial effects of administering MSC’s after 
MI occur through paracrine mechanisms that enhance neo angiogenesis, reduce 
fibrosis and inflammation, and promote the proliferation of endogenous cardiac 
stem cell populations (53 55).  Further understanding of these mechanism is 
likely to lead to the development of new drugs or growth factors that can be 
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A further concern from administering progenitor or stem cells is that they could 
engraft and differentiate toward undesirable cells types that have detrimental 
effects on tissue and organ function.  Calcification has been identified in the 
hearts of animals receiving whole BM after MI (56) and injection of MSC’s 
appears to pose an even greater risk (57).  Further studies are required to 
confirm if the administered cells underwent osteogenic differentiation or 
contributed to increased tissue calcification after injury.  These findings 
highlight the need to use sophisticated imaging techniques in future clinical 
trials of cell therapy to track administered cells and assess changes in treated 
organs and tissues.  To understand the exact physiological relevance of MSC’s in 
vivo and their response after tissue injury, specific surface markers that 
prospectively identify and isolate MSC’s are definitely required.  At present, the 
agreed minimal criteria to define MSC’s remains: plastic adherence; fibroblast 
like morphology; specific surface marker profile and differentiation into bone, 
fat and cartilage in vitro (33). 
1.1.2 Factors Affecting Mesenchymal Stem Cell Proliferation 
Although an agreement has been reached on criteria to define MSC’s, there is no 
consensus on the culture protocols used by researchers.  To determine optimal 
culture conditions for clinical scale up, Sotiropolou et al investigated the effects 
of different tissue culture plastic, growth factors, basal media, glucose 
concentration, glutamine and plating density on the proliferation kinetics of 
MSC’s (58).  Importantly, all variables were shown to significantly influence the 
proliferation of MSC’s over the first three passages.  MSC’s proliferated to the 
greatest extent in low glucose conditions, in media supplemented with Glutamax 
and when plated at low density.  Earlier studies have demonstrated that low 
plating densities enrich for primitive MSC’s with enhanced proliferative capacity 
although the absolute number of cells generated using this approach is reduced 
(32;59).  For clinical purposes, a compromise between culture conditions that 
yield sufficient numbers of cells and those that enrich for MSC progenitors are 
required. 
Like other cell types, MSC’s require serum (typically 10 20%) for proliferation 
and some researchers select batches that sustain the proliferative and 
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serum free conditions or even autologous serum has been described to avoid 
exposure to animal products.  Pochampally et al demonstrated that serum free 
conditions selected for a rare population of MSC’s expressing the pluripotency 
gene, Oct 4 and displayed much longer telomeres when compared to those 
cultured with serum (60).  Despite the fact that these cells generated colonies 
and underwent multi lineage differentiation, growth arrest occurred quickly and 
within ten population doublings.  The results infer critical components of serum 
sustain the self renewal and long term proliferation of MSC’s and at present it 
has not been possible to reliably generate cultures using serum free protocols.  
In contrast, MSC’s cultured in autologous human serum proliferate to a similar 
extent than those in bovine serum and demonstrate an enhanced capacity for 
osteogenic differentiation although the differences in the exact components of 
either serum have not been determined (61).  The problem that arises when 
using autologous serum is that the absolute amounts obtained are limited and 
appear insufficient for long term culture protocols and at present clinical 
application seems unlikely. 
Ambient oxygen levels and specific growth factors can also influence the 
proliferative potential of MSC’s.  MSC’s cultured in low oxygen conditions (2%) 
are enriched for progenitors that express pluripotency genes and an enhanced 
capacity for osteogenic differentiation in vitro and in vivo (62).  MSC’s with 
similar properties have been demonstrated using media supplemented with 
fibroblast growth factor 2 (FGF 2) and these cells achieved 70 population 
doublings before the onset of growth arrest (63).  MSC’s cultured in media 
supplemented with FGF 2 displayed longer telomeres and maintained 
differentiation capacity for almost 50 population doublings which was twice that 
seen in MSC’s cultured in standard media without the growth factor.  FGF 2 has 
been shown to inhibit the expression of transforming growth factor β2 (TGF β2) 
and the activation of downstream tumour suppressor genes confirming an 
important role in delaying the onset of senescence and maintaining the 
proliferation of MSC’s during prolonged culture (64). 
Donor characteristics, particularly age appears to be one of the most important 
factors influencing the proliferation of MSC’s in vitro.  Studies have confirmed 
that the proliferative lifespan of MSC’s from aged donors is almost half that of 
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tissues proliferate to a much greater extent than those derived from tissues of 
young adults (65).  Foetal MSC’s display increased expression of genes involved 
in proliferation and DNA repair and decreased expression of genes associated 
with differentiation when compared to their adult counterparts and this is likely 
to explain these differences (66).  Therefore, ageing affects the characteristics 
of MSC’s at the molecular level although the exact effects on their stem cell 
properties remains poorly understood.  Further study is also required to 
determine if foetal MSC’s have superior capacity to re generate tissues when 
used for cell therapy when compared to autologous adult cells as one might 
predict. 
1.1.3 Ageing and Senescence of Mesenchymal Stem Cells 
MSC’s, like other somatic cells have a finite replicative lifespan and enter a 
state of irreversible growth arrest called cellular senescence.  Senescence was 
first described in the 1960’s in studies on normal human fibroblasts and referred 
to as the Hayflick limit (67).  MSC’s have similar growth profile to fibroblasts and 
undergo 30 40 population doublings before the onset of growth arrest.  The 
replicative lifespan is significantly influenced by donor characteristics and 
culture conditions as described earlier.  MSC’s at growth arrest are large, flat 
and display prominent actin stress filaments (11;12;40).  MSC’s from aged donors 
display this phenotype almost immediately upon isolation and proliferate poorly 
in comparison to cells from young donors (11).  A similar phenotype can be found 
in other senescent cell types and is not specific to MSC’s suggesting that 
increasing cell size could be used as a surrogate marker of MSC ageing in vitro. 
During prolonged culture, MSC’s also display increased expression of senescence 
associated β galactosidase (SA β Gal) (12;40;68).  SA β Gal was first described in 
studies of senescent fibroblasts and later shown to reflect the increase in 
lysosomal activity seen in senescent cells (69;70).  Studies have confirmed that 
the expression of SA β Gal increases with each passage and can be visualised in 
40 to 80% of late passage MSC’s (12;40;68).  Importantly, two studies 
demonstrated that SA β Gal is expressed in only a small percentage of MSC’s at 
early passage and therefore expression is a late marker of MSC ageing and 
senscence in vitro and its use appears limited (40;68).  Lipofuscin, which is a 
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damage to cell membranes is also a marker of cell ageing and Roura et al 
demonstrated that lipofuscin accumulated in MSC’s derived from young and old 
donors cultured for fourteen days (71).  Similar levels of expression were seen in 
cells from both age groups confirming that oxidative damage of MSC’s occurs in 
vitro and is a generalised phenomenon of routine culture.  The absence of other 
reports makes it difficult to comment on the ability of lipofuscin to detect 
ageing and senescence of MSC’s and further studies are required. 
One of the most widely used markers of cell ageing is a reduction in telomere 
length.  Telomeres are DNA repeats (TTAGGG) that play an essential role in the 
stable maintenance of eukaryotic chromosomes within a cell by specific binding 
to structural proteins.  Telomeres shorten in dividing cells and these proteins 
cap the end of linear chromosomes, preventing nucleolytic degradation, end to 
end fusion, irregular combination, and other events that are normally lethal to 
the cell.  The ends of telomeres are maintained by the enzyme telomerase that 
is composed of an RNA subunit (hTR   human Telomerase RNA template), and a 
catalytic protein subunit (hTERT   human Telomerase Reverse Transcriptase).  
Similar to fibroblasts, MSC’s lose telomeric DNA at a rate of 50 to 100bp per 
population doubling and senesce when a critical length is reached (11;12;72).  
Baxter et al confirmed a critical telomere length of approximately 10kB and by 
comparing young and old donors it was estimated that MSC’s lost 17bp of 
telomeric DNA per year in vivo.  The heterogeneity in telomere length described 
in studies of MSC’s is difficult to fully explain although the relatively long 
telomeres seen at growth arrest infer telomere independent mechanisms of 
senescence may in fact predominate. 
The enzyme telomerase functions to counteract the loss of telomeric DNA during 
successive cell divisions by the synthesis of TTAGGG repeats.  Telomerase is 
expressed at high levels in cancer cells, ESC’s and germ cells and is absent or 
barely detected in normal human somatic cells (73 75).  Although telomerase 
activity was first demonstrated in MSC’s by Pittenger et al, other researchers 
could not reproduce these findings in MSC’s cultured in standard conditions 
(12;17;72;76).  The conflicting results may be explained by the existence of rare 
telomerase positive cells within MSC cultures and also the poor sensitivity of the 
telomeric repeat amplication protocol (TRAP) itself.  The primitive stem cell 
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isolate telomerase positive cells that can generate MSC cultures indistinguishable 
to those obtained using the plastic adherence technique (34;35).  Furthermore, 
fibroblasts and more recently MSC’s were found to express hTERT using 
immunoprecipitation and synchronising cells in S phase when the TRAP assay 
failed to detect telomerase activity (77;78).  Similar to other somatic cells, 
hTERT is known to be actively repressed in human MSC’s via chromatin 
modifications that can be reversed by treating cells with de methylating agents 
and histone deacetylase inhibitors (79;80).  Together, the results of these 
studies highlight that telomerase activity in MSC’s is tightly regulated in a cell 
cycle dependent manner although at levels insufficient to prevent loss of 
telomeric DNA during extended proliferation. 
Lending support to these findings, the onset of senescence in MSC’s can be 
overcome by forced over expression of hTERT (81).  hTERT transduced MSC’s 
displayed increased telomerase activity and long telomeres and proliferated for 
more than 260 population doublings while maintaining the capacity for 
osteogenic differentiation in vitro and in vivo (81;82).  Unfortunately, the 
transduced cells were shown to accumulate genetic alterations that led to 
transformation and tumour formation when cells were injected into immune 
deficient mice (83).  hTERT transduction alone appeared insufficient to result in 
transformation because multiple genetic events including activating mutations of 
KRAS, deletion of the tumour suppressor p16
INK4α  and ARF gene loci and 
promoter hypermethylation of the cell cycle regulator DBCCR1 were identifed in 
the transformed cells.  Together, the results infer that telomerase activity in 
MSC’s functions to regulate proliferation and lifespan as well as a barrier to cell 
transformation through its active repression. 
In fact, although reports are rare spontaneous transformation of human MSC’s in 
vitro has been described and the transformed cells expressed high levels of 
telomerase activity (13;14).  The cells appeared remarkably similar to hTERT 
transduced MSC’s and could generate sarcomas when delivered subcutaneously 
into immune deficient mice.  Wang et al reported that the transformed cells 
expressed the stem cell marker CD133 raising the possibility that the 
transformation event occurred in a primitive stem cell population (14).  A 
further communication from Rubio et al confirmed that chromosomal 
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themselves carried genetic abnormalities (84).  Providing some reassurance, 
another study could not demonstrate transformation of ten MSC cultures 
expanded up to and beyond senescence and in addition the cells displayed 
normal karyotype by cytogenetic and array comparative genomic hybridisation 
(aCGH) techniques (85).  Despite this, the confirmation of side population (SP) 
cells in both benign and malignant human mesenchymal tumours that have been 
shown to initiate tumour formation in immune deficient animals provides further 
evidence that primitive MSC’s are indeed the target of transformation events 
(86).  The overwhelming message is that for clinical trial purposes, MSC’s will 
require robust molecular characterisation and karyotype analysis prior to 
administration in patients. 
A further role of telomerase in MSC’s is for the maintenance of normal 
differentiation as shown from studies on telomerase deficient mice (mTR
 / ).  
Although early generations display a normal phenotype, animals from the fourth 
generation onwards shown signs of premature ageing including defective 
haematopoiesis and impaired tissue healing after injury (87 89).  In primary 
cultures derived from mTR
 /  animals, MSC’s lost their normal differentiation 
capacity and displayed impaired chondrogenic and adipogenic differentiation in 
comparison to cells derived from wild type animals (90).  Another report linking 
telomerase activity in MSC’s with differentiation in vitro was by Zhao et al (78).  
A slight increase in telomerase activity was detected in normal MSC’s during 
adipogenic differentiation in comparison to their undifferentiated counterparts 
although this was not demonstrated in cells undergoing osteogenic 
differentiation.  Together, the reports highlight a link between telomerase 
activity in vitro and the maintenance of normal stem cell properties of MSC’s. 
Ageing and senescence of MSC’s in vivo can contribute to the decline in 
proliferation and differentiation capacity seen in vitro.  In MSC’s derived from 
young donors, osteogenic differentiation capacity appears maintained (19;37;38) 
or increased at late passage when compared to early passage cells (40).  At the 
clonal level it has been demonstrated that the adipogenic differentiation 
capacity of MSC’s is lost earliest during prolonged culture (38).  In addition, 
MSC’s from aged donors contained fewer multi potent clones.  In other studies, 
MSC’s from aged donors show a similar decline in adipogenic and osteogenic 
differentiation capacity at late passage (12;91) whilst in a different study Malcolm B Will 2010    Chapter 1, 25 
osteogenic differentiation decreased to a much greater extent (71).  Therefore, 
ageing and senescence of MSC’s is associated with a reduction in differentiation 
capacity and the typical default pathway appears influenced by the age of the 
donors from which cultures were established.  The conflicting results of studies 
to date makes it impossible to make a definitive statement regarding the exact 
restriction in lineage fate that occurs with prolonged expansion. 
When this research commenced the molecular mechanisms that regulate ageing 
and senescence of MSC’s were largely unknown.  In studies of fibroblasts, 
senescence is associated with the altered expression of numerous genes 
important for key aspects of cellular physiology (92).  The down regulation of 
cell cycle control genes maintains an irreversible growth arrest that is regarded 
as a barrier to cell transformation.  The two main tumour suppressor pathways, 
p53 – p21
WAF1 and p16
INK4A –Rb are activated in response to telomere shortening 
and dysfunction or cellular stress (93;94).  Importantly, transgenic animals 
deficient in these genes displays modest increases in stem cells numbers and 
function suggesting that tumour suppressor pathways contribute to ageing and 
loss of function in stem cells (reviewed in (95)).  Evidence exists that the same 
genes contribute to the decline in function and senescence of MSC’s during 
expansion and Park et al demonstrated increased expression of p53, p21
WAF1 and 
p16
INK4A in senescent MSC’s (96).  Confirming a role of p16
INK4A as a tumour 
suppressor in MSC’s , transduction with hTERT resulted in transformation due to 
a deletion in the p16
INK4A gene locus during extended culture (83).  The 
expression of many of these genes are regulated by complex cell signalling 
pathways including TGF β that are themselves regulated by growth factors such 
as FGF 2 (64). 
Recently, a gene expression profile of senescent MSC’s has been determined by 
microarray and validation studies in multiple samples confirmed that replicative 
senescence was a continuous process with transcriptional changes detected from 
the first passage (40).  In addition, this study identified and validated increased 
expression of the five micro RNA’s (miRNA) has mir 371, has mir 369 5P, has 
mir 29C, has mir 499 and has mir 217 in senescent MSC’s.  MiRNA’s are short 
non coding molecules that are highly conserved and regulate protein expression 
through interactions with the 3’ untranslated region of mRNA.  There exact role 
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expression of thousands of genes (97).  Lafferty Whyte et al identified twelve 
miRNA’s associated with senescence from review of published literature and 
target genes for each miRNA were assigned to cellular pathways using systems 
biology software (98).  The pathways most significantly associated with these 
genes included cytoskeletal re modelling, cell cycle and metabolism which are 
characteristic alterations seen in senescent cells.  Importantly, two miRNA’s 
(hsa miR 499 and has miR 34c) were shown to regulate the onset of senescence 
regardless of the intiating mechanism and the development of small molecules 
to manipulate their activity was suggested as a novel approach to modify 
senescence in MSC’s and other cell types. 
1.2 Gene Expression Profiling 
Comprehensive gene expression profiling has been utilised to identify novel 
genes and their function, generate a transcriptome of different cell and tissue 
types, and to compare the profiles of gene expression between normal and 
pathological conditions.  Techniques such as serial analysis of gene expression 
(SAGE) and DNA microarray have enabled researchers to identify and determine 
the expression of thousands of genes simultaneously.  Apart from simply 
identifying gene expression, SAGE and microarrays represent powerful tools that 
have been used to identify diagnostic and prognostic markers, as well as 
therapeutic targets in human diseases such as cancer (99 102).  In the last 
decade, the same techniques have been applied to enhance our understanding of 
developmental (103) and stem cell biology (104;105). 
The SAGE technique was first described in 1995 by Velculescu et al from the 
Kinzler and Vogelstein laboratory at John Hopkins University (106).  The 
technique is based on generating clones of short sequence tags (10 27bp) 
derived from mRNA from cells or tissue of interest.  Each tag is sufficiently 
unique to identify one mRNA transcript and tags are joined to form long DNA 
fragments called concatamers that can be cloned and sequenced.  Each 
concatamer can contain up to forty tags and therefore efficiency is greatly 
increased when compared with conventional analysis of expressed sequence tags 
(EST’s) (107).  The expression level of each transcript is therefore equal to the 
number of times a particular tag is observed in a SAGE library and reflects the 
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corresponding to the SAGE tag is then identified from publicly available 
databases and web based software such as SAGE Map (108) and SAGE Genie 
(109). 
Since the original SAGE protocol, a number of modifications have been 
developed.  Firstly, using different tagging enzymes it has been possible to 
generate longer SAGE tags (17 27bp) and as a consequence improve tag to gene 
annotation (110;111).  Saha et al calculated that 17bp and 21bp tags have 64.0% 
and 99.8% probability of being unique if the genome contained approximately 30 
x 10
6 NlaIII derived tags and is compromised of random sequences (110).  One 
disadvantage of choosing a longer tag length is a reduction in SAGE efficiency 
because almost half the number of tags will make up a concatamer of equivalent 
length (112).  Therefore, it has been suggested that researchers consider the 
need to identify transcripts accurately or identify more differentially expressed 
tags that have an increased chance of being wrongly annotated. 
Other modifications have been described that enhance the applicability of SAGE.   
For example, if the amount of RNA is limited optimised protocols (113;114) or 
PCR amplification (115) can be performed prior to the generation of cDNA.  In 
fact, the technique by Datson et al was used to generate a SAGE library from a 
single colony of MSC’s (1 x 10
4 cells) using 0.1ng of mRNA (115).  Other 
modifications of SAGE have been developed that include the derivation of tags 
from the 5’ end rather than the 3’ end (start site) of mRNA to identify 
transcription initiation sites and alternative polyadenylation sites (116;117).  
These studies not only allow us to analyse the complete transcriptome but also 
demonstrate its remarkable complexity.  
All the available methods of gene expression profiling are useful in their 
appropriate context.  The greatest advantage of SAGE is that it does not require 
prior knowledge of the genes to be analysed and therefore allows the detection 
of truly novel transcripts (118).  The technique is therefore attractive when 
applied to stem cell populations that until recently remained poorly 
characterised.  In its current form, SAGE remains low throughput and labour 
intensive and hence limited to a small number of experiments.  As a result, 
candidate genes must be validated in a in a larger set of samples and a number 
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contrast to microarrays which are usually performed on multiple experiments 
and are to an extent self validating.  Another consideration when using SAGE is 
the demand on sequencing services and the associated cost.  These are 
important considerations for any researcher although new developments in 
sequencing technology are likely to improve efficiency and reduce costs in the 
future (119;120). 
Apart from these factors SAGE and microarray techniques are fairly comparable 
in their ability to detect abundant genes and large differences (five to ten fold) 
in gene expression (112;121).  SAGE can outperform microarrays for low 
abundance genes and small changes in expression if the library is sufficiently 
large (122).  Most studies develop SAGE libraries of approximately fifty thousand 
tags which are thought to give a 95% chance of detecting a transcript that has at 
least five copies per cell.  Accurate quantitation of transcripts of lower 
abundance would require library sizes at least five times this number although 
such studies offer the potential to identify novel genes.  On this basis and 
experience within our research group (123) we used the long SAGE (17bp) and 
details of the technique and bioinformatics are discussed further in chapter four. 
1.2.1  Insights into Stem Cell Biology through Gene Expression 
Profiling 
Gene expression profiling studies are widely criticised for being fishing 
expeditions rather than hypothesis driven experiments although the approach 
has been useful in the comparison of embryonic and adult stem cell populations.  
The availability of transcriptional signatures of haematopoietic stem cells 
(HSC’s) (124), embryonic stem cells (ESC’s) (125) and neural stem cells (NSC’s) 
(126) has led to important findings. 
By SAGE, stem cell transcriptomes are complex with a significant proportion of 
tags either unknown or matching transcripts with poorly defined functions 
(124;125).  Georgantas et al showed that SAGE could identify almost 30% more 
unknown transcripts that microarray when used to profile HSC’s obtained from 
different sources (127).  Furthermore, the difference is greater than that 
expected from sequence error or alternative spliced transcripts combined 
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demonstrated that HSC’s were enriched for transcription factors known to be 
important for haematopoiesis, DNA repair and quiescence confirming the unique 
characteristics of these cells.  In fact, at the gene expression level, leukemic 
stem cell (LSC’s) and normal HSC’s are remarkably similar adding further 
evidence that cancer may in fact be a stem cell disease (128 130).  Although this 
would suggest conventional treatments are not selective for cancer stem cells 
the study by Gal et al was able to identify up regulation of Notch signalling that 
could be targeted using pharmacological approaches.  Therefore, expression 
profiling can be used to identify novel pathways that can be manipulated using 
targeted small molecules. 
In a similar fashion, gene expression profiling of mouse and human ESC’s has 
improved understanding of mechanisms that regulate pluripotency and cell fate 
during development (reviewed in (131)).  The transcription factors Pou5f1 (Oct 
4) and Sox2, signalling molecules Nodal and Lefty and the growth factor FGF 2 
have been shown to be markers of ESC’s that are maintained in an 
undifferentiated state.  Furthermore, transcripts enriched in ESC’s are 
associated with FGF, TGF β and Wnt signalling pathways that can be 
manipulated by pharmacological approaches to influence cell fate (132).  It has 
been recognised that the same pathways are in fact shared by embryonic and 
adult stem cells (126;133).  The recognition of genes important for maintenance 
of pluripotency has led to fascinating experiments in recent years.  Three 
studies have demonstrated that embryonic and adult mouse fibroblasts can be 
reprogrammed into pluripotent stem cells that form viable chimeras that 
contribute to the germline (134 136).  The studies used retroviruses to over 
express the transcription factors Oct 4, Sox2, c Myc and Klf4 which are required 
for the maintenance of pluripotency in ESC’s.  Interestingly, the cells were 
similar to ESC’s at the epigenetic level and in their ability to form teratomas in 
immune deficient animals.  Although experimental, Okita et al have recently 
described a virus free approach suggesting it could be possible to reprogram 
autologous cells for tissue repair or replacement (137).  Therefore, 
understanding mechanism of self renewal and ageing through gene expression 
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1.2.2 Gene Expression Profiling Studies of MSC’s 
Compared to the extensive studies performed with ESC’s, research into the 
molecular mechanisms that regulate self renewal and differentiation of MSC’s 
remains at an early stage.  The transcriptome of undifferentiated MSC’s from 
different sources has been well characterised using SAGE (45;105), microarray 
(46;138 140) and EST analysis (107). Gene expression profiling of MSC’s has 
provided an explanation for their unique biological properties and therapeutic 
efficiency when used for tissue repair.  Phinney et al performed SAGE on mouse 
MSC’s derived using immunodepletion to minimise contamination with other cell 
populations (141).  A library of 59,007 tags was produced and almost 3% of 
assigned tags matched genes known to regulate mesoderm specification and the 
differentiation pathways typical of MSC’s.  Furthermore, by assigning tags to 
gene ontological (GO) descriptions, many of the transcripts were shown to 
participate in angiogenesis, cell motility and communication, haematopoiesis, 
immunity, and neural activity which might explain the basis for their effects in 
animal models of tissue repair.  Another finding was that almost a third of SAGE 
tags encode proteins with indeterminate function and therefore MSC’s have 
additional properties that are yet to be defined. 
The most abundant genes in MSC’s include collagens (e.g. COL1A1 and  COL1A2), 
vimentin (VIM), connective tissue growth factor (CTGF), transgelin (TAGLN) and 
eukaryotic translation elongation factor 1, alpha 1 (EEF1A1) (45;105;141;142).  
Although considered as the molecular foundation of MSC’s, they are in fact 
widely expressed in different cells and tissues, albeit at lower levels.  In fact, 
the inability to identify markers of MSC’s remains a limitation of MSC biology.  
One explanation is that the MSC cultures are heterogeneous and composed of 
cells with varying proliferative and differentiation capacity (32;143).  In fact, 
this would appear to be the case at the molecular level as well.  In a study by 
Tremain et al, micro SAGE was used to determine the gene expression profile of 
a single colony of MSC’s (45).  In addition to the transcripts commonly found in 
MSC’s, epithelial and neural cells markers including cytokeratins and 
neurofilaments were also detected.  A similar finding was reported using 
microarray to analyse gene expression in a single BM stromal cell isolated by 
laser capture micro dissection (46).  Transcripts within the cell included those 
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progenitors.  Together, the results partly explain the broad differentiation 
capacity of MSC’s but also that cultures are composed of cells with varying 
potential or at different stages of differentiation. 
Gene expression profiling of MSC’s has confirmed the absence or low expression 
of genes associated with stemness.  Katz et al were unable to detect CD133 and 
ATP binding cassette (ABC) membrane transporter, ABCG2 in a SAGE library 
generated from adipose derived MSC’s (139).  Both are expressed in primitive 
HSC’s and side population (SP) cells, a rare stem cell population within the BM.  
Furthermore, a recent study has confirmed that bone marrow derived MSC’s do 
not express the transcription factors Oct 4, Nanog and Sox2 that are markers of 
pluripotency in ESC’s (144).  However, Song et al were able match a significant 
proportion of genes to the JAK STAT, TGF β and Wnt signalling pathways that 
appear common to both embryonic and adult stem cells (133).  Together, the 
results of these studies highlight important differences in both adult and 
embryonic stem cells but also the lack of sensitivity of such approaches to 
detect rare stem cell populations within MSC cultures themselves.  Indeed, 
description of such cells exist and pluripotency genes have been detected in 
primitive MSC’s (35;60;145;146). 
The expression profiles of MSC’s obtained from bone marrow (105), umbilical 
cord blood (140;142) and adipose tissue (139) appear remarkably similar.  
Pannepucci et al demonstrated that umbilical cord blood MSC’s were enriched 
for genes that are important for angiogenesisis and bone marrow MSC’s those 
important for osteogenesis (142).  This probably reflects the tissue of origin of 
MSC’s and differentiation studies were not performed to confirm differences in 
MSC properties.  A similar study could not demonstrate any difference although 
their data set was compared to publicly available expression profiles and 
correlated poorly (140).  More recently, an elegant study has identified signalling 
pathways important for self renewal and differentiation of MSC’s (144).  
Microarrays were used to compare expression profiles of undifferentiated, 
differentiated and de differentiated MSC’s (the induction media was 
withdrawn).  Signalling pathways associated with adipogenic, osteogenic and 
chondrogenic differentiation included NF κB, p38 MAPK, PPAR and IL 6 and in 
undifferentiated MSC’s, PI3K and Wnt signalling.  Interestingly, the profiles of 
de differentiated and undifferentiated MSC’s were similar and the de Malcolm B Will 2010    Chapter 1, 32 
differentiated MSC’s could still differentiate into a different lineage.  The 
importance of these findings is that in vitro models of MSC differentiation offer 
the potential to identify new gene mutations in musculoskeletal disorders and 
strategies to identify targets of transcription factors that regulate 
differentiation have been described (147). 
Therefore, gene expression profiling of ageing and senescence of MSC’s should 
provide insight into novel strategies to modify stem behaviour and enhance the 
use of these cells for cell based therapies.   
1.3 Aims 
The use of MSC’s as an autologous cell based therapy will require robust 
characterisation of the cell therapy product at the cellular and molecular level.  
MSC’s have limited proliferative ability although the exact molecular 
mechanisms of ageing and senescence in vitro are not understood.  Therefore, 
our aims were to: 
1.  Establish a model of MSC isolation and characterisation from the sternal bone 
marrow of patients undergoing CABG. 
2.  Understand the transcriptional changes that occur during prolonged 
expansion of MSC’s in vitro using SAGE. 
3.  Identify and validate genes that represent biomarkers of aged MSC cultures.  
4.  Explore the use of small molecule inhibitors to alter MSC proliferation and 
ageing in vitro. 
 33 
2  Materials and Methods 
2.1 Materials 
2.1.1 Equipment 
Equipment which is standard in most laboratories and used in this work, but not 
listed by supplier included: wet and dry ice, water baths, vortex mixers, 
centrifuges, refrigerators;  20ºC,  70ºC and  150ºC freezers; liquid N2 cryostorage 
containers; microwave oven; tissue culture plastics, sterile and non sterile glass 
pipettes, bottles, flasks and beakers; plastic bottles, beakers, measuring 
cylinders and boxes; aluminium foil, cling film and plastic wrapping; rocker 
platform and shaker; laboratory digital balance and pH meters; magnetic stirrer 
and hotplate and metal ware including forceps and spatulas. 
Agilent Technologies Ltd (West Lothian, UK) 
2100 Bioanalyser and Expert 2100 software B.02.03 (including upgrade)  
Applied Biosystems Ltd (Warrington, UK) 
ABI Prism Automated Sequencer (Models 373 and 377) 
7900HT Fast Real Time PCR system with SDS 2.3 and RQ 1.2 software 
Beckman (RIIC) Ltd (High Wycombe, UK) 
Avanti™ J 25 centrifuge (high speed refrigerated centrifuge) 
GS 6R centrifuge (low speed refrigerated centrifuge) 
Microfuge
® R centrifuge (refrigerated microcentrifuge) 
Becton Dickinson (BD) Ltd (Oxford, UK) 
BD FACSCalibur™ flow cytometer with BD CellQuest Pro™ software (version 
1.a.2f5b) Malcolm B Will 2010     Chapter 2, 34 
Carl Zeiss MicroImaging GmbH (Göttingen, Germany) 
Axio Observer.A1 inverted microscope with Axio Vision software (version 4.6) 
Charles Austin Pumps Ltd (Byfleet, UK) 
Capex L2C vacuum pump (for use with QIAvac Multiwell vacuum manifold) 
Fisher Scientific (part of ThermoScientific) UK Ltd (Loughborough, UK) 
Cell Shock Electroporator electroporation cuvettes 
Electro 4 system (for standard and large scale agarose gel electrophoresis) 
HERA Cell 150 Tri Gas cell culture incubator 
Genetic Research Instrumentation (Braintree, UK) 
Atto Maxi Slab for vertical PAGE: gel tank and pouring apparatus with 160 x 160 
mm glass gel plates, 1.5 mm spacers and 12 and 20 well combs 
Labcaire Systems Ltd (North Somerset, UK) 
PCR6 Mini Vertical Laminar Flow cabinet 
Millipore (Watford, UK) 
Milli Q plus PF water purification system 
MJ Research Inc (Watertown, MA, USA) 
DYAD Disciple™ Peltier thermal cycler stacked upon a DNA Engine
® DYAD Peltier 
to form a 4 bay system including dual 96 heads with independent block control 
PTC 200™ Peltier thermal cycler with dual 48 heads 
Nalge (Europe) Ltd (Hereford, UK) 
Cryo 1ºC “Mr Frosty” freezing container Malcolm B Will 2010     Chapter 2, 35 
NanoDrop Technologies (Wilmington, USA) 
ND 1000 spectrophotometer with ND 1000 software (version 3.3) 
Novex 
XCell SureLock electrophoresis cell 
Olympus UK Ltd (London, UK) 
CKX41 inverted microscope + Cell
B imaging software 
Pharmacia Biotech Ltd (St Albans, UK) 
GeneQuant RNA/DNA calculator (spectrophotometer) 
Qiagen Ltd (Crawley, UK) 
QIAvac Multiwell Vacuum Manifold and Regulator (for large scale DNA 
purification using Qiagen MinElute™ or Edge ExcelaPure™ 96 well UF PCR 
Purification Kits) 
Stratagene Ltd (Cambridge, UK) 
UV Stratalinker 2400 (for UV cross linking) 
Syngene Europe Ltd (Cambridge, UK) 
Gene Genius Bio Imaging System with GeneSnap Software (version 6.03) 
2.1.2 Tissue Culture Reagents 
Becton Dickinson (BD) Ltd (Oxford, UK) 
Dispase 
Matrigel Malcolm B Will 2010     Chapter 2, 36 
Fisher Scientific (part of ThermoScientific) UK Ltd (Loughborough, UK) 
Hyclone Defined Fetal Bovine Serum (FBS) (U.S Origin) 
Invitrogen Ltd (Paisley, UK) 
Alpha Minimum Essential Media (α MEM) (1X) 
DMEM/F 12 Media (1:1) (1X) 
Dulbecco’s Modified Eagle Media (D MEM) (1X) (low glucose 1000mg/l, sodium 
pyruvate and GlutaMAX™) 
Dulbecco’s Phosphate Buffered Saline (D PBS) (1X, without Ca2+and Mg2+) 
Insulin Transferrin Selenium Supplement (ITS) (100X) 
Penicillin Streptomycin Glutamine (PSG) (100X) solution 
RPMI 1640 Media (1X)  
Sterile Distilled Water  
Trypsin EDTA (1X), liquid – 0.25% Trypsin 1mM EDTA 4Na 
Sigma-Aldrich Company Ltd (Dorset, UK) 
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2.1.3 Media Formulations, Wash Buffers and Solutions 
2.1.3.1  MNC Medium 
Reagent  Amount  Concentration 
RPMI 1640  95ml  95% 
FBS  5ml  5% 
 
2.1.3.2  MSC Medium 
Reagent  Amount  Concentration 
D MEM low glucose (1000mg/l), sodium pyruvate and 
GlutaMAX™ 
500ml  83% 
FBS  100ml  17% 
 
2.1.3.3  α-MEM Basal Medium 
Reagents  Amount  Concentration 
α MEM  90ml  90% 
FBS  10ml  10% 
PSG  1ml  100U/ml Penicillin, 100 g/ml Streptomycin, 2nM L 
Glutamine 
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2.1.3.4  D-MEM/F-12 Basal Medium 
Reagents  Amount  Concentration 
D MEM/F 12  49ml  99% 
ITS  500 l  1% 
PSG  500 l  100U/ml Penicillin, 100 g/ml 
Streptomycin, 2nM L Glutamine 
 
2.1.3.5  Adipogenic Differentiation Medium 
Reagents  Amount  Concentration 
α MEM Basal Medium  5ml  99% 
Adipogenic supplement (100X solution containing 
hydrocortisone, isobutylmethylxanthine and 
indomethacin)   
50 l  1% 
 
2.1.3.6  Osteogenic Differentiation Medium 
Reagents  Amount  Concentration 
α MEM Basal Medium  5ml  95% 
Osteogenic supplement (20X solution of 
dexamethasone, ascorbate phosphate and β 
glycerolphosphate) 
250 l  5% 
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2.1.3.7  Chondrogenic Differentiation Medium 
Reagents  Amount  Concentration 
D MEM/F 12 Basal 
Medium 
2.5ml  99% 
Chondrogenic 
supplement (100X 
solution of 
dexamethasone, 
ascorbate phosphate, 
proline, pyruvate and 
TGF β3 
25 l  1% 
 
2.1.3.8  MSC Cryopreservation Medium 
Reagents  Amount  Concentration 
D MEM low glucose 
(1000mg/l), sodium 
pyruvate and GlutaMAX™ 
6ml  60% 
FBS  2ml  20% 
DMSO  2ml  20% 
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2.1.3.9  Wash Buffer 
Reagent  Amount  Concentration 
D PBS( Ca
2+,  Mg
2+)  490ml  98% 
FBS  10ml  2% 
 
2.1.3.10  FACS Fix 
Reagent  Amount  Concentration 
D PBS ( Ca
2+,  Mg
2+)  17.6ml  88% 
Formalin solution (37% formaldehyde)   2ml  10% (3.7% formaldehyde) 
FBS  400 l  2% 
 
2.1.4 Flow Cytometry Reagents 
AbD Serotec Ltd (Oxford, UK) 
R PE conjugated Mouse Anti Human CD105 Monoclonal Antibody (MCA1557PE) 
Becton Dickinson (BD) Ltd (Oxford, UK) 
FITC conjugated Mouse IgG1, κ Monoclonal Isotype Control (555909) 
R PE conjugated Mouse IgG1, κ Monoclonal Isotype Control (555749) 
R PE conjugated Goat Anti Mouse Immunoglobulin Specific Polyclonal Antibody 
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R PE conjugated Mouse Anti Human CD13 Monoclonal Antibody (555394) 
R PE conjugated Mouse Anti Human CD14 Monoclonal Antibody (555398) 
R PE conjugated Mouse Anti Human CD29 Monoclonal Antibody (555443) 
FITC conjugated Mouse Anti Human CD31 Monoclonal Antibody (555445) 
R PE conjugated Mouse Anti Human CD34 Monoclonal Antibody (550761) 
FITC conjugated Mouse Anti Human CD44 Monoclonal Antibody (555478) 
FITC conjugated Mouse Anti Human CD45 Monoclonal Antibody (555482) 
R PE conjugated Mouse Anti Human CD45 Monoclonal Antibody (555483) 
R PE conjugated Mouse Anti Human CD49d Monoclonal Antibody (555503) 
R PE conjugated Mouse Anti Human CD49e Monoclonal Antibody (555617) 
FITC conjugated Mouse Anti Human CD71 Monoclonal Antibody (555536) 
R PE conjugated Mouse Anti Human CD73 Monoclonal Antibody (550257) 
FITC conjugated Mouse Anti Human CD90 Monoclonal Antibody (555595) 
FITC conjugated Mouse Anti Human CD106 Monoclonal Antibody (551146) 
R PE conjugated Mouse Anti Human CD166 Monoclonal Antibody (559263) 
FITC conjugated Mouse Anti Human HLA A, B, C Monoclonal Antibody (555552) 
FITC conjugated Mouse Anti Human HLA DR, DP, DQ Monoclonal Antibody 
(555558) 
FACSClean™ Solution 
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Miltenyi Biotec Ltd (Surrey, UK) 
R PE conjugated Mouse Anti Human CD133 Monoclonal Antibody (120 001 243) 
Molecular Probes™, Invitrogen Ltd (Paisley, UK) 
CellTrace™ CFSE Cell Proliferation Kit 
R&D Systems (Oxford, UK) 
Mouse Anti Human STRO 1 Monoclonal Antibody (MAB1038) 
Upstate Ltd (now part of Millipore) (Hampshire, UK) 
H2A.X Phosphorylation Assay Kit (Flow Cytometry) 
2.1.5 MSC Differentiation Reagents 
R&D Systems (Oxford, UK) 
Human Mesenchymal Stem Cell Functional Identification Kit 
2.1.6 Cell Staining Reagents and Antibodies  
AbD Serotec Ltd (Oxford, UK) 
Normal donkey serum 
R&D Systems (Oxford, UK) 
Mounting medium 
Mouse IgG1 Isotype Control (MAB002) 
Normal Goat IgG (AB 108 C) 
Sigma-Aldrich Company Ltd (Dorset, UK) Malcolm B Will 2010     Chapter 2, 43 
Alcian Blue 
Alizarin Red S 
(3 Aminopropyl) triethoxysilane 
Bovine serum albumin (BSA) 
Haematoxylin 
Oil Red O  
Senescent Cells Staining Kit 
Triton X 100 
Stratech Scientific Ltd (Soham, UK) 
Jackson Immuno Rhodamine (TRITC) conjugated AffiniPure F (ab’) 2 Fragment 
Donkey Anti Goat IgG (705 026 147) 
Jackson Immuno Fluorescein Isothiocyanate (FITC) conjugated AffiniPure F (ab’) 
2 Fragment Donkey Anti Mouse IgG (715 096 150) 
Upstate Ltd (now part of Millipore) (Hampshire, UK) 
Anti phospho Histone H2A.X (Ser139) (05 636) 
Vector Laboratories Ltd (Peterborough, UK) 
VECTASHIELD™ Mounting Medium   
VECTASHIELD™ Mounting Medium with DAPI 
ImmEdge™ Hydrophobic Barrier Pen 
VWR International Ltd (Lutterworth, UK) 
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Rectangular cover glass (24x60mm) 
Staining racks 
Superfrost™ microscope slides with frosted ends 
Whatman Filter Paper  
2.1.7 Molecular Biology Reagents and Kits 
ABgene (Epsom, UK) 
Nucleospin RNA II Kit 
Applied Biosystems Ltd (Warrington, UK) 
Ambion RNAseZap 
Agilent Technologies Ltd (West Lothian, UK) 
RNA 6000 Nano LabChip kit 
Invitrogen Ltd (Paisley, UK) 
DNA molecular markers 
I SAGE™ Long Kit 
S.O.C medium 
Qiagen Ltd (Crawley, UK) 
DNEasy Blood and Tissue Kit 
MinElute 96 UF PCR Purification Kit 
Taq PCR core kit 
Roche Diagnostics Ltd (Sussex, UK) Malcolm B Will 2010     Chapter 2, 45 
Glycogen 
TeloTAGGG Telomere Length Assay 
VH BIO Ltd (Newcastle, UK) 
Edge ExcelaPure™ 96 Well UF PCR Purification Kit 
2.1.8 Chemicals 
Braun Medical Ltd (Sheffield, UK) 
Water for injections BP 
Fisher Scientific UK Ltd (Loughborough, UK) 
Acetic acid, glacial 
Ammonium persulphate (10% stock solution) 
Chloroform 
Glycerol 
Hydrochloric acid 
Propan 2 ol (isopropanol) 
Xylene 
Hayman Ltd (James Borrough) (Witham, UK) 
Absolute alcohol (ethanol) (analytical reagent grade) (100% and 70% stock 
solutions) 
Invitrogen (Paisley, UK) 
Agarose Malcolm B Will 2010     Chapter 2, 46 
TRIzol
® 
Merck Chemicals Ltd (Nottingham, UK) 
BIO ((2′Z, 3′E) 6 Bromoindirubin 3′ oxime) (361550) 
SB 203580 (4 (4 Fluorophenyl) 2 (4 methylsulfinylphenyl) 5 (4 pyridyl) 1H 
imidazole) (559389) 
Sigma-Aldrich Company Ltd (Dorset, UK) 
Ammonium hydroxide solution (25% NH3 in water) 
β   Mercaptoethanol 
Bromophenol blue 
Diethylpyrocarbonate (DEPC) 
Dimethyl sulfoxide (DMSO) 
Ethidium bromide (10 mg/ml stock solution) 
Formalin solution (37% Formaldehyde) 
Glycerol 
Iron III chloride 
Hydrogen peroxide solution (0.98M) 
Mitomycin C 
N, N, N’, N’ tetramethylethylenediamine (TEMED) 
Saturated phenol (25:24:1 phenol: chloroform: iso amyl alcohol) 
Xylene cyanol Malcolm B Will 2010     Chapter 2, 47 
2.1.9 Buffers 
These were kindly provided by Beatson Institute Central Services. 
Sterile phosphate buffered saline (PBS) 
10x Tris Borate/EDTA (TBE) electrophoresis buffer 
2.1.10  Sequencing 
PerkinElmer from Applied Biosystems (Warrington, UK) 
BigDye Primer Kit 
2.1.11  Bioinformatics 
Metacore™, GeneGo Inc (St Joseph’s, MI, USA) 
MetaCore™ is an integrated software suite for functional analysis of 
experimental data. The scope of data types includes microarray and SAGE gene 
expression, SNPs and CGH arrays, proteomics, metabolomics, pathway analysis, 
Y2H and other custom interactions. MetaCore™ is based on a proprietary 
manually curated database (MetaBase™) of human protein protein, protein DNA 
and protein compound interactions, metabolic and signalling pathways and the 
effects of bioactive molecules in gene expression. The analytical package 
includes easy to use, intuitive tools for data visualization, mapping and 
exchange, multiple networking algorithms and filters.  Data analysis was carried 
out on line via web portal access requiring annual subscription. 
National Centre for Biotechnology Information (NCBI) (Bethesda, MD, USA) 
http://www.ncbi.nlm.nih.gov 
NCBI is an international resource for molecular biology information. 
http://www.ncbi.nlm.nih.gov/SAGE/ Malcolm B Will 2010     Chapter 2, 48 
SAGE databases, reference files and SAGEmap tools for on line analysis are 
available for download or on line analysis.  From September 2006, the website 
has been undergoing re structuring and up dating of tag to gene mappings with 
limited usability.  
http://www.ncbi.nlm.nih.gov/UniGene/ 
NCBI’s UniGene database and tools for on line analysis clusters all transcripts 
corresponding to one gene and one name. 
http://www.ncbi.nlm.nih.gov/BLAST/ 
NCBI’s BLAST
® (Basic Local Alignment Search Tool) for searching DNA or protein 
similarity through all the available sequence databases and alignment programs. 
http://www.ncbi.nlm.nih.gov/PubMed/ 
The National Library of Medicine’s PubMed database, providing access to over 17 
million MEDLINE citations back to the 1950’s and used for all literature searches. 
SAGE Genie, Cancer Genome Anatomy Project (CGAP), National Cancer 
Institute (NCI) (Bethesda, MD, USA) 
http://cgap.nci.nih.gov/SAGE 
The SAGE Genie website provides highly intuitive and visual displays of human 
gene expression and is based on a unique analytical process that reliably 
matches 10 or 17 bp SAGE tags to known genes.  It includes a reference database 
of single nucleotide polymorphism (SNP) associated alternative tags in order to 
enhance tag to gene mapping.  The website offers multiple functions such as the 
detailed analysis of individual genes or tags, and also the comparison of SAGE 
libraries either uploaded by the user or available online.  Statistical significance 
and tag fold differences can be defined by the user and this site was used for the 
analysis of the MSC SAGE libraries. 
SAGE website at John Hopkins University (Baltimore, MD, USA) 
http://www.sagenet.org Malcolm B Will 2010     Chapter 2, 49 
This is the web site of the scientists who originally designed SAGE.  SAGE 2000 
software can be downloaded from the web site after registration or following 
the instructions provided with the SAGE kit. 
SAGEstat (Version 4) Software from Department of Anatomy and Embryology, 
Academic Medical Centre (Amsterdam, Netherlands) 
Kind gift from Dr J.M.Ruijter (j.m.ruijter@amc.uva.nl).  SAGEstat can be used 
for the evaluation and planning of SAGE analysis and is based on the Z test which 
is a test between two proportions and based on the normal approximation of the 
binomial distribution.  The software was used to compare the results to those 
generated by SAGE Genie.  
2.1.12  Software 
GraphPad Software (San Diego, CA, USA) 
GraphPad Prism
® 4 for basic biostatistics and scientific graphing 
Microsoft
® (Reading, UK) 
Microsoft
® Office 2003 including Word, Excel, Access and Powerpoint 
  
Tree Star Inc (Ashland, OR, USA) 
FlowJo 6.0 flow cytometry analysis software 
2.1.13  Taqman
® Low Density Array and Reagents 
Applied Biosystems Ltd (Warrington, UK) 
Taqman
® Universal PCR Mastermix 
Taqman
® low density human endogenous control array (4367563) 
Taqman
® low density arrays (Format 96b) were custom designed to contain 
GAPDH as the endogenous control and 95 target assays as shown below: Malcolm B Will 2010     Chapter 2, 50 
Gene  Gene Name  Assay ID  Ref Seq ID 
ACTB  actin, beta  Hs99999903_m1  NM_001101.2 
ADAMTS1  ADAM metallopeptidase with 
thrombospondin type 1 motif, 1 
Hs00199608_m1  NM_006988.3 
AKR1C1, AKR1C2  aldo keto reductase family 1, 
member C1 (dihydrodiol 
dehydrogenase 1; 20 alpha (3 alpha) 
hydroxysteroid dehydrogenase),aldo 
keto reductase family 1, member C2 
(dihydrodiol dehydrogenase 2; bile 
acid binding protein; 3 alpha 
hydroxysteroid dehydrogenase, type 
III) 
Hs00413886_m1  NM_001353.5 NM_205845.1 
NM_001354.4 
ANXA2  Annexin A2  Hs00733393_m1  NM_001002857.1 
APLP2  Amyloid beta (A4) precursor like 
protein 2 
Hs00155778_m1  NM_001642.1 
ARPC2  actin related protein 2/3 complex, 
subunit 2, 34kDa 
Hs00194852_m1  NM_152862.1 NM_005731.2 
ATP5G3  ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit 
C3 (subunit 9) 
Hs00266085_m1  NM_001002258.2NM_001689
.3 
BLVRB  Biliverdin reductase B (flavin 
reductase (NADPH)) 
Hs00355972_m1  NM_000713.1 
BSCL2, HNRPUL2  Bernardinelli Seip congenital 
lipodystrophy 2 (seipin), 
heterogeneous nuclear 
ribonucleoprotein U like 2 
Hs00369057_m1  NM_032667.4 
CALM1, CALM2  calmodulin 1 (phosphorylase kinase, 
delta), calmodulin 2 (phosphorylase 
kinase, delta) 
Hs00237233_m1  NM_006888.3 
CAV1  caveolin 1, caveolae protein, 22kDa  Hs00184697_m1  NM_001753.3 
CCND1  Cyclin D1  Hs00277039_m1  NM_053056.2 
CCT7  chaperonin containing TCP1, subunit 
7 (eta) 
Hs00362446_m1  NM_001009570.1NM_006429
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CD44  CD44 molecule (Indian blood group)  Hs00153304_m1  NM_001001389.1NM_001001
390.1NM_001001391.1NM_0
01001392.1NM_000610.3 
CD63  CD63 molecule  Hs00156390_m1  NM_001040034.1NM_001780
.4 
CDKN1A  Cyclin dependent kinase inhibitor 1A 
(p21, Cip1) 
Hs00355782_m1  NM_078467.1, NM_000389.2 
CDKN1B  Cyclin dependent kinase inhibitor 1B 
(p27, Kip1) 
Hs00153277_m1  NM_004064.2 
CDKN2A  Cyclin dependent kinase inhibitor 2A 
(melanoma, p16, inhibits CDK4) 
Hs00233365_m1  NM_058195.2 NM_058197.3 
NM_000077.3 
CEECAM1  cerebral endothelial cell adhesion 
molecule 1 
Hs00170969_m1  NM_016174.3 
CLIC1  chloride intracellular channel 1  Hs00559461_m1  NM_001288.4 
COL1A1  collagen, type I, alpha 1  Hs00164004_m1  NM_000088.3 
COL1A2  collagen, type I, alpha 2  Hs00164099_m1  NM_000089.3 
COL3A1  collagen, type III, alpha 1 (Ehlers 
Danlos syndrome type IV, autosomal 
dominant) 
Hs00164103_m1  NM_000090.3 
COL5A1  collagen, type V, alpha 1  Hs00609088_m1  NM_000093.3 
COTL1  coactosin like 1 (Dictyostelium)  Hs00332755_m1  NM_021149.2 
COX5B  cytochrome c oxidase subunit Vb  Hs00426948_m1  NM_001862.2 
CST3  cystatin C (amyloid angiopathy and 
cerebral haemorrhage) 
Hs00264679_m1  NM_000099.2 
CTGF  connective tissue growth factor  Hs00170014_m1  NM_001901.2 
CTSS  cathepsin S  Hs00175403_m1  NM_004079.3 
DEGS1  Degenerative spermatocyte homolog 
1, lipid desaturase (Drosophila) 
Hs00186447_m1  NM_144780.1 NM_003676.2 
DPYSL3  dihydropyrimidinase like 3  Hs00181665_m1  NM_001387.2 Malcolm B Will 2010     Chapter 2, 52 
DSP  Desmoplakin  Hs00189422_m1  NM_001008844.1NM_004415
.2 
DUSP6  dual specificity phosphatise 6  Hs00169257_m1  NM_001946.2 
DVL1  dishevelled, dsh homolog 1 
(Drosophila) 
Hs00182896_m1  NM_004421.2 
ELN  elastin (supravalvular aortic stenosis, 
Williams Beuren syndrome) 
Hs00355783_m1  NM_000501.1 
FBXO18  F box protein, helicase, 18  Hs00262318_m1  NM_032807.3 NM_178150.1 
FOS  v fos FBJ murine osteosarcoma viral 
oncogene homolog 
Hs00170630_m1  NM_005252.2 
FOXO3A  forkhead box O3A  Hs00818121_m1  NM_201559.1 NM_001455.2 
GARS  Glycyl tRNA synthetase  Hs00157653_m1  NM_002047.1 
GPX4  glutathione peroxidase 4 
(phospholipid hydroperoxidase) 
Hs00157812_m1  NM_001039847.1NM_002085
.3 
HMGA1  high mobility group AT hook 1  Hs00431242_m1  NM_145905.1 
HMOX1  Heme oxygenase (decycling) 1  Hs00157965_m1  NM_002133.1 
HNF4A  hepatocyte nuclear factor 4, alpha  Hs00230853_m1  NM_178849.1 NM_178850.1 
NM_175914.3 
NM_001030004.1NM_001030
003.1NM_000457.3 
HSPA8  heat shock 70kDa protein 8  Hs00852842_gH  NM_006597.3 
HTRA1  HtrA serine peptidase 1  Hs00170197_m1  NM_002775.3 
IFI30  interferon, gamma inducible protein 
30 
Hs00173838_m1  NM_006332.3 
IGFBP4  insulin like growth factor binding 
protein 4 
Hs00181767_m1  NM_001552.2 
IL6ST  interleukin 6 signal transducer 
(gp130, oncostatin M receptor) 
Hs00174360_m1  NM_175767.1 NM_002184.2 
ITGA11  integrin, alpha 11  Hs00201927_m1  NM_001004439.1NM_012211
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KDELR2  KDEL (Lys Asp Glu Leu) endoplasmic 
reticulum protein retention receptor 
2 
Hs00199277_m1  NM_006854.2 
KIAA1199  KIAA1199  Hs00378530_m1  NM_018689.1 
KLF9  Kruppel like factor 9  Hs00230918_m1  NM_001206.2 
LMO7  LIM domain 7  Hs00245600_m1  NM_005358.4 
LOC401152  HCV F transactivated protein 1  Hs00386171_m1  NM_001001701.1 
LOXL1  lysyl oxidase like 1  Hs00173746_m1  NM_005576.2 
LUM  Lumican  Hs00158940_m1  NM_002345.3 
MRC2  mannose receptor, C type 2  Hs00195862_m1  NM_006039.3 
MVP  Major vault protein  Hs00245438_m1  NM_017458.2 NM_005115.3 
MYL9  myosin, light chain 9, regulatory  Hs00382913_m1  NM_181526.1 
MYO10  myosin X  Hs00202485_m1  NM_012334.1 
OAZ2  ornithine decarboxylase antizyme 2  Hs00159726_m1  NM_002537.1 
OLFML3  Olfactomedin like 3  Hs00220180_m1  NM_020190.2 
PEA15  phosphoprotein enriched in 
astrocytes 15 
Hs00269428_m1  NM_003768.2 
PLAT  plasminogen activator, tissue  Hs00263492_m1  NM_033011.1 NM_000930.2 
NM_000931.2 
POLR2A  polymerase (RNA) II (DNA directed) 
polypeptide A, 220kDa 
Hs00172187_m1  NM_000937.2 
PRG1  Proteoglycan 1, secretory granule  Hs00160444_m1   
PRSS23  protease, serine, 23  Hs00359912_m1  NM_007173.3 
PSAP  prosaposin (variant Gaucher disease 
and variant metachromatic 
leukodystrophy) 
Hs00358165_m1  NM_002778.2 
PTGS2  Prostaglandin endoperoxide synthase 
2 (prostaglandin G/H synthase and 
Hs00153133_m1  NM_000963.1 Malcolm B Will 2010     Chapter 2, 54 
cyclooxygenase) 
ROR1  receptor tyrosine kinase like orphan 
receptor 1 
Hs00178178_m1  NM_005012.1 
RPLP0  ribosomal protein, large, P0  Hs99999902_m1  NM_053275.3 NM_001002.3 
RTN4  reticulon 4  Hs00199671_m1  NM_207520.1 NM_207521.1 
NM_153828.2 NM_020532.4 
NM_007008.2 
S100A6  S100 calcium binding protein A6  Hs00170953_m1  NM_014624.3 
SERPINE1  Serpin peptidase inhibitor, clade E 
(nexin, plasminogen activator 
inhibitor type 1), member 1 
Hs00167155_m1  NM_000602.1 
SERPINE2  Serpin peptidase inhibitor, clade E 
(nexin, plasminogen activator 
inhibitor type 1), member 2 
Hs00299953_m1  NM_006216.2 
SHC1  SHC (Src homology 2 domain 
containing) transforming protein 1 
Hs00427539_m1  NM_183001.3 NM_003029.3 
SLC38A2  Solute carrier family 38, member 2  Hs00255854_m1  NM_018976.3 
SOD1  superoxide dismutase 1, soluble 
(amyotrophic lateral sclerosis 1 
(adult)) 
Hs00166575_m1  NM_000454.4 
SPARC  secreted protein, acidic, cysteine 
rich (osteonectin) 
Hs00277762_m1  NM_003118.2 
SRM  spermidine synthase  Hs00162307_m1  NM_003132.2 
STAT1  Signal transducer and activator of 
transcription 1, 91kDa 
Hs00234829_m1  NM_139266.1 NM_007315.2 
STC2  Stanniocalcin 2  Hs00175027_m1  NM_003714.2 
TGFBI  transforming growth factor, beta 
induced, 68kDa 
Hs00165908_m1  NM_000358.1 
TGM2  transglutaminase 2 (C polypeptide, 
protein glutamine gamma 
glutamyltransferase) 
Hs00190278_m1  NM_198951.1 NM_004613.2 Malcolm B Will 2010     Chapter 2, 55 
THY1  Thy 1 cell surface antigen  Hs00174816_m1  NM_006288.2 
TM4SF1  transmembrane 4 L six family 
member 1 
Hs00371997_m1  NM_014220.2 
TMEM47  Transmembrane protein 47  Hs00230190_m1  NM_031442.2 
TRAM2  translocation associated membrane 
protein 2 
Hs00202213_m1  NM_012288.3 
TUBB6  tubulin, beta 6  Hs00603164_m1  NM_032525.1 
UBC  ubiquitin C  Hs00824723_m1  NM_021009.3 
VCP  valosin containing protein  Hs00997642_m1  NM_007126.2 
VIM  Vimentin  Hs00185584_m1  NM_003380.2 
WBSCR1  Williams Beuren syndrome 
chromosome region 1 
Hs00254535_m1  NM_022170.1 
YIPF5  Yip1 domain family, member 5  Hs00229305_m1  NM_030799.6 
NM_001024947.1 
YWHAB  tyrosine 3 
monooxygenase/tryptophan 5 
monooxygenase activation protein, 
beta polypeptide 
Hs00793604_m1  NM_139323.2 NM_003404.3 
 
2.1.14  TeloTAGGG Telomere Length Assay Buffers and 
Solutions 
1X TAE buffer 
0.04M Tris Acetate 
0.001M EDTA 
pH8.0 
HCl Solution Malcolm B Will 2010     Chapter 2, 56 
0.25M HCl 
Denaturation Solution 
0.5M NaOH 
1.5M NaCl 
Neutralisation Buffer 
0.5M Tris HCl 
3M NaCl 
pH7.5 
20X SSC 
3M NaCl 
0.3M Na Citrate 
pH 7.0 
2X SSC 
200mls 20 x SSC (solution 5) 
1800mls dH2O 
DIG Easy Hyb Solution 
Add 64mls dH2O to 1 bottle DIG Easy Hyb granules (provided with TeloTAGGG 
kit). 
Incubate at 37oC until complete reconstitution (prepare in advance). 
Stringent Wash Buffer I Malcolm B Will 2010     Chapter 2, 57 
2 x SSC  
0.1% SDS 
Stringent Wash Buffer II 
0.2 x SSC 
O.1% SDS 
1 x Washing Buffer 
50mls 10 x washing buffer (provided with TeloTAGGG kit) 
450mls dH2O 
1 x Blocking Solution 
20mls 10 x blocking buffer (provided with TeloTAGGG kit) 
180mls Maleic acid buffer 
1 x Maleic Acid Buffer 
50mls 10 x Maleic acid buffer (provided with TeloTAGGG kit) 
450mls dH2O 
Anti-DIG-AP  
10ul Anti DIG AP antibody 
100mls 1 x Blocking Solution 
1 x Detection Buffer 
50mls 10 x Detection Buffer (provided with TeloTAGGG kit) 
450mls dH2O Malcolm B Will 2010     Chapter 2, 58 
Stripping Buffer 
0.8% NaOH 
0.1% SDS 
2.2 Cell Culture and Flow Cytometry Methods 
2.2.1 Cell Culture 
Ethical approval for the research was granted from the Local Research and 
Ethics Committee (LREC) at Glasgow Royal Infirmary (Project number: 02SC005).  
On the day prior to surgery, informed consent was obtained from patients 
undergoing CABG within the Department of Cardiac Surgery, Glasgow Royal 
Infirmary.  Copies of the consent and research protocol were kept by me, the 
patient and filed in the case notes.  Thirty of thirty three (91%) patients 
approached agreed to participate in the research.  Patients were excluded from 
the study if: age >80; osteoporosis; alcoholism; on immunosuppressive 
medications or previous cardiac surgery. 
2.2.1.1  Cell Counting and Viability Assessment 
All cell counts were performed on a Hawksley BS.748 improved Neubauer 
counting chamber using the trypan blue exclusion assay.  Stock trypan blue 
solution was diluted at 1:10 with PBS, and 10 l added to 10 l of the cell 
suspension (1:1 dilution).  Approximately 10 l of the mixture was transferred by 
capillary action to a haemocytometer and viewed under an inverted microscope 
at 10x magnification.  Viable cells exclude the dye and non viable cells stain 
blue due to a breakdown in cell membrane integrity.   Viable and total cells 
were counted on two diagonally opposite 16 square (1mm
2) grids and averaged.  
The total number of viable cells is equal to the viable cell concentration 
multiplied by the dilution factor (e.g. multiply by two if cell: dye ratio is 1:1).  
Cell viability was calculated by the equation: % cell viability = total viable cells 
(unstained) / total cells (stained plus unstained) x 100. Malcolm B Will 2010     Chapter 2, 59 
2.2.1.2  Aspiration of Sternal Bone Marrow 
With the patient in theatre and under general anaesthesia, the chest wall was 
prepared and draped in the usual manner for CABG.  A single skin incision was 
made from the sternal notch to the xiphisternum using a scalpel.  Dissection of 
the subcutaneous tissue down to the pre sternal fascia was performed using 
diathermy.  A standard 14 gauge BM aspiration needle was assembled and 
inserted into the manubrium perpendicular to the periosteum, using a twisting 
motion.  Care was taken to avoid excessive force that could push the needle 
through the sternum and into the anterior mediastinum (with potential injury to 
the heart or great vessels).  The needle stylet was removed and bone marrow 
aspirated into a 5ml syringe containing 1ml preservative free heparin (1000units 
per ml).  The syringe was inverted and BM injected through a white needle into 
a 25ml Universal container containing 14ml BM media and 1ml Heparin 
(1000units per ml).  Two further aspirations were performed in the upper and 
middle thirds of the sternum.  This increased the yield of mononuclear cells and 
reduced venous blood contamination compared to a large aspiration at one site.    
The samples are taken immediately to the laboratory for separation of the 
mononuclear cell fraction. 
2.2.1.3  Preparation of Human Bone Marrow Mononuclear Cells 
Histopaque 1077 is solution of polysucrose and sodium diatrizoate, adjusted to 
form a density of 1077 ± 0.001 g/ml and is routinely used for the isolation of 
mononuclear cells from anti coagulated peripheral blood or bone marrow.  
During centrifugation, erythrocytes and granulocytes are aggregated by 
polysucrose and rapidly sediment, whereas, lymphocytes and other mononuclear 
cells remain at the plasma Histopaque interface.  Erythrocyte contamination is 
negligible and platelets are removed by subsequent wash steps. 
15ml of Histopaque 1077 was transferred to two 50ml tubes and brought to RT 
(colder temperatures cause clumping and decreased cell recovery).  The BM was 
re suspended and 30ml carefully layered onto Histopaque 1077 in each tube.  
The tubes were centrifuged at 400 x g for 30 minutes at RT with the brake 
turned off.  The upper layer was aspirated to within 1cm of the opaque interface 
and discarded.  The opaque interface was transferred into a Universal container Malcolm B Will 2010     Chapter 2, 60 
and washed twice by adding 20ml Wash Buffer, then centrifuged at 200 x g for 
10 minutes.  The supernatant was discarded and the MNC’s re suspended in 10ml 
MSC media.  A 10 l sample was counted using a haemocytometer. 
2.2.1.4  Colony Forming Unit – Fibroblast (CFU–F) Assay 
The CFU F assay is a well established method for the quantification of MSC’s 
from a human bone marrow sample.  CFU F’s represent stem/progenitor cells 
with non haematopoietic differentiation potential.  Therefore, the assay can be 
used for quality testing of the MSC source and isolation procedure.  The assay 
can be performed in a dilution series or set up with a defined cell concentration 
with replicates. 
Preparing the CFU-F Assay in a Dilution Series 
MSC media was pre warmed to 37ºC in a waterbath.  Re suspend an aliquot of 
the MNC suspension at 2 x 10
7 cells per ml in MSC media.  Dilute the suspension 
by pipetting 100 l into a 15ml tube containing 10ml MSC medium to give a 
concentration of 2 x 10
5 cells per ml.  Repeat with 50 l and 25 l to give two 
further concentrations of 1 x 10
5 and 0.5 x 10
5 cells per ml respectively.  Re 
suspend the cells and transfer to three labelled 100 mm culture dishes and 
incubate in a 37ºC incubator with 5% CO2 and >95% humidity for 2 weeks.  The 
media is not replenished during this period.  
Staining and Enumeration of CFU-Fs 
MSC media was discarded and cells washed twice with 5ml D PBS ( Ca
2+,  Mg
2+). 
The cells were fixed in 5ml of methanol by incubation at RT for 5 minutes.  The 
methanol was then discarded and the culture dishes allowed to air dry.  Dilute 
the Giemsa staining solution 1:20 with dH2O and filter through a folded filter 
paper.  Add 5ml Giemsa staining solution to each dish and incubate for 10 
minutes.  Remove the stain, wash each dish twice with dH2O and discard.  Allow 
the culture dishes to air dry and perform the scoring procedure.  CFU F colonies 
containing at least 20 cells were scored macroscopically (typically 1 – 8 mm in 
diameter).  In a dilution series, the correlation between the numbers of MNC’s 
plated and CFU Fs counted should be linear.  Malcolm B Will 2010     Chapter 2, 61 
2.2.1.5  Expansion and Handling of Human MSC’s 
MSC’s are present a low frequency in human BM samples and require expansion 
to generate sufficient numbers for further experiments.  We used the plastic 
adherence method and a cell density of 2000 cells per cm
2 although alternative 
selection methods and plating densities are described. 
Set-up of the MSC Expansion Procedure 
Reagents were pre warmed to 37ºC in a waterbath, and BM MNC’s re suspended 
at a concentration of 1.5 x 10
6 cells per ml in MSC media.  0.32 ml MSC media 
per cm
2 culture flask (e.g. 8ml media in a T 25, 24ml media in a T 75) were 
transferred to a culture flask and cultured at 37ºC in an incubator, with 5% CO2 
and > 95% humidity.  After 72 hours, the media was aspirated to discard the non 
adherent fraction.  Cells were replenished with fresh MSC media every 3 4 days 
and observed daily under an inverted microscope.  When the cells reached 80 
90% confluence, they were passaged.  “Passaging” simply refers to the process 
of detaching adherent cells from a culture flask and re plating at the required 
cell density. 
Passaging of Human MSC’s 
Reagents were pre warmed to 37ºC in a waterbath.  Media was discarded and 
the cells rinsed with D PBS ( Ca
2+/ Mg
2+) equivalent to half the volume of MSC 
media.  Rock the culture flask for 30 seconds to bathe the cell monolayer and 
discard the D PBS ( Ca
2+,  Mg
2+).  Add 1ml T/E per 25cm
2 of the culture flask 
area and incubate for 5 – 10 minutes in an incubator.  Gently tapping the flask 
helps dislodge the monolayer of cells and the cells were viewed under an 
inverted microscope to ensure detachment.  T/E was inactivated by adding 2ml 
MSC media per ml of T/E, and the cells re suspend by repetitive pipetting.  The 
cells were transferred to a sterile tube and centrifuged at 200 x g for 5 minutes.  
The cells were re suspended in a small volume of MSC media and viable counts 
assessed using a haemocytometer.  MSC’s were further expanded by re plating at 
2000 viable cells/cm
2 in a culture flask and changing the MSC media twice a 
week.  The cells were observed daily and passaged when 80 90% confluent.  
Long term MSC’s cultures were deemed senescent or growth arrested when they 
failed to reach near confluence after a minimum of three weeks in culture. Malcolm B Will 2010     Chapter 2, 62 
Cryopreservation Protocol for MSC’s 
Passaged MSC’s were re suspended in MSC media at 2 x 10
6 cells per ml and an 
equal volume of cryopreservation media added to cells and mixed well (final 
concentration DMSO 10%).  1ml (1 x 10
6 cells) was added to each CryoTube™ and 
placed in a “Mr Frosty” containing 250ml of fresh propan 2 ol and stored at  
70ºC overnight.  For long term storage, the CryoTubes™ were transferred to a 
liquid N2 container or ultra low temperature (–150ºC) freezer. 
Thawing Protocol for MSC’s 
CryoTubes™ were removed from storage and thawed in at 37ºC in a waterbath.  
The vials were disinfected by soaking in 70% ethanol and dried with a paper 
towel.  Cells were transferred to a 15ml tube and 10ml pre warmed MSC media 
added drop wise over 5 minutes.  Centrifuge at 200 x g for 5 minutes to pellet 
the cells, re suspend in fresh media and transfer to a T 75 culture flask.  
Incubate overnight at 37ºC 5% CO2 and > 95% humidity for at least 16 hours.  The 
following day, the MSC’s are harvested and viability counts assessed by trypan 
blue exclusion.  On occasion, MSC viability was carried out prior to the overnight 
incubation in order to assess storage and recovery procedures.    
2.2.1.6  Colony Forming Efficiency – Fibroblast (CFE–F) Assay 
The CFE F assay is a method for the quantification of stem/progenitor cells 
within established MSC cultures and can be used to assess individual donor 
differences. 
Preparing the CFE-F Assay in Triplicate 
Pre warm the MSC media to 37ºC in a waterbath.  Re suspend an aliquot of the 
MSC suspension at 57 x 10
3 cells per ml in MSC media.  Dilute the suspension by 
pipetting 100 l into a 15ml tube containing 10ml MSC medium to give a final 
concentration of 57 x 10
1 cells per ml (this will give a cell density of 10 cells per 
cm
2  in a 100mm culture dish).  Repeat twice , re suspend the cells carefully and 
transfer to three 100mm culture dishes and incubate in a 37ºC incubator with 5% 
CO2 and >95% humidity for 2 weeks.  The media is not replaced during this 
period. Malcolm B Will 2010     Chapter 2, 63 
Staining and Enumeration of CFE-Fs 
This procedure is identical to that described for staining and enumeration of 
CFU–Fs.  The percentage CFE F is calculated by dividing total number of colonies 
counted in three dishes by the total number of MSC’s seeded and multiplying by 
100. 
2.2.2 Flow Cytometry Analysis of MSC’s 
Flow cytometry is a quantitative technique that permits the visualisation of cells 
by multiple parameters using fluorescence. In comparison to 
spectrophotometers, it is able to measure fluorescence per cell and will allow 
accurate counting of single cells.  All flow cytometry experiments were 
performed on a BD FACSCalibur™. 
Following antibody staining, the cells were visualised with either a linear or log 
scale, as appropriate, on a Forward Scatter (FSC) versus Side Scatter (SSC) dot 
plot.  FSC detects cell size whilst SSC determines cellular granularity.  This view 
allows a gate to be drawn around the main population of cells and to exclude 
debris and dead cells that can be seen in the lower left corner of the plot.  The 
cells within this graphical boundary formed the basis for all further analysis. 
The cells were visualised in a log scale FL1 vs FL2 dot plot or a histogram. 
Unstained and isotype controls were used to determine auto fluorescence and 
non specific background staining and the cells were positioned in the first log 
decade of the parameter(s) by altering the voltage settings. Additionally, 
positive controls were required to compensate for spectral overlap between 
fluorochromes using the compensation settings. This was achieved by subtracting 
as a percentage the fluorescence observed in the detector that should not emit 
fluorescence. This allocates the cells in the bottom right hand and top left hand 
corners of the FACS dot plot according to the fluorescent conjugate used.  Once 
optimal compensation was achieved, the test samples were run and the 
percentage of discrete populations calculated.  Ten thousand gated events were 
collected for each experiment. Malcolm B Will 2010     Chapter 2, 64 
2.2.2.1  Characterisation of MSC cultures 
Passaged MSC’s were re suspended at 1 x 10
6 cells per ml and 100 l of the cell 
suspension added to each FACS tube containing the following amounts of 
antibody as recommended by the manufacturer: 
Tube No.  FITC Ab  Vol (m m m ml)  PE Ab  Vol (m m m ml) 
1  IgG1  2  IgG1  2 
2  IgG1  2  CD 13  2 
3  CD 90  1  IgG1  2 
4  CD 90   1  CD 13   2 
5  CD 90   1  CD 45  2 
6  CD 31  2  CD 34   2 
7  45  2  CD 34  2 
8  CD 31   2  CD 105  1 
9  HLA – A, B, C  2  CD 45   2 
10  HLA   DR, DP, DQ  2  CD 45   2 
11  CD 45  2  CD 13  2 
12  CD 45  2  CD 14  2 
13  CD 90   1  CD 133  2 
14        Goat Anti Mouse Ig  2 
15  Stro1 unconjugated  10      
16  Stro1 unconjugated  10  Goat Anti Mouse Ig  5 
17  CD 71  2  CD 73  2 
18  CD 44  2  CD 29  2 
19  HLA – A, B, C  2  CD 49d   2 
20  CD 31   2  CD 49e  2 
21  CD 106  2  CD 166  2 
 
The tubes were incubated at RT for 30 minutes in the dark.  The cells were 
washed twice with RT wash buffer and centrifuged at 200 x g for 5 minutes.  The 
supernatant was discarded and the cells were re suspended in FACSFlow™ then 
analysed immediately on a flow cytometer.  Cells were re suspended in ice cold 
FACS Fix solution and stored at 4ºC in the dark if analysis could not be performed 
on the same day as staining. 
2.2.2.2   Carboxy-fluorescein diacetate succinimidyl diester (CFSE) 
Assay 
CFSE is a colourless dye that passively diffuses into cells and remains non 
fluorescent until the acetate groups are removed by intracellular esterases.  The 
resulting carboxyfluorescein succinimidyl ester is highly fluorescent and reacts Malcolm B Will 2010     Chapter 2, 65 
with intracellular amines to form fluorescent conjugates that are retained by the 
cell.  CFSE is partitioned equally between daughter cells during cell division and 
as a result high resolution tracking of cell division can be monitored by the 
reduction in fluorescence seen using flow cytometry.  The CellTrace™ CFSE Cell 
Proliferation Kit (Molecular Probes, Invitrogen) and the manufacturer’s protocol 
with minor modifications were followed for these experiments. 
Briefly, passaged MSC’s were re plated at 2000 viable cells per cm
2 in nine wells 
of two 6 well plates.  The following day the media was discarded and replaced 
with 1ml of wash buffer containing 1 M CFSE and incubated for 15 minutes at 
37ºC.  Media was again discarded and replaced with 3ml of MSC medium 
containing either DMSO, 1 M SB203580 or 15nM Mitomycin C.  Mitomycin C was 
used to determine the maximum brightness of cells after uptake of CFSE by 
inhibiting cell division – referred to as the CFSEMax.  Cells were analysed at days 
one, three and five using a flow cytometer.  Briefly, MSC’s were detached from 
each well with T/E, washed three times in wash buffer and centrifuged at 200 x 
g for 5 minutes.  The supernatant was discarded and cells re suspended in 
FACSFlow™ before analysis on a flow cytometer. 
2.2.2.3  H2AX DNA Damage Detection Assay 
H2AX is a variant of histone H2A protein and is a major substrate of kinases 
involved in the ATM initiated signalling cascade in response to DNA damage.  
H2AX contains several serine residues and phosphorylation of serine 139 occurs 
in response to DNA double strand breaks, leading to recruitment of DNA repair 
mechanisms.  If damage is too severe, cells will undergo apoptosis leading to 
fragmentation of the genome and an increase in DNA double strand breaks.  
Thus, H2AX functions as a marker of DNA damage and its expression occurs 
before the morphological changes of apoptosis are detectable. 
On the previous day, passaged MSC’s were re suspended in MSC media at 1 x 10
5 
viable cells per ml and 3ml added to 3 wells of a 6 well plate.  The cells were 
incubated overnight and the next day positive controls set up by incubating the 
cells of two wells for 1 hour in 3ml MSC media containing either 75 M H2O2 or 
300nM Mitomycin C.  The media in each well was discarded and the cells washed 
twice in PBS and allowed to recover over 1 hour in fresh MSC media.  The cells Malcolm B Will 2010     Chapter 2, 66 
were stained using the Flow Cytometry H2A.X Phosphorylation Assay Kit 
(Upstate) following the manufacturers instructions. 
Briefly, MSC’s were detached from each well with T/E, washed three times in 
wash buffer and centrifuged at 200 x g for 5 minutes.  For each well, the cells 
were re suspended in 150 l PBS and 50 l (1 x 10
5) aliquoted into 3 FACS tubes.  
The cells were fixed on ice, permeabilized and either 3.5 l of PBS, FITC IgG or 
FITC anti phospho Histone H2A.X antibody added to each tube.  The tubes were 
incubated on ice for 20 minutes in the dark, washed and analysed on a flow 
cytometer. 
2.2.3 Differentiation of MSC’s In Vitro 
The ability of MSC’s to differentiate into multiple mesenchymal lineages is a 
defining characteristic and can be used to monitor the effects of prolonged 
expansion on MSC properties.  The Human Mesenchymal Stem Cell Functional 
Identification Kit (R&D Systems) was used following the manufacturers protocols. 
2.2.3.1  Adipogenic Differentiation and Detection 
Passaged MSC’s were re suspended in α MEM basal medium at 1 x 10
5 cells per 
ml and 250 l per well added to two wells (1 control and 1 for differentiation) of 
a 48 well plate.  The cells were incubated overnight and viewed under an 
inverted microscope to ensure 100% confluence prior to the addition of 
differentiation medium.  250 l per well of adipogenic differentiation medium or 
α MEM basal medium (control) was added and replaced twice a week for 21 
days.  The cells were observed daily for the appearance of lipid vacuoles in the 
cytoplasm. 
The media was aspirated and discarded and each well washed twice with 0.5ml 
of D PBS ( Ca
2+,  Mg
2+).  The cells were fixed by adding 0.5ml of 10% Formalin 
solution and incubating at RT for 30 minutes.  During fixation a working solution 
of Oil Red O was prepared by adding three parts Oil Red O stock solution (0.5g 
Oil Red O in 99% isopropanol) to two parts dH2O and filtering through a folded 
Whatman #1 filter paper.  The formalin was aspirated and 0.5ml of Oil Red O 
working solution added to each well and incubated at RT for 20 minutes on a 
plate shaker.  The stain was aspirated completely, the cells washed twice with Malcolm B Will 2010     Chapter 2, 67 
dH2O and 0.5ml dH2O added to each well to keep the cells moist.  Lipid vacuoles 
stain bright red when viewed under an inverted microscope. 
The immunofluorescence protocol provided with the Human Mesenchymal Stem 
Cell Functional Identification Kit was then followed.  Briefly, media was 
discarded and each well washed twice with 0.5ml of D PBS ( Ca
2+,  Mg
2+).  The 
cells were fixed by adding 0.5ml of 10% Formalin solution and incubating at RT 
for 10 minutes.  Cells were then washed three times with 1ml 1% BSA D PBS ( 
Ca
2+,  Mg
2+).  The cells were permeabilized and blocked using 0.5ml of 0.3% 
Triton X 1% BSA 10% Donkey serum D PBS ( Ca
2+,  Mg
2+) and incubating at RT for 
45 minutes.  300 l of FABP4 Ab (1 g per 100 l) in 1% BSA 10% Donkey serum D 
PBS ( Ca
2+,  Mg
2+) was then added to each well and incubated for 1 hour at RT.  
Cells were washed three times with 1ml 1% BSA D PBS ( Ca
2+,  Mg
2+).  300 l of a 
TRITC conjugated donkey anti goat secondary Ab (15 g per ml) was added to 
each well and incubated in the dark for 1 hour.  Cells were washed a further 
three times with 1ml 1% BSA D PBS ( Ca
2+,  Mg
2+), mounted in DAPI and cover 
slipped before viewing. 
2.2.3.2  Osteogenic Differentiation and Detection 
Passaged MSC’s were re suspended in α MEM basal medium at 2 x 10
4 cells per 
ml and 250 l per well added to two wells (1 control and 1 for differentiation) of 
a 48 well plate.  The cells were incubated overnight and viewed under an 
inverted microscope to ensure 50 70% confluence prior to the addition of 
differentiation medium.  250 l of osteogenic differentiation medium was added 
and replaced twice a week for 21 days.  The cells were observed daily for 
increasing granularity in the cytoplasm. 
The media was aspirated and discarded and each well washed twice with 0.5ml 
of D PBS ( Ca
2+,  Mg
2+).  The cells were fixed by adding 0.5ml of ice cold 70% 
Ethanol and incubating a 4ºC for 30 minutes.  To prepare the stain, 0.5g of 
Alizarin Red S was added to 50ml of distilled H2O and 1% Ammonium Hydroxide 
solution added drop wise to achieve a pH of 4.2.  The fixative was discarded, 
cells washed twice with distilled H2O and 0.5ml of the stain added to each well.  
The cells were incubated at RT for 30 minutes on a rocker platform.  The stain Malcolm B Will 2010     Chapter 2, 68 
was discarded and the cells washed twice with distilled H2O.  Areas of calcium 
deposition appeared bright red when viewed under an inverted microscope. 
The immunofluorescence protocol provided with the Human Mesenchymal Stem 
Cell Functional Identification Kit was then followed.  Briefly, media was 
discarded and each well washed twice with 0.5ml of D PBS ( Ca
2+,  Mg
2+).  The 
cells were fixed by adding 0.5ml of 10% Formalin solution and incubating at RT 
for 10 minutes.  Cell were then washed three times with 1ml 1% BSA D PBS ( 
Ca
2+,  Mg
2+).  The cells were permeabilized and blocked using 0.5ml of 0.3% 
Triton X 1% BSA 10% Donkey serum D PBS ( Ca
2+,  Mg
2+) and incubating at RT for 
45 minutes.  300 l of Osteocalcin Ab (1 g per 100 l) in 1% BSA 10% Donkey serum 
D PBS ( Ca
2+,  Mg
2+) was then added to each well and incubated for 1 hour at RT.  
Cells were washed three times with 1ml 1% BSA D PBS ( Ca
2+,  Mg
2+).  300 l of 
FITC conjugated donkey anti mouse secondary Ab (15 g per ml) was added to 
each well and incubated in the dark for 1 hour.  Cells were washed a further 
three times with 1ml 1% BSA D PBS ( Ca
2+,  Mg
2+), mounted in DAPI and cover 
slipped before viewing. 
2.2.3.3  Chondrogenic Differentiation and Detection 
Passaged MSC’s were re suspended in MSC medium at 2.5 x 10
5 cells per ml and 
1ml transferred to a 15ml conical tube.  The cells were centrifuged at 200 x g 
for 5 minutes and re suspended in DMEM/F 12 basal medium.  The above step 
was repeated although the cells were not resuspended although media was 
replaced with either 0.5ml Chondrogenic differentiation medium or DMEM/F 12 
basal medium (control).  The cell pellets were then cultured for 24 days with 
media changed twice a week. 
At the end of the culture period media was discarded and cell pellets washed 
once with D PBS ( Ca
2+,  Mg
2+).  The pellets were fixed by incubating in 0.5ml 
10% Formalin solution overnight and processed by an ethanol dilution series and 
paraffin embedding. The pellets were then cut into 2 M sections and mounted 
on sialene coated slides.  Proteoglycans found in cartilage, such as chondroitin 
sulphate were detected in the pellets using Alcian blue and a baseline stain with 
Haematoxylin and Eosin (H+E) was performed to demonstrate basophilic 
structures purple (nuclei) and eosinophilic structures pink (intra and Malcolm B Will 2010     Chapter 2, 69 
extracellular proteins).  The protocol was performed by Histology services, 
Beatson Institute, Glasgow. 
To perform immunofluorescence, the paraffin mounted sections were 
deparaffinised in an ethanol dilution series (provided by Department of Surgery, 
Glasgow Royal Infirmary) and then rinsed with de ionised water.  Slides were 
transferred to D PBS ( Ca
2+,  Mg
2+) for 5 minutes and permeabilized and blocked 
using 0.5 ml of 0.3% Triton X 1% BSA 10% Donkey serum D PBS ( Ca
2+,  Mg
2+) and 
incubating at RT for 45 minutes.  Slides were dabbed dry and the section 
encircled using a hydrophobic pen.  150 l of Aggrecan Ab (1 g per 100 l) in 1% 
BSA 10% Donkey serum D PBS ( Ca
2+,  Mg
2+) was added to each slide and 
incubated for 1 hour at RT.  Slides were washed three times with 1ml 1% BSA D 
PBS ( Ca
2+,  Mg
2+).  150 l of TRITC conjugated donkey anti goat secondary Ab 
(15 g per ml) was added to each slide and incubated in the dark for 1 hour.  
Slides were washed a further three times with 1ml 1% BSA D PBS ( Ca
2+,  Mg
2+) 
and sections mounted in DAPI and cover slipped before viewing. 
2.2.4 Senescence Associated β-Galactosidase Staining of MSC’s 
Senescence associated β galactosidase (SA β Gal) activity at pH 6.0 is used as a 
marker of senescence and is thought to represent the increase in lysosomal mass 
found in senescent cells.  The enzyme is found in lysosomal compartments and 
has an optimal pH of 4   4.5.  When β galactosidase cleaves the colourless 
substrate X gal (5 bromo 4 chloro 3 indolyl β–galactopyranoside), galactose and 
an insoluble blue coloured dye are produced with the intensity of the blue stain 
a measure of enzyme expression within cells.  The Senescent Cells Staining Kit 
(Sigma) for the detection of β galactosidase activity at pH 6.0 was used 
following the manufacturers protocol. 
Passaged MSC’s were re suspended at 5 x 10
4 cells per ml in MSC medium and 
1ml aliquots added to 3 wells of a 24 well plate.  Empty wells were filled with D 
PBS ( Ca
2+,  Mg
2+) and the cells were incubated overnight.  The following day, 
media was removed and the cells washed twice with 1ml D PBS ( Ca
2+,  Mg
2+).  
The cells were fixed by adding 300 l 1X Fixation buffer to each well and 
incubating for 7 minutes at RT.  During this time, the staining mixture was made 
up containing: 500 l 10X staining solution, 62.5 l reagent B, 62.5 l Reagent C, Malcolm B Will 2010     Chapter 2, 70 
125 l X gal solution (pre warmed for 1 hour in a 37ºC waterbath) and 4.25ml H20 
and passed through a 0.2 m filter.  After incubation, fixative was removed and 
the cells washed 3 times with 1ml D PBS ( Ca
2+,  Mg
2+).  300 l of staining mixture 
was added to each well and the plates were wrapped in foil and incubated at 
37ºC without C02 for 16hours (important as the stain is pH specific).  The staining 
mix was removed and replaced with dH2O and the cells viewed under an inverted 
microscope at 10x magnification.  At least 300 cells in random fields were 
counted, and the number cells staining blue and total counted were used to 
calculate the percentage of senescent (β galactosidase positive) cells. 
2.2.5 H2AX Detection by Immunofluorescence  
Passaged MSC’s were re suspended in MSC media at 1 x 10
5 viable cells per ml 
and 1ml added to 4 well chamber slides.  The next day positive controls were set 
up by incubating some wells for 1 hour in 3ml MSC media containing 75 M H2O2 
or exposure to U.V irradiation (200,000J) using a Strata linker.  The media in 
each well was discarded and the cells washed twice in PBS and allowed to 
recover over 1 hour in fresh MSC media.  The immunofluorescence protocol used 
for the differentiation studies was the followed.  Briefly, media was discarded 
and each well washed twice with 0.5ml of D PBS ( Ca
2+,  Mg
2+).  The cells were 
fixed by adding 0.5ml of 10% Formalin solution and incubating at RT for 10 
minutes.  Cell were then washed three times with 1ml 1% BSA D PBS ( Ca
2+,  
Mg
2+).  The cells were permeabilized and blocked using 0.5 ml of 0.3% Triton X 
1% BSA 10% Donkey serum D PBS ( Ca
2+,  Mg
2+) and incubating at RT for 45 
minutes.  250 l of H2AX Ab (2 g per ml in 1% BSA 10% Donkey serum D PBS ( 
Ca
2+,  Mg
2+) was then added to each well and incubated for 1 hour at RT.  Cells 
were washed three times with 1ml 1% BSA D PBS ( Ca
2+,  Mg
2+).  300 l of a 1:100 
dilution of FITC conjugated donkey anti mouse secondary was added to each 
well and incubated in the dark for 1 hour.  Cells were washed a further three 
times with 1ml 1% BSA D PBS ( Ca
2+,  Mg
2+), mounted in DAPI and cover slipped 
before viewing. Malcolm B Will 2010     Chapter 2, 71 
2.3 Molecular Biology Methods 
2.3.1 Cell Pellets for Storage 
Harvested cells that were required for subsequent RNA extraction were washed 
twice in ice cold PBS and spun at 200 x g for 10 minutes. The pellet was then 
air dried and snap frozen in liquid nitrogen.  The pellet was stored at  70ºC until 
further use. 
2.3.2 Extraction of RNA 
Before extraction, surfaces and pipettes were wiped with RNaseZap to remove 
traces of RNase’s.  RNase free pipette tips were used and microcentrifuge tubes 
were pre treated with DEPC water (Add 0.1% DEPC to dH20.  Bring the DEPC into 
solution and incubate at 37ºC for 12 hours, then autoclave the solution for 15 
minutes to remove DEPC).  Total RNA was extracted using the techniques 
described below. 
2.3.2.1  RNA isolation using TRIzol
® reagent 
In a fume hood, TRIzol
® reagent was allowed to warm to RT and 1ml added to a 
snap frozen cell pellet which was then homogenised by repetitive pipetting.  The 
sample was incubated for 5 minutes and transferred to a 1.5ml micro centrifuge 
tube.  200 l of chloroform was added and the tube shaken by hand for 15 
seconds.  Incubate for a further 2 3 minutes and then centrifuge at 4°C 12000 x g 
for 15 minutes.  Remove the upper aqueous layer into a new tube, add 500 l 
isopropylalcohol and incubate for 10 minutes.  The interface contains proteins 
and the lower layer genomic DNA.  Centrifuge the tube at 4°C 12000 x g for 10 
minutes and remove the supernatant without disturbing the pellet.  Add 1.2ml 
70% ethanol and mix by vortex.  Centrifuge 4°C 7500 x g for 5 minutes.  Discard 
the ethanol and allow the pellet to air dry.  The RNA is dissolved in RNase free 
water and heated to 55°C to aid solubilisation.  The sample is divided into 
multiple aliquots and stored at  70ºC. Malcolm B Will 2010     Chapter 2, 72 
2.3.2.2   RNA Extraction by Nucleospin RNA II kit 
Total RNA was isolated from snap frozen cell pellets as per the manufacturer’s 
instructions (Macherey Nagel).  Approximately 1 x 10
6 cells were lysed by 
addition of 350 l of buffer RA1 and 3.5 l β mercaptoethanol and vortexing.  The 
lysate was homogenised by passing through a 21 gauge needle 5 to 6 times and 
then applied to a NucleoSpin filter which contains the silica membrane.  
Contaminating genomic DNA, which is also bound to the silica membrane, was 
removed by treatment with DNase 1 solution for 15 minutes at RT.  Salts, 
metabolites and macromolecular cellular components were removed in 
subsequent wash steps and pure RNA eluted under low ionic strength conditions 
with RNase free water.  The sample is divided into multiple aliquots and stored 
at  70ºC. 
2.3.3 Assessment of RNA quality 
RNA quality was assessed using the following three techniques: 
2.3.3.1  Genequant DNA/RNA calculator 
The instrument was first calibrated with a blank and samples transferred to 
quartz capillary tubes for measurement.  Optical density measurements were 
taken at 260nm.  An OD measurement of 1 at 260 (A260=1) corresponds to a 
concentration of approximately 50 g per ml double stranded DNA or 40 g per ml 
RNA.  The ratio between the readings at 260nm and 280nm (OD260:280) provides a 
measure of the sample purity.  Samples of RNA with an OD260:280 of 2.0 to 2.2 
were of sufficient quality to be used for the techniques described in this 
research. 
2.3.3.2  Agilent 2100 Bio-analyser 
The integrity of the RNA was observed on an Agilent 2100 Bioanalyser using the 
RNA 6000 LabChip™ kit.  The LabChip™ contains multiple micro channels etched 
into glass, and the channels are filled with a sieving polymer containing a 
fluorescent dye and molecular weight marker.  The RNA is separated 
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well is required for analysis and up to twelve samples can be analysed at once 
with results generated within thirty minutes.  The RNA components are detected 
by fluorescence and translated into virtual gel images, sized and quantified in 
relation to internal standards.  In addition, the software will analyse the 
electropherogram and generate an RNA integrity (RIN) number that can provide 
a numerical assessment of RNA integrity.  RNA samples used for this study 
displayed two discrete ribosomal peaks, RNA ratio of between 2.0 and 2.2 and 
RIN values close or equal to 10.  The samples and chips were prepared according 
to the manufacturer’s instructions.  
2.3.3.3  NanoDrop ND-1000 Spectrophotometer 
The Nanodrop ND 1000 spectrophotometer will measure RNA concentrations over 
a range of 2 3000ng per  l with a typical coefficient of variation of 2%.  The 
instrument automatically calculates the high concentration and utilises the 
0.2mm path length to calculate the absorbance.  RNA was analysed following the 
manufacturer’s protocol.  Briefly, within the ND 1000 software Nucleic Acid 
application module, sample type was set to RNA 40.  The instrument was 
calibrated with a blank and 1.5 l of RNA sample measured on the pedestals as a 
fluid column.  Pedestals were wiped with a paper towel between samples to 
prevent carry over.  Spectral measurement for each sample is rapid (less than 
ten seconds) and absorbance spectrum, OD260:280 ratio and RNA concentrations 
are displayed as a printable report.  An OD260:280 of between 2.0 and 2.2 were 
used as a measure of sufficiently good quality RNA to be used for the techniques 
described in this research. 
2.3.4 cDNA Synthesis 
cDNA was prepared using the High Capacity cDNA Reverse Transcription kit 
(Applied Biosystems) as per the manufacturer’s instructions.  Stored, high 
quality RNA was adjusted to 1 g in 10 l RNase free H2O.  Low concentration RNA 
samples were scaled up.  Reactions were prepared in a PCR workstation 
(Labcaire) using RNase free tubes and tips which were UV cross linked prior to 
use.  The RT master mix was made up on ice and contained 2 l 10X RT buffer, 
0.8 l 25X dNTP Mix (100mM), 2 l 10X RT Random Primers, 1 l MultiScribe
TM 
Reverse Transcriptase and 4.2 l RNase free H2O per reaction.  To the 10 l of Malcolm B Will 2010     Chapter 2, 74 
master mix, 10 l of RNA sample was added and mixed by gentle pipetting.  The 
tubes were sealed and briefly centrifuged.  For each sample a no RT control mix, 
no template RT and no template no RT sample were also prepared.  Samples 
were loaded onto a thermal cycler with the following conditions:  25ºC for 10 
minutes, 37ºC for 120 minutes, 85ºC for 5 secs then 4ºC forever.  1 l of cDNA 
was subsequently used in a GAPDH specific PCR for all RT PCR reaction products 
and analysed on a 1% agarose gel containing ethidium bromide.  This was done to 
determine the generation of cDNA and absence of genomic DNA contamination in 
the RNA sample and kit reagents (including the reverse transcriptase). 
2.3.5 Gel Electrophoresis and UV Documentation 
2.3.5.1  Agarose Gel Electrophoresis 
DNA produced by PCR was analysed using non denaturing agarose gel 
electrophoresis which separates nucleic acids according to size.  Electrophoresis 
grade agarose was added to 0.5X TBE buffer and heated in a microwave oven to 
dissolve the agarose to a final concentration of between 1 and 3% (w/v).  The 
molten gel was allowed to cool to approximately 60ºC then poured into a casting 
tray and left to set.  The gel was run in 0.5X TBE buffer at 100 200V.  For 
loading, the samples were mixed with 1/5 the volume of gel loading buffer.  DNA 
molecular weight standards were run alongside the samples.  To visualise the 
nucleic acids, ethidium bromide (0.5 g per ml) was added to the molten gel and 
after electrophoresis the gel was visualised using UV transillumination. 
2.3.5.2  Polyacrylamide Gel Electrophoresis (PAGE) 
During SAGE, the PCR products and ditags were isolated by 12% PAGE and the 
ligated concatamers were separated by 8% PAGE.  12% PAGE contained 14ml of 
40% polyacrylamide (19:1 acrylamide:bis) and 31.3ml dH2O.  8% PAGE contained 
9.3ml of 40% polyacrylamide (37.5:1 acrylamide:bis) and 36ml dH2O.  To either 
mix, 930 l of 50X Tris Acetate Buffer, 470 l 10% APS and 30 l TEMED were 
added.  The mixture was poured into a vertical gel apparatus and left to 
polymerise for 30 minutes.  The gel was run in 1X TAE buffer at 130 160V for 2 
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minutes in 0.5X TBE containing ethidium bromide then visualised using UV 
transillumination. 
2.3.5.3  UV Gel Transillumination and Documentation 
Analysis and photography of ethidium bromide agarose and polyacrylamide gels 
was performed using the Syngene Gene Genius Bio Imaging System with 
GeneSnap version 6.03 software.  The gel image was printed and saved to file. 
2.3.6 Serial Analysis of Gene Expression Protocol 
The I SAGE Long Kit (Invitrogen) for generating Long SAGE libraries was used 
following the manufacturers protocol as described below. 
2.3.6.1   Preparing Adapter Linked cDNA 
Oligo (dT) beads were re suspended by vortex and 100ml transferred to an 
RNase free siliconized 1.5ml microcentrifuge tube.  The tube was placed on a 
magnetic stand for 2 minutes, the supernatant removed and beads washed with 
500ml of Lysis/Binding buffer (37ºC).  The tube was placed on a magnetic stand 
for 2 minutes. 
To bind the mRNA, 10 50 g total RNA was made up to 1ml in Lysis/Binding 
Buffer, the supernatant removed from the beads and the entire 1ml of RNA 
sample added.  The tube was placed on a rocking platform for 30 minutes at RT 
to ensure mixing of the beads and RNA.  Place the tube on a magnetic stand for 
2 minutes and discard the supernatant.  Beads were washed twice with 1ml of 
Wash Buffer A and once with 1 ml of Wash Buffer B.  The beads were washed a 
further four times with 1X First Strand Buffer. 
The following reagents were mixed on ice for first strand synthesis: 18 l 5X First 
Strand Buffer  , 1 l RNaseOUT, 54.5 l DEPC Water, 9 l 0.1 M DTT and 4.5 l dNTP 
Mix (10mM). Supernatant was discarded and the beads re suspended in first 
strand mix (87.0 l) by slow vortex.  The tube was incubated for 2 minutes at 
37ºC and 3 l SuperScript II Reverse Transcriptase added.  The tube was then 
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The tube was chilled on wet ice for 2 minutes and the following added in order 
for second strand DNA synthesis: 465 l DEPC Water, 150 l 5X Second Strand 
Buffer, 15 l dNTP Mix (10mM), 5 l E.Coli DNA Ligase, 20 l E.Coli DNA 
Polymerase and 5 l E.Coli RNase H.  Mix by vortex and pulse centrifuge to gather 
the beads. The tube was incubated at 16ºC for 2 hours with mixing by slow 
vortex every 15 minutes.  The reaction tube was placed on ice and 45 l 0.5M 
EDTA added to stop the reaction.  The tube was placed on a magnetic stand for 
2 minutes and the supernatant removed.  The beads were washed with 750 l of 
warm Wash Buffer C (75ºC) and the sample heated to 75ºC for 12 minutes to 
inactivate the polymerase.  The beads were washed again with 750 l Wash 
Buffer C and then three times in Wash Buffer D.  The beads were re suspended 
in Wash Buffer D and a small sample (5 l) removed and stored at 4ºC for 
verification of cDNA synthesis in a separate PCR reaction.  The tube was placed 
back on a magnetic stand and the supernatant discarded.  The beads were re 
suspended in 200 l of 1X Buffer 4 and transferred to a new tube.  The old tube 
was washed once with 200 l of 1X Buffer 4 which was then transferred to a new 
tube.  The tube was placed on a magnetic stand for 2 minutes and the 
supernatant discarded.  The beads were washed once more in 200 l of 1X Buffer 
4 and the tube placed on a magnetic stand. 
To digest the cDNA with Nla III, the supernatant was discarded and the beads re 
suspended in the following mix: 172 l LoTE, 2 l 100X BSA, 20 l 10X Buffer 4 and 
6 l Nla III.  The reaction was incubated at 37ºC for 1 hour and mixed by 
occasional slow vortex.  The Nla III was then inactivated by washing twice with 
750 l warm Wash Buffer C (37ºC).  The beads were then washed three times 
with 750 l of Wash Buffer D and re suspended in 750 l Wash Buffer D.  5 l of the 
sample was removed and stored at 4ºC to determine the efficiency of Nla III 
digestion in separate PCR reaction.  Store the tube at 4ºC overnight and continue 
the protocol the following day. 
2.3.6.2   Preparing Ditags 
To ligate the LS adapters to the cDNA, the sample tube was placed on a 
magnetic stand for 2 minutes and the supernatant removed.  The beads were 
washed twice with 150 l 1X Ligase Buffer, re suspended in 100 l of 1X Ligase 
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tubes were washed once with 50 l 1X Ligase buffer, placed on a magnetic stand 
for 2 minutes and the supernatant discarded.  The tubes were placed on ice and 
14 l LoTE and 2 l 10X Ligase Buffer added.  1.5 l LS Adapter A (40ng per  l) was 
added to tube A and 1.5 l LS Adapter B (40ng per  l) to tube B.  The beads were 
re suspended and heated to 50ºC for 2 minutes, cooled at RT for 15 minutes and 
then placed on wet ice.  2.5 l of T4 DNA Ligase was added to each tube and 
incubated at 16ºC for 2 hours.  Both tubes were washed three times with 500 l 
of Wash Buffer D and the beads re suspended in 500 l of Wash Buffer D.  A 5 l 
sample was removed and stored at 4ºC for use in a separate PCR reaction to 
confirm ligation of the adapters. 
To releases the adapter and a short tag of cDNA from the beads, the ligation 
products were digested with Mme I.  A solution of 10X SAM (400 M) was prepared 
by adding 1 l 32mM SAM to 79 l DEPC H2O.  A solution of 1X Buffer 4/1X SAM was 
prepared by adding 1 l 32mM SAM and 799 l 1X Buffer 4.  Tubes A and B were 
placed on a magnetic stand for 2 minutes and the supernatant discarded.  Each 
tube was washed twice with 200 l of 1X Buffer 4/1X SAM, the supernatant 
discarded and the tubes placed on wet ice.  The following reagents were added 
to each tube: 70 l LoTE, 10 l 10X Buffer 4, 10 l 1X SAM (400mM) and 10 l Mme I.  
The tubes were incubated at 37ºC for 2.5 hours and occasionally mixed.  The 
tubes were placed on a magnetic stand for 2 minutes and the supernatant 
(100 l) removed and transferred to two new microcentrifuge tubes.  Do not 
discard the supernatant at this stage because it contains the tags. 
The tags were pooled by combining supernatants into tube B and washing tube A 
once with 100 l LoTE (final volume tube B is 300 l) and then ethanol 
precipitated.  300 l Phenol/Chloroform (P/C) was added and mixed well by 
vortex.  The tube was centrifuged at 13200rpm for 5 minutes at RT.  The upper 
aqueous phase (300 l) was transferred to a new tube and 200 l removed to a 
new tube to be used as the template.  100 l DEPC H2O was added to the other 
100 l and used as a negative control.  To each tube was added: 133 l ammonium 
acetate (7.5M), 3 l mussel glycogen and 1ml 100% ethanol.  Tubes were 
vortexed, placed on dry ice for 20 minutes and centrifuged at 15400rpm for 30 
minutes at 4ºC.  Supernatants were discarded and the pellets washed twice with 
1ml ice cold 70% ethanol.  The ethanol was discarded and the pellets allowed to 
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in 4 l and 2 l LoTE respectively, and dissolved by incubation at 37ºC for 15 
minutes. 
Tags were ligated to form ditags by setting up the following reactions on ice: 
1.  2X Ditag reaction: 1.5 l 3mM Tris HCl (pH 7.5), 0.9 l 10X ligase buffer, 
0.9 l DEPC H2O and 1.2 l T4 DNA ligase. 
2.  2X Negative control: 2.25 l 3mM Tris HCl (pH 7.5), 0.75 l 10X ligase 
buffer and 0.75 l DEPC H2O. 
4 l of the 2X Ditag reaction mix was added to the tags re suspended in 4 l LoTE 
(template) and 2 l of 2X Negative control mix added to the negative control (no 
ligase).  Tubes were incubated at 16ºC overnight. 
2.3.6.3   Amplifying Ditags 
After the overnight incubation, 6 l LoTE was added to the sample and 10 l LoTE 
to the negative control (no ligase).  To optimise the Ditag PCR and avoid cross 
contamination, the negative control and sample were transferred to separate 
PCR workstations and the following diluted in sterile H2O: 
1.  Negative control (no ligase) to 1/20 at Location 1. 
2.  Template (ligated product) to 1/20, 1/40, and 1/80 at Location 2. 
3.  LS Control Template (supplied at 10pg/ml) to 1/10 at Location 1. 
Six tubes were set up on ice containing either 1 l of the negative control (no 
ligase), diluted templates, LS control template (positive control) or H2O 
(negative control, no template) and 49 l of a PCR master mix containing: 5 l 
10X BV Buffer, 3 l DMSO, 7.5 l dNTP mix (10mM), 2 l LS DTP 1, 2 l LS DTP 2, 
29 l DEPC H2O and 0.5 l Platinum
® Taq DNA polymerase.  The tubes were mixed, 
pulse centrifuged and amplified on a thermal cycler using the following cycling 
parameters: 95ºC 2 minutes (1 cycle); 95ºC 30 seconds, 55ºC 1 minutes and 70ºC 
1min (25 35 cycles) and 70ºC for 5 minutes (1 cycle).  PCR products were 
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ditag band (130bp) and a faint smaller band (100bp) containing adapter 
sequences without any transcript sequence should be seen and the negative 
controls free of contamination. 
After optimisation, the ditags were scaled up in 600 reactions.  A PCR master 
mix was made up on ice in a 25ml Universal container with the following 
reagents: 3ml 10X BV Buffer, 1.8ml DMSO, 1.2ml LS DTP 1,1.2ml LS DTP 2, 18ml 
DEPC H2O and 300 l Platinum
® Taq DNA polymerase.  50 l of the PCR mix was 
added to wells 1A and 12H of a 96 well PCR plate and 1 l of the 1:10 LS Control 
template (positive control) added to 1A and 1 l DEPC H2O added to 12H.  All the 
diluted and undiluted ditag templates were then added to the PCR master mix, 
mixed well and 50 l added to the remaining wells and another five 96 well PCR 
plates.  The plates were sealed with adhesive PCR film, briefly centrifuged and 
amplified on a thermal cycler using the following parameters: 95ºC 2 minutes (1 
cycle); 95ºC 30 seconds, 55ºC 1 minutes and 70ºC 1minute (27 cycles) and 70ºC 
for 5 minutes (1 cycle).  5 l of the PCR products from 5 random wells and the 
controls were combined with 1ul PCR dye and analysed on a 3% agarose gel. The 
96 well plates were stored at  20ºC overnight. 
2.3.6.4   Isolating the 130bp Ditags 
The ditags were pooled by thawing the six 96 well plates on ice and combining 
the PCR products into two 50ml tubes (discard the control templates!).  12.5ml 
of P/C was added to each tube which was then vortexed and centrifuged at 
2000rpm for 10 minutes at RT.  The upper aqueous phase (~12.5ml) from each 
tube was transferred to two clean 50ml tubes and the following reagents added: 
3.2ml ammonium acetate (7.5M), 48 l mussel glycogen and 34ml 100% ethanol.  
The tubes were vortexed, placed on dry ice for 20 minutes and centrifuged at 
4000rpm for 30 minutes at 4ºC.  The supernatant was discarded and the pellets 
washed twice with 25ml ice cold 70% ethanol by vortex and centrifuged at 
4000rpm for 5 minutes at 4ºC.  The ethanol was discarded and the pellets air 
dried for 30 minutes.  The ditags were dissolved by vortex and incubation at 
37ºC in LoTE (300 l) for 15 minutes. 
The ditags were purified by combining the entire ditag sample (300 l) with 60 l 
PCR dye and loading multiple wells of a large format 12% polyacrylamide gel.  Malcolm B Will 2010     Chapter 2, 80 
The gel was electrophoresed until the bromophenol blue dye front ran off the 
gel and the xylene cyanol dye front was 2cm from the bottom of the gel.  The 
gel was removed and stained in buffer containing ethidium bromide. 
To elute the DNA from the gel, the 130bp bands were excised from the gel using 
a scalpel in a dark room under U.V light.  The gel was divided into small pieces 
and added to 0.5ml microcentrifuge tubes with holes in the bottom (made using 
a green needle) and placed within a 1.5ml microcentrifuge tube.  To break up 
the gel, the tubes were centrifuged at 13200rpm RT for 3 minutes and the gel 
collected in the lower tube.  150ul of 5:1 LoTE: ammonium acetate (7.5M) mix 
was added and the tubes vortexed.  To elute the DNA the tubes were incubated 
at 65ºC in a water bath for 2 hours.  The contents of two tubes were combined 
into a S.N.A.P™ column fitted to a collection tube and centrifuged at 13200rpm 
for 2 minutes.  All eluates were combined and 300ml aliquots put into new 1.5 ml 
tubes. 
To precipitate the DNA, the following reagents were added to each 300 l 
aliquot: 133 l ammonium acetate (7.5M), 3 l mussel glycogen and 1ml 100% 
ethanol.  The tubes were vortexed, placed on dry ice for 20 minutes and 
centrifuged at 15400rpm for 30 minutes at 4ºC.  The supernatant was discarded 
and the pellets washed twice with 500 l of ice cold 70% ethanol.  The ethanol 
was discarded and the pellets allow to air dry over 30 minutes.  14 l of LoTE was 
added to each pellet and the pooled into one tube (~126ml).  The tube was 
stored at –20ºC overnight. 
2.3.6.5   Isolating the 34-bp Ditags 
34bp tags were produced by Nla III digestion of the 130 bp product.  126 l of 
130bp ditags from the previous day were mixed with the following reagents: 45 l 
10X buffer 4, 6 l 100X BSA, 36 l Nla III and 237 l DEPC H2O.  The tube was 
incubated at 37ºC for 2 hours.  150 l aliquots were transferred to 3 sterile tubes 
and 50 l LoTE added to each.  A 5 l sample from 1 tube was analysed on a 3% 
agarose gel to assess Nla III digestion efficiency and we carried on to ethanol 
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200 l of P/C was added to each tube and the tubes centrifuged at 13200rpm for 
5 minutes RT.  The upper aqueous phase (200 l) was transferred to three new 
tubes and the following added: 90 l ammonium acetate (7.5M), 3 l mussel 
glycogen and 850 l 100% ethanol.  The tubes were place on dry ice for 20 
minutes and centrifuged at 154000rpm for 30 minutes at 4ºC.  Pellets were 
washed twice with 1ml ice cold 70% ethanol and allowed to air dry at RT for 30 
minutes.  The pellets were dissolved in 10.8 l LoTE and combined into one tube 
(total volume 32 l). 
The 34bp ditags were purified by combining with 8 l PCR dye and loading 6 wells 
of a 12% polyacrylamide gel (1mm cassette) containing molecular weight 
ladders.  Electrophoresis was performed in 1X TBE buffer at 200V for 1 hour.  
The gel was removed from the cassette and stained in buffer containing 
ethidium bromide on a rocking platform for 15 minutes. 
In a dark room and under U.V light, the 34bp region was excised from the gel 
using a scalpel.  Small gel pieces were placed in 0.5ml tubes with holes in the 
bottom (made by a green needle) within a 1.5ml tube and centrifuged at 
13200rpm for 2 minutes to break up the gel.  To each tube was added 150 l of a 
5:1 LoTE: ammonium acetate (7.5M) mix (125ml: 25ml) mix and mixed by vortex.  
The tubes were incubated at 37ºC in a water bath for 2 hours to elute the DNA 
from the gel. 
The eluates were combined into S.N.A.P™ columns fitted to a collection tubes 
and centrifuged at 13200rpm for 2 minutes.  The eluate (up to 900ml) was 
combined and 200 l aliquots added to fresh 1.5ml microcentrifuge tubes. 
To precipitate the DNA, to each 200 l was added: 90 l ammonium acetate 
(7.5M), 3 l mussel glycogen and 850 l 100% ethanol.  The tubes were vortexed, 
placed on dry ice for 20 minutes and centrifuged at 15400rpm for 30 minutes at 
4ºC.  The supernatant was discarded and the pellets washed twice with 1ml of 
ice cold 70% ethanol.  Discard the ethanol and air dry the pellets for 20 minutes 
on ice.  The pellets were pooled, re suspended in 7.75 l of LoTE and 1 l of 10X 
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2.3.6.6   Forming Concatamers 
1.25 l T4 DNA Ligase was added to 8.75 l of the 34bp DNA on ice.  The tube was 
incubated at 16ºC for 3 hours on a thermal cycler.  2.4 l of PCR Dye was added 
to the mix and heated to 65ºC for 10 minutes on a thermal cycler.  The reaction 
mix was pulse centrifuged and the entire sample loaded in one well of an 8% 
polyacrylamide gel (1mm cassette) along with molecular weight markers.  
Electrophoresis was performed in 1X TBE Buffer for ~ 1hour at 200V.  The gel 
was removed from the cassette and stained in buffer containing ethidium 
bromide (1 g/ml) on a rocking platform for 15 minutes. 
In the dark room and under U.V light, the concatamer ‘smear’ was excised and 
divided approximately into the following three regions: 
1.  300 – 500bp 
2.  500 – 800bp 
3.  800 – 1kb 
Each region was divided into two pieces and placed in a 0.5ml tube with a hole 
in the bottom (made using a green needle) within a labelled 1.5ml tube to 
identify the gel region.  The gel was broken up by centrifuging at 13200rpm for 5 
minutes at RT.  200 l of a 5:1 LoTE: ammonium acetate (7.5M) mix was added to 
each tube and mixed by vortex.  To elute the DNA the tubes were incubated at 
65ºC in a water bath for 2 hours.  The contents of each tube were transferred to 
three S.N.A.P™ columns fitted to collecting tubes and centrifuged at 13200rpm 
for 2 minutes at RT. The eluate (200 l) from each tube was transferred to three 
fresh, labelled 1.5ml microcentrifuge tubes. 
To ethanol precipitate the DNA, 200 l of P/C was added to each tube and mixed 
by vortex.  The tubes were centrifuged at 13200rpm for 5 minutes at RT and the 
upper aqueous layer (200 l) transferred to new labelled 1.5 ml tubes.  The 
following reagents were added to each tube: 133 l ammonium acetate (7.5M), 
3 l mussel glycogen and 1ml 100% ethanol.  The tubes were mixed by vortex, 
placed on dry ice for 20 minutes and centrifuged at 15400rpm for 30 minutes at Malcolm B Will 2010     Chapter 2, 83 
4ºC.  The pellets were washed twice with 1ml ice cold 70% ethanol and air dried 
for 20 minutes.  Each pellet was re suspended in 6ml of LoTE and stored at  20ºC. 
2.3.6.7  Cloning Concatamers into pZERO
®-1 
The pZERO
® 1 vector was linearised by Sph I as recommended in the protocol.  A 
tube containing the following reagents was set up on ice: 2 l pZERO
® 1 
(1 g/ml), 2.5 l 10X buffer 2, 1.4 l Sph I and 19.1 l sterile H2O.  The tube was 
incubated at 37ºC for exactly 30 minutes.  175 l LoTE was added to the digestion 
mix and 200 l P/C and mixed by vortex.  The tube was centrifuged at 13200rpm 
for 3 minutes at RT.  The aqueous upper layer (200 l) was transferred to a new 
tube and the following added: 65ml ammonium acetate (7.5M), 1.5 l mussel 
glycogen and 600 l 100% ethanol.  The tube was mixed by vortex, placed on dry 
ice for 10 minutes and centrifuged at 15400rpm for 30 minutes at 4ºC.  The 
supernatant was discarded, the pellet washed twice in ice cold 70% ethanol and 
allowed to air dry for 10 minutes.  The pellet was re suspended in 60ml of LoTE 
and 10 l aliquots stored at –20ºC.  To check the efficiency of Sph I digestion, 2 l 
of the digestion mixture and undigested pZERO 1 were analysed on a 1% agarose 
gel. 
To ligate the concatamer into pZERO
® 1, 6 l of each concatamer was added on 
ice to separate tubes and the following reagents: 1 l digested pZERO
® 1, 1 l 10X 
ligase buffer and 2 l T4 DNA ligase.  A no DNA and no ligase reaction were also 
set up replacing each reagent with an equivalent volume of H2O.  The tubes 
were incubated at 16ºC for 3 hours on a thermal cycler.  190 l of LoTE and 200 l 
of P/C was added to each tube, mixed by vortex and the tubes centrifuged at 
13200rpm 5 minutes at RT.  The upper aqueous layer was transferred to a clean 
tube and the following added: 133 l ammonium acetate (7.5M), 3 l mussel 
glycogen and 1ml 100% ethanol.  The tubes were mixed by vortex, placed on dry 
ice for 10 minutes and centrifuged at 15400rpm for 30 minutes at 4ºC.  The 
supernatant was discarded and the pellets washed four times with ice cold 70% 
ethanol.  The pellets were air dried for 20 minutes, each one re suspended in 
12 l LoTE and stored at –20ºC. Malcolm B Will 2010     Chapter 2, 84 
2.3.6.8  Making Low Salt LB Plates with Zeocin 
For 1 litre of low salt LB agar, 10g of tryptone, 5 g yeast extract, and 5g sodium 
chloride were dissolved in 950ml dH2O.  The pH of the solution was adjusted to 
7.5 with sodium hydroxide (5M).  15g agar was added and the volume made up to 
1litre.  The broth was divided into two 500ml glass bottles and autoclaved on a 
liquid cycle.  The agar was cooled by placing the bottles in a waterbath at 55ºC.  
Zeocin™ stock solution (100mg/ml) was thawed on ice in the dark and 500 l 
added to the agar (final concentration 50 g/ml).  The agar was mixed and 
poured into 10cm petri dishes and allowed to set at RT.  Once set, the plates 
were inverted and stored at 4ºC in the dark until use. 
 
2.3.6.9  Transformation Reaction  
SOC medium and the low salt LB plates containing Zeocin™ were brought to RT.  
Vials of One Shot Top10 Electrocomp E.Coli were thawed on ice and 1 2 l of the 
ligation reactions added to separate vials containing 40 l electrocompetent 
E.Coli.  The cells were mixed gently, transferred to a chilled 0.1cm cuvette and 
shocked at 1400V using an electroporator (Cell Shock, Hybaid).  The cells were 
recovered in 250 l SOC medium and incubated at 37ºC 300rpm for 1 hour using a 
heated shaker.  A further 750 l SOC medium was added to each tube and mixed.  
200 l of the No DNA and No Ligase transformation reactions and 100 l of the 
concatamer transformation reactions were plated on low salt LB plates 
containing Zeocin™.  All the concatamer transformation reaction was plated out.  
Plates were inverted and incubated at 37ºC overnight.  An efficient ligation 
reaction produced 100 150 colonies per plate, while the controls had less than 
10 colonies per plate. 
2.3.6.10   Screening and Sequencing Clones 
In a PCR workstation, random colonies were picked using a pipette tip and 
placed in a 0.5ml tube containing the following PCR mix: 2.5 l 10X BV buffer, 
1.25 l DMSO, 1.25 l dNTP mix (10mM), 1 l M13 Forward primer (5 M), 1 l M13 
Reverse primere (5 M), 18 l DEPC H2O and 0.2 l Platinum Taq DNA polymerase.  
The tubes containing the tips were kept on an ice block and put on a rotating 
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tubes amplified on a thermal cycler using the following parameters: 94ºC 2 
minutes (1 cycle), 94ºC 30 seconds, 55ºC 1 minute, 70ºC 1 minute (24 cycles) and 
70º 5 minutes (1 cycle). 
4 l of the PCR products were analysed on a 2% agarose gel to determine the size 
and the percent of inserts in the SAGE library.  For large scale PCR, the 
remaining colonies were picked into 96 well plates containing the same PCR mix 
and amplified in a thermal cycler using the above conditions.  1% agarose 
stacking gels were used to analyse two 96 well plates at once and inserts > 
300bp in size put forward for PCR clean up. 
2.3.7  PCR Clean Up 
PCR clean up was performed using the Using ExcelaPure 96 well UF PCR 
Purification Kit and following the manufacturers protocol.  A QIAvac multi well 
vacuum manifold (Qiagen) and pressure regulator was connected to a pump and 
one ExcelaPure 96 well UF Plate positioned on top of the manifold.  The PCR 
products were made up to 100 l with dH2O and transferred to the centre of the 
membranes using a multi channel pipette.  A vacuum of  700mbar was applied 
for 10 minutes to dry the wells.  The wash step was repeated to ensure optimal 
purity of the PCR products for downstream sequencing.  DNA was recovered in 
30 l dH2O by placing on a plate shaker for 10 minutes or repetitive pipetting (20 
times).  Purified PCR products were transferred to a 96 well V bottomed plate, 
sealed with an adhesive cover and stored at –20ºC until sequenced. 
2.3.8 Sequencing of SAGE concatamer inserts 
Cleaned up PCR products of 300 – 1200bp in size were kindly sequenced by the 
staff of the Molecular Services Unit, Beatson Laboratories.  The PCR products 
were sequenced using the BigDye Kit and M13 Forward primer with one tenth of 
the purified PCR product per sequencing reaction. 
2.3.9 SAGE bioinformatics 
Within a concatamer, linked ditags of approximately 34bp length are separated 
by a CATG sequence (the recognition site of Nla III).  SAGE 2000 software uses 
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individual tags.  The software quantifies the number of times the tag occurs 
within a given population of clone inserts to generate a report for the abundance 
of an individual tag.  The report can be exported as a text file and linked to 
gene databases for identification of the gene(s) corresponding to the tags or may 
be used to compare the abundance of tags in different SAGE libraries. 
Within the SAGE 2000 software, a new project was created with the anchoring 
enzyme set as Nla III and the tag length set to 36bp.  Before allowing the 
software to analyse all the sequence files, a few sequences were checked by eye 
to ensure they gave the expected intermittent CATG pattern.  The sequence 
data of clones containing concatenated SAGE ditags was then entered.  The 
SAGE 2000 software extracted tag data from the sequence files and added them 
to the opened project.  After checking for duplicate ditags, individual tags were 
assigned a tag number and recorded.  Tags derived from oligonucleotide linkers 
were excluded from further analysis. 
The SAGE report was saved as both a text file and Microsoft
® Access database 
file, which allowed more complex analysis of the data.  Potential matching 
transcripts were identified by linking the report to the SAGEmap reference 
sequence database (downloaded by anonymous file transfer protocol (FTP) from 
ftp://ftp.ncbi.nlm.nih.gov/pub/sage/mappings/).  The zip file selected was for 
Homo sapiens and the Nla III recognition site (SAGEmap_Hs_NlaIII_full.gz) and 
the file was up to date as of the 26
th September 2007. 
2.3.9.1  Comparison of SAGE libraries 
The SAGE 2000 software was unable to compare libraries using the 17bp tag so 
two published methods (SAGEstat and SAGEGenie) were used with different 
statistical methods.  Previous work has shown that similar results are obtained 
when comparing two SAGE libraries of equivalent size regardless of the 
statistical technique used. 
Differential expression of tags (genes) has been defined in previous SAGE studies 
by various criteria, including: two fold, five fold or ten fold differences in tag 
ratio; p values below 0.05, 0.01 and 0.001; and combinations thereof.  For 
validation purposes, genes differentially expressed more than two fold 
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chapter 5.  For interest, the MSC SAGE libraries were analysed online by pair 
wise comparison with normal tissue, cancer tissue and stem cell SAGE libraries 
available at the SAGE genie website using selected criteria and discussed further 
in chapter 4. 
2.3.10  Quantitative RT-PCR using Taqman Low Density 
Arrays 
The expressions of candidate genes were measured using Taqman
® Low Density 
Array (TLDA) cards (Applied Biosystems). TLDA cards are micro fluidic cards that 
allow 384 reactions to run simultaneously. Each well contains custom made 
lyophilised primers and probes and supplied by 8 ports in total, with each port 
delivering 100 l of a cDNA/PCR master mix to 48 wells (final volume 2 l/well). 
The plate can be custom designed with multiple formats e.g. 12 genes in 
quadruplicate across 8 samples, 96 genes in duplicate across 2 samples or 384 
genes for one sample without replicates.  Either 18S or GAPDH are provided as 
the endogenous control gene, although other candidate housekeeping genes can 
be added to the card so that relative quantification can be performed with 
reference to multiple housekeeping genes.  The genes of interest for this project 
were chosen, ordered and preloaded from a database of ~47,000 optimised 
human, mouse and rat assays (http://www.appliedbiosystems.com).  The 
customised TLDA card ordered had 96 genes enabling analysis of two individual 
cDNA samples in duplicate and 20 cards were supplied.  The cDNA required for 
Taqman was synthesized from 1 g of RNA.  400ng was made up to 200 l in dH2O 
and added to an equal volume of Taqman universal master mix (Applied 
Biosystems, Warrington, UK).  100µl was added to each port equating to 100ng of 
RNA.  The plate was centrifuged twice at 1200rpm for 1 min, sealed and 
analysed using an ABI PRISM 7900HT Fast Real Time PCR system. 
2.3.11  TeloTAGGG Telomere Length Assay 
Genomic DNA was extracted from frozen cell pellets using the DNEasy Blood and 
Tissue Kit (Qiagen) following the manufacturer’s protocol.  Extracted DNA was 
used in the TeloTAGGG Telomere Length Assay (Roche) following the 
manufacturer’s protocol with minor modifications and is briefly described below. Malcolm B Will 2010     Chapter 2, 88 
2.3.11.1  Sample Preparation and Digestion 
All samples were prepared and analysed simultaneously with handling and 
pipetting of solutions performed on ice.  1ul of enzyme mix was used per sample 
(1 l HinfI and 1 l RsaI is enough for two samples) and controls were included.  
Dilute 10 l each control DNA (1 g) with 7ul nuclease free water and dilute 
sample DNA (1 g) with dH2O and to each add 1 l enzyme mix and 2 l 10x 
digestion buffer.  Incubate at 37ºC for 2 hours and stop the reaction by adding 
4ul 5x gel electrophoresis loading buffer.  At this stage samples can be stored at 
4ºC. 
2.3.11.2  Gel Electrophoresis 
Prepare a 0.8% Agarose gel (15cm in length) in 1xTAE buffer.  Mix 4 l DIG 
molecular weight marker, 12 l dH2O and 4 l loading buffer.  Load the 24ul 
samples, and add 4ul 5x gel electrophoresis loading buffer to 10ul of DIG 
molecular weight marker mix & load either side of the sample lanes.  Run the 
gel at 5V per cm in 1x TAE buffer until the bromophenol blue dye has travelled 
10 cm from the wells (2 4 hours). 
2.3.11.3  Blotting 
Submerge the gel in HCl solution for 5 10 minutes until the bromophenol blue 
turns yellow with gentle agitation.  Rinse the gel twice in water and submerge in 
denaturation solution twice for 15 minutes at RT.  Rinse the gel twice in water 
and submerge in neutralisation buffer twice for 15 minutes at RT.  Blot the gel 
onto a nylon membrane overnight by capillary transfer using 20X SSC as a 
transfer buffer.  After transfer fix the DNA to the membrane by U.V crosslinking 
and then wash the membrane in 2X SSC. 
2.3.11.4  Hybridisation 
Pre warm 50ml DIG Easy Hyb solution to 42ºC and submerge the blot in 35ml of 
this solution and incubate at 42ºC for 30 60 minutes with gentle agitation.  
Prepare telomere hybridisation solution by adding 3ul telomere probe to 15mls 
Easy Hyb solution.  Discard the pre hybridisation solution and immediately add Malcolm B Will 2010     Chapter 2, 89 
the telomere hybridisation solution to the membrane and incubate at 42ºC for 3 
hours (or overnight).  Discard the hybridisation solution and wash the membrane 
twice with stringent wash buffer I for 5 minutes at RT with gentle agitation.  
Wash the membrane twice with stringent wash buffer II for 15 20 minutes at 
50ºC with gentle agitation. 
2.3.11.5  Chemoluminescence Detection 
Rinse the membrane in 200ml 1X washing buffer for 1 5 minutes at RT with 
gentle agitation.  Incubate the membrane in 200mls freshly prepared 1X blocking 
solution for 30 minutes at RT with gentle agitation.  Prepare the anti DIG AP 
working solution immediately before use containing 10mls 10X blocking solution, 
90mls dH2O and 10 l anti DIG AP.  Incubate the membrane in 100mls anti DIG AP 
working solution for 30 minutes at RT with gentle agitation.  Wash the 
membrane twice in 200mls 1X washing buffer for 15 minutes.  Incubate the 
membrane in 200mls 1X detection buffer for 2 5 minutes at RT with gentle 
agitation.  Discard 1X detection buffer and blot the membrane DNA side up on a 
sheet of blotting paper (do not let the membrane dry).  Place the membrane on 
saran wrap and apply 40 drops (~ 3mls) of substrate solution then wrap the 
membrane and incubate for 5 minutes at RT.  Squeeze out the excess liquid and 
seal the edges.  Expose the membrane to x ray film for 5 20 minutes at RT. 
2.3.11.6  Stripping 
Warm 500mls stripping buffer to 37ºC and add 250mls to the membrane and 
wash for 15 minutes with agitation.  Discard the stripping buffer and replace 
with the remaining 250mls and wash for a further 15 minutes with agitation.  
Discard the used stripping buffer and rinse the membrane with 2XSSC then blot 
dry with filter paper and wrap in cling film (store the membrane at RT). 
2.3.11.7  Re-Probing 
Continue from hybridisation section as described above. Malcolm B Will 2010     Chapter 2, 90 
2.3.11.8  Densitometry 
Switch on the densitometer and wait for the lights to stop flashing before 
switching on the computer.  Click on Staff and double click on Quantity One.  
From Volumes Quick Guide, click on Select Scanner.  Select GS-800 from pop up 
and place autorad on scan plate.  Select X-ray film and Blue film.  Click on 
Preview scan and draw a box around the required area of the blot and click on 
Acquire.  Save as a named file then close the scanner window.  Click on View 
and Rotate/Flip until autorad is in the correct orientation.  Save again and from 
drop down menu select Lane, Frame Lanes and enter the number of lanes on the 
gel.  Stretch the frame to fit the gel and place anchors, if necessary, to bend the 
frame to fit the lanes.  Select Bands, Detect bands/Create bands to detect 
bands in the standards lanes.  Remove all bands except the ones in the 
molecular weight marker lanes.  Zoom in to ensure all 21 bands on the markers 
have been identified in the correct places.  Insert extra bands where needed and 
remove any excess.  From the Band analysis quick guide select Standards to 
apply standards values to the marker lanes.  Select Edit then Gel layout and add 
gel description and labels to each lane.  Select Bands then Detect bands, 
Contour and Create contours and highlight smear on the autorad. Select band to 
contour and repeat for all smears.  Save all lanes as a report and export table to 
an external memory stick/drive. 
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3  Characterisation of Mesenchymal Stem Cells 
from Ischaemic Heart Disease Patients 
3.1 Introduction 
The ease of isolation, expansion and differentiation capacity of MSC’s make 
them ideal candidate cells for myocardial repair.  Loss of cardiomyocytes 
following myocardial infarction induces contractile dysfunction of the heart and 
the muscle is gradually replaced with fibroblasts that contribute to scar tissue.  
Animal models have confirmed that the beneficial effects seen after 
intramyocardial or intravascular injection of MSC’s occur via paracrine 
mechanisms that promote angiogenesis and minimise scarring.  Only a small 
number of administered cells engraft and differentiate into endothelial cells or 
cardiomyocytes.  The findings have encouraged researchers to use MSC’s after MI 
in humans and early clinical trials have confirmed small benefits in myocardial 
contractility and perfusion (10;148). 
Although these findings have demonstrated the feasibility of this approach, 
characterisation of administered cells was limited and did not meet the minimal 
criteria agreed by lead researchers in the field (33).  MSC’s were isolated from 
BM using standard methods and the surface marker profiles were typical of 
MSC’s.  However, differentiation studies were not carried out and therefore the 
stem cell characteristics of administered cells remain unknown.  Somewhat 
surprisingly, in the study by Chen et al MSC’s proliferated ten times greater than 
that typically seen by other researchers using similar volumes of BM and culture 
protocols.  The results are in contrast to findings from studies using MSC’s from 
aged donors that demonstrated cells proliferated poorly and appeared senescent 
almost immediately from isolation (11). 
The lack of rigorous characterisation and perceived limitations of MSC’s from 
this patient group has encouraged researchers to derive MSC’s from healthy 
young donors in advance and store the cells as an ‘off the shelf’ allogeneic 
therapy.  This approach has also been encouraged by the unique 
immunosuppressive properties of MSC’s demonstrated in vitro (149;150) although 
recent in vivo studies demonstrated that allogeneic cells were rejected Malcolm B Will 2010    Chapter 3, 92 
suggesting this strategy may be inherently flawed (151;152).  The results could 
explain the low levels of engraftment seen after cell administration in animal 
models and also suggest clinical trials using allogeneic cells are likely to under 
report potential benefits of this therapy. 
Another concern that arises is that medical conditions impact on the absolute 
numbers and function of endogenous stem cell populations and in these patients 
typical MSC properties are lost.  Endothelial progenitor cells (EPC’s) obtained 
from patients with IHD have reduced frequency and impaired functional capacity 
when compared to those obtained from healthy age matched donors (153;154).  
Telomere shortening of peripheral blood MNC’s has been shown to predict the 
development of IHD in healthy subjects suggesting stem cell ageing may be 
linked to the development of the disease (155).  Whether this is a cause or a 
consequence of IHD and other age related conditions remains unknown and 
further research in this area is required to explain these findings. 
Together these results question the suitability of autologous MSC’s from aged 
patients with IHD for clinical application and to address this basic research in 
this area is required.  Therefore, studying autologous MSC’s from patients with 
IHD is essential to not only establish the characteristics of the cells themselves 
but also inform on suitability for clinical use.  In vitro models of MSC ageing 
could also enhance understanding of the molecular mechanisms that regulate 
this process in vitro and also improve our ability to use autologous cells in cell 
based therapies.  The results in this chapter describe the most comprehensive 
characterisation of MSC’s derived from patients with severe IHD undergoing 
coronary artery bypass grafting (CABG). Malcolm B Will 2010    Chapter 3, 93 
3.2  Results 
3.2.1 Donor Characteristics and Isolation of MSC’s 
MSC’s were isolated from thirty patients undergoing CABG and nine were used 
for the work described in this thesis (donors 12 and 23 30).  The characteristics 
of the individual donors are shown in Table 1.  Mean age of the donors was 59.9 
± 9.4 years and all were male except donor 29.  Past medical history included 
smoking, diabetes and hyperlipidaemia which are common risk factors associated 
with IHD.  Donor medications included anti platelet, anti anginal, anti 
hypertensive and lipid lowering therapies which are used for symptom relief and 
secondary prevention.  On average, 13.6 ± 1.2 ml of bone marrow was aspirated 
from three sites of the sternum and yielded a mean of 12.9 ± 13.5 x 10
7 MNC’s 
after density centrifugation.  Two days after plating the MNC fraction, adherent 
spindle shape cells with fibroblastic morphology were indentified as colonies 
that expanded to confluence when the non adherent fraction was removed 
(Figure 3 1 A C).  MSC cultures were heterogeneous in morphology as some cells 
appeared spread out and others were small and round with high nuclear 
cytoplasm ratio (Figure 3 1 D). 
The incidence of true MSC’s in the bone marrow samples was calculated by 
evaluating the ability of the donor MNC samples to form fibroblastic colonies 
using the CFU F assay.  For each sample, MNC’s were plated at three different 
concentrations and Giemsa stained colonies counted (Figure 3 2 A+B).  MNC’s 
from donor 24 contained the most colonies and donor 26 the lowest.  The mean 
number of colonies in the eight samples was 10.1 ± 2.5 per 1 x 10
6 MNC’s giving a 
frequency of ‘true’ MSC’s of 1 in 105,905 MNC’s (range 1 in 75,397 to 1 in 
150,794). 
MSC’s from each donor were cultured to passage two and evaluated for their 
ability to form fibroblastic colonies when plated at low density using the CFE F 
assay.  For each sample, MSC’s were plated at 10 cells per cm
2 in triplicate and 
Giemsa stained colonies counted (Figure 3 3 A+B).  MSC’s from donor 30 
contained the most colonies and donor 28 the lowest.  The mean percentage of 
MSC’s at passage two that formed colonies was 28.7 ± 6.5 %. Malcolm B Will 2010    Chapter 3, 94 
 
Table 1 Donor characteristics Malcolm B Will 2010    Chapter 3, 95 
 
Figure 3-1 MSC’s display characteristic morphology  
Within 48 hours of plating the BM MNC fraction, rare spindle shaped cells were 
identified (black arrow) that were characteristic of MSC’s while most nucleated 
cells were non adherent (green arrow) and red blood cells infrequent (blue 
arrow) (A) (20x).  MSC’s rapidly expanded from single colonies after the first 
media change (B) and achieved confluence in approximately seven days (C) 
(10x).  At high magnification, MSC cultures contained cells heterogenous in size 
and shape (D) (40x). Malcolm B Will 2010    Chapter 3, 96 
 
Figure 3-2 MSC’s occur at low frequency in the sternal bone marrow using colony forming 
unit-fibroblast (CFU-F) assay  
The BM MNC fraction from each donor was plated once in a dilution series at 
three concentrations and cultured for two weeks.  Cells were stained using  
Giemsa and colonies containing at least 20 cells were counted (A) (10x).  Bars 
represent the mean number of colonies per million MNC’s plated derived from 
the three dilutions.  Error bars show the standard deviation (B). Malcolm B Will 2010    Chapter 3, 97 
 
Figure 3-3 Progenitor potential of MSC’s at passage two was determined using the colony 
forming efficiency-fibroblast (CFE-F) assay 
MSC’s at passage two were serially diluted and plated in triplicate at low density 
(10 cells per cm
2) in 100mm culture dishes.  Giemsa stained colonies were 
counted to determine the percentage cells forming colonies (A).  Bars represent 
the mean percentage of cells forming colonies from the three plates for each 
donor.  Error bars show the standard deviation (B). Malcolm B Will 2010    Chapter 3, 98 
3.2.2 Surface Marker Profiles of Early Passage MSC’s 
Two colour flow cytometry was used to determine that MSC’s displayed a non 
haematopoietic, non endothelial surface marker profile.  MSC cultures were 
analysed at passage two and representative plots are shown in Figure 3 4, Figure 
3 5, Figure 3 6 and Figure 3 7.  The percentage expression of each surface 
marker for the donors and the overall mean are shown in Table 2.  The gated 
MSC population was heterogeneous in size and granularity as demonstrated by 
forward and side scatter properties (Figure 3 4A).  The mean percentage of 
gated cells was 90.5 ± 2.1% and the geometric mean of the forward and side 
scatter was 511.4 ± 49.9 and 429.9 ± 59.1 respectively. 
More than 90% of cells in the culture expressed the surface markers CD13, 29, 
44, 49e, 73, 90, 105, 166 and HLA Class I.  Two discrete populations of MSC’s 
that lacked expression of CD105 and co expression of CD29 and 44 were 
identified as shown in Figure 3 5 and Figure 3 6 respectively.  The absence of 
significant haematopoietic or endothelial cell contamination was confirmed in 
that less than 1% of cells expressed the surface markers CD14, 31, 34, 45 and 
133.  Surface markers expressed on a small number (3 32%) of MSC’s included 
CD49d, 71, 106, HLA Class II and the stem cell marker Stro 1. 
To determine differences in the surface marker prolife at passage one and two, 
the results from five donors (18, 20 and 22 24) were compared using a paired 
student’s t test (Table 3).  A significantly greater percentage of MSC’s expressed 
the surface markers CD14, 31, 34 and 45 at passage one when compared to 
passage two.  Dot plots revealed a discrete sub population of cells expressing 
these markers which are likely to represent contamination with endothelial and 
haematopoietic cells (Figure 3 8). Malcolm B Will 2010    Chapter 3, 99 
 
Figure 3-4 MSC’s at passage two displayed characteristic surface marker profiles 
Passage two cells were analysed using two colour flow cytometry after staining 
with phycoerythrin (PE) or fluorescein isothiocyanate (FITC) conjugated 
monoclonal antibodies.  The plots were obtained by collecting 10,000 events and 
representative of the eight MSC cultures analysed.  Within each quadrant of the 
grid the percentage of total cells analysed is shown.  The gated MSC population 
demonstrated variability in forward and side scatter properties (A).  
Compensation was performed using isotype controls (B) and CD13 and 90 that 
are expressed on almost all MSC’s in vitro (C, D and E).  The majority of MSC’s 
did not express CD45, a marker of committed haematopoietic cells (F). Malcolm B Will 2010    Chapter 3, 100 
 
Figure 3-5 MSC’s at passage two displayed characteristic surface marker profiles 
The majority of MSC’s did not express the surface markers CD31, 34 and 45 
which confirmed the absence of significant endothelial or haematopoietic cell 
contamination (A, B and F).  CD105 was expressed on most MSC’s although a 
discrete CD105 negative population was identified of uncertain significance (C).  
HLA Class I antigens were expressed on the majority of cells (D) and although 
only a minority expressed Class II antigens (E). Malcolm B Will 2010    Chapter 3, 101 
 
Figure 3-6 MSC’s at passage two displayed characteristic surface marker profiles 
The majority of MSC’s did not express the stem cell marker CD133 (A) although 
Stro 1, which selects for a highly proliferative subset was confirmed on a small 
percentage of cells using secondary detection methods (B D).  Most MSC’s 
expressed CD73 although CD71, an indicator of proliferation was found on less 
than a one third of cells assayed at near confluence (E).  The markers CD29 
(integrin β1) and CD44 (hyaluronic acid receptor) were expressed on the 
majority of cells although a discrete population lacking these markers was 
identified (F). Malcolm B Will 2010    Chapter 3, 102 
 
Figure 3-7 MSC’s at passage two displayed characteristic surface marker profiles  
The majority of MSC’s were negative for the marker CD49d (integrin α4) (A) in 
contrast to CD49e (integrinα5) that was detected on virtually all cells (B).  
Similarly, CD166 (ALCAM) was detected on the majority ofcells whilst CD106 
(VCAM 1) was found on a small percentage of MSC’s in culture (C). Malcolm B Will 2010    Chapter 3, 103 
 
Table 2 Surface marker profiles of MSC’s at passage two by flow cytometry 
The percentage of MSC’s expressing each surface marker for the individual 
donors and overall mean including standard deviation are shown (N/A – result 
not available). Malcolm B Will 2010    Chapter 3, 104 
 
Table 3 Comparison of surface marker profiles of MSC’s at passage one and two by flow 
cytometry 
The overall mean percentage surface marker expression and the standard 
deviation at passage one and two from five donor MSC cultures are shown.  
Comparisons were made using a paired student’s t test and p values are shown 
(n.s – not significant). Malcolm B Will 2010    Chapter 3, 105 
 
Figure 3-8 Contaminating cell populations were present in MSC’s at passage one  
Passage two cells were analysed using two colour flow cytometry after staining 
with phycoerythrin (PE) or fluorescein isothiocyanate (FITC) conjugated 
monoclonal antibodies.  The plots shown were obtained after collecting 10,000 
events and representative of the five MSC cultures analysed.  Discrete 
populations of cells expressing macrophage (A), haematopoietic progenitor (B) 
and endothelial progenitor cell markers were identified at passage one but not 
passage two. Malcolm B Will 2010    Chapter 3, 106 
3.2.3 Differentiation of Early Passage MSC’s 
The differentiation potential of MSC’s at passage two was determined by 
culturing in either adipogenic, osteogenic or chondrogenic medium for 21 days.  
Adipogenic differentiation was confirmed by the accumulation of large 
cytoplasmic lipid vacuoles that stained red using Oil Red O (Figure 3 9 E H and 
M P).  MSC’s cultured in control media did not stain (Figure 3 9 A D and I L).  
Immunofluorescence demonstrated that the adipogenic specific gene, fatty acid 
binding protein 4 (FABP 4) was highly expressed around the periphery of the 
lipid vacuoles (Figure 3 10).  Osteogenic differentiation was confirmed by the 
accumulation of cell aggregates and calcium deposits that stained red with 
Alizarin Red S (Figure 3 11 E H and M P).  MSC’s cultured in control media did 
not stain (Figure 3 11 A D and I L).  Immunofluorescence with the osteogenic 
specific gene, osteocalcin was problematic due to high background staining that 
could not be resolved using the antibody provided with the kit (images are not 
shown). 
MSC’s pellets in chondrogenic differentiation medium were larger than controls 
due to increased deposition of proteogylcans that stained with Alcian blue 
(Figure 3 12 A D and I L).  Vacuoles were identified in differentiated pellets but 
not the controls.  Control pellets were fragile because of their smaller size and 
only three out of eight remained intact after fixation and processing (images are 
not shown).  The processing, staining and sectioning was performed by Histology 
Services, Beatson Institute, Glasgow.  Immunofluorescence using the 
chondrogenic specific gene, aggrecan showed increased staining in the 
differentiated cells compared to the controls (Figure 3 13). 
3.2.4 Growth Kinetics of MSC’s 
Under the culture conditions defined in this research, the growth kinetics of 
MSC’s from eight donors were analysed from isolation until the ninth passage 
(Figure 3 14 A C).  From the time of plating the MNC fraction, MSC’s reached 
passage one and two after 11.0 ± 1.3 days and 18.5 ± 3.4 days respectively.  
MSC’s at passage two were counted on a daily basis in order to establish growth 
profiles from plating to near confluence (Figure 3 14 C). Malcolm B Will 2010    Chapter 3, 107 
 
Figure 3-9 MSC’s samples undergo adipogenic differentiation in defined conditions 
Eight MSC cultures (Donors 23 30) at passage two were grown to 100% confluence 
before culturing for three weeks in control or adipogenic culture medium 
containing hydrocortisone, isobutylmethylxanthine and indomethacin.  Control 
MSC’s (A D, I L) did not stain with lipid soluble Oil Red O while those in 
adipogenic media (E H, M P) stained red confirming differentiation to this 
lineage (4x magnification). Malcolm B Will 2010    Chapter 3, 108 
 
Figure 3-10 MSC’s express fatty acid binding protein 4 (FABP-4) after adipogenic 
differentiation 
MSC’s stained red with Oil Red O after adipogenic differentiation (A) (10x 
magnification).  At high magnification the stain was shown to accumulate within 
lipid droplets in the cell cytoplasm (B) (40x magnification).  FABP 4, found 
expressed on adipocytes was demonstrated in MSC’s using polyclonal goat anti 
mouse FABP 4 labelled with a tetramethylrhodamine isothiocyanate (TRITC) 
conjugated donkey anti goat secondary (C) (10x magnification).  The expression 
of FABP 4 was most intense around the periphery of lipid droplets (D) (100x 
magnification).  Nuclei were stained using 4', 6 diamidino 2 phenylindole (DAPI) 
and appear blue.  Immunofluorescence images were taken with fixed exposure 
times. Malcolm B Will 2010    Chapter 3, 109 
 
Figure 3-11 MSC samples undergo osteogenic differentiation in defined conditions 
Eight MSC cultures (Donors 23 30) at passage two were grown to 70% confluence 
before culturing for three weeks in control or osteogenic culture medium 
containing dexamethasone, ascorbate phosphate and β glycerol phosphate.  
Control MSC’s (A D, I L) did not stain with the calcium stain, Alizarin Red S while 
those in osteogenic media (E H, M P) were bright red confirming osteogenic 
differentiation and mineralisation (4x magnification). Malcolm B Will 2010    Chapter 3, 110 
 
Figure 3-12 MSC samples undergo chondrogenic differentiation in defined conditions 
Eight MSC cultures (Donors 23 30) at passage two were centrifuged into pellets 
before culturing for three weeks in chondrogenic culture medium containing 
dexamethasone and transforming growth factor β3 (TGF β3).  The differentiated 
pellets were formalin fixed, paraffin embedded pellets and cut into 2 M 
sections.  Proteoglycans found in cartilage, such as chondroitin sulphate were 
detected in the pellets using Alcian blue (A D, I L).  A baseline stain with 
Haematoxylin and Eosin (H+E) (E H, M P) was performed that demonstrates 
basophilic structures purple (nuclei) and eosinophilic structures pink (intra and 
extracellular proteins) (4x magnification). Malcolm B Will 2010    Chapter 3, 111 
 
Figure 3-13 Expression of aggrecan increased in MSC pellets undergoing chondrogenic 
differentiation 
MSC pellets treated for 21 days in chondrogenic culture medium (C) were larger 
in comparison to the controls (A) (10x magnification).  Increased deposition of 
aggrecan, an extracellular matrix protein abundant in cartilage was seen in the 
differentiated pellets (D) in comparison to controls (B) (40x magnification).  
Expression was detected using goat anti human aggrecan labelled with a TRITC 
conjugated donkey anti goat secondary (B and D).  Nuclei are stained blue 
(DAPI).  Images were taken with fixed exposure times. Malcolm B Will 2010    Chapter 3, 112 
 
Figure 3-14 Growth kinetics of MSC’s during expansion in vitro  
The cumulative number of population doublings until passage nine was plotted 
against time in culture for eight cultures (A).  Population doublings were 
determined from viable cell counts using the formula: PD = (log (no. MSC’s harvested) – 
log (no. MSC’s plated)) / log 2.  The overall mean and standard deviation derived from 
the eight samples are shown in the table (B).  At passage two, three samples 
(donors 23, 24 and 25) were counted on a daily basis in duplicate wells to 
determine the growth profile of MSC’s from initial plating to confluence (C). Malcolm B Will 2010    Chapter 3, 113 
MSC’s displayed a characteristic lag phase for two days followed by logarithmic 
growth until day six when proliferation decreased and the cells reached 
confluence.  With prolonged culture the interval between passages increased 
and showed greater variation between MSC’s from different donors.  Mean 
population doubling time increased from 58.6 ± 27.3 to 92.2 ± 23.5 hours to 
366.1 ± 152.8 hours at passages two, five and nine respectively. 
By determining the frequency of true MSC’s by CFU F and the number of MNC’s 
plated, the number of population doublings from isolation to the first passage 
was estimated.  MSC’s underwent 12.4 ± 1.6 population doublings by passage 
one, equivalent to 38.1 ± 5.4 % of the total culture period.  The rapid early 
growth of MSC’s occurred in only 11 ± 1.3 days, equivalent to 9.7 ± 0.9 % of the 
total culture period. 
3.2.5 Surface Marker Profile of Late Passage MSC’s 
The percentage expression of a limited number of surface markers was analysed 
at passage nine in cells from four donors (23 25 and 27) and compared to those 
at passage two using a paired student’s t test (Figure 3 15).  Late passage MSC’s 
showed decreased viability as shown by the accumulation of cells in the bottom 
left of the forward and side scatter dot plot (Figure 3 15A).  The percentage of 
MSC’s gated for analysis was significantly decreased in comparison to cell at 
passage two (69.9% ± 8.5 % versus 90.2 ± 1.4%, p 0.003).  There was no 
difference in the forward scatter properties of gated late passage MSC’s 
(geometric mean of 490.7 ± 51.5 versus 478.6 ± 40.9, n.s) although there was 
significant reduction in side scatter properties (geometric mean 363.2 ± 43.9 
versus 449.4 ± 48.7, p 0.04) in comparison to cells at passage two.  A smaller 
percentage of MSC’s at passage nine expressed the surface markers CD29, 44, 
105 and HLA Class I (Figure 3 15E). 
3.2.6 Differentiation of Late Passage MSC’s 
The differentiation potential of MSC’s at passage nine was determined by 
culturing the cells in either adipogenic or osteogenic differentiation medium for 
21 days.  MSC’s cultured in adipogenic differentiation media accumulated less 
cytoplasmic lipid vacuoles that stained with Oil Red O when compared to cells Malcolm B Will 2010    Chapter 3, 114 
 
Figure 3-15 Late passage MSC’s show alterations in surface marker expression 
Four MSC cultures at passage nine were analysed using a restricted set of surface 
markers and representative plots shown.  The gated MSC population 
demonstrated greater variability in forward and side scatter properties and cell 
viability was decreased (A).  A significant percentage of MSC’s lost expression of 
the surface markers CD29, 44, 105 and HLA Class I in comparison to those at 
passage two and representative plots shown (B D).  The mean percentage 
expression and standard deviation from the four cultures are shown in the table 
(E).  Comparisons were made using a paired student’s t test and p values are 
shown (n.s – not significant). Malcolm B Will 2010    Chapter 3, 115 
at passage two (Figure 3 16).  MSC’s cultured in osteogenic differentiation media 
developed aggregates and calcium deposits that stained red with Alizarin Red S 
(Figure 3 17).  The aggregates were smaller and the extent of the staining 
reduced in comparison to cells at passage two.  Chondrogenic differentiation 
was not performed because cell numbers were limited and required for other 
assays at passage nine. 
3.2.7 Telomere Lengths of Early and Late Passage MSC’s 
Genomic DNA was extracted from eight cultures at passage two and nine and 
used in the TeloTAGGG telomere length assay (Roche Diagnostics Ltd).  
Telomere lengths were determined from southern blot by densitometry (Figure 
3 18).  The protocol and results were produced by Sharon Burns, research 
assistant within the group of Professor W.N Keith. 
The mean telomere length of MSC’s at passage two was 7.3 ± 0.8 kB and donor 
23 displayed the longest and donor 27 the shortest telomeres (8.3 and 6.2 kB, 
respectively).  At passage nine, MSC’s displayed telomere losses apart from 
donors 25 and 30 that showed gains of 0.08 and 4.7 kB respectively.  The overall 
mean telomere length of MSC’s at passage nine was 7.0 ± 2.3 kB (6.2 ± 0.7 kB 
excluding donor 30) and the mean telomere loss in comparison to passage two 
was 0.3 ± 2.2 kB (1.0 ± 0.9 kB excluding donor 30).  MSC’s from donor 23 showed 
the greatest telomere loss between passages two and nine equivalent to 2kB of 
telomeric DNA.  Overall, eight cultures underwent a mean of 17.2 ± 3.2 
population doublings between passages two and nine equivalent to a mean 
telomere loss per population doubling of 17.5 ± 141.7 bp (64.4 ± 53.6 bp 
excluding donor 30). 
To determine telomerase expression, three MSC samples (donors 23, 24 and 25) 
were analysed using the Telomeric Repeat Amplification Protocol (TRAP).  The 
technique was performed by Stacey Hoare, research assistant within the group 
of Professor W.N Keith.  Telomerase expression was not detected in any of the 
samples (results are not shown). Malcolm B Will 2010    Chapter 3, 116 
 
Figure 3-16 Late passage MSC’s had decreased adipogenic differentiation capacity 
Eight MSC cultures (Donors 23 30) at passage nine were plated at 100% 
confluence before culturing for three weeks in control or adipogenic culture 
medium containing hydrocortisone, isobutylmethylxanthine and indomethacin.  
In control MSC’s (A C, G J), a few cells accumulated Oil Red O suggesting 
spontaneous differentiation had occurred.  MSC’s grown in adipogenic media (D 
F, K N) retained the capacity for adipogenic differentiation although to a lesser 
extent than cells at passage two (4x magnification).  Cells from donor 26 were 
destroyed as a result of contamination and images are not shown. Malcolm B Will 2010    Chapter 3, 117 
 
Figure 3-17 Late passage MSC’s show decreased osteogenic differentiation capacity 
Eight MSC cultures (Donors 23 30) at passage nine were grown to 70% confluence 
before culturing for three weeks in control or osteogenic culture medium 
containing dexamethasone, ascorbate phosphate and β glycerol phosphate.  
Control MSC’s (A C, G J) did not stain for calcium using Alizarin Red S while 
those in osteogenic media (D F, K N) showed variable staining confirming that 
the osteogenic differentiation capacity of MSC’s significantly decreased at late 
passage (4x magnification).  Cells from donor 26 were destroyed as a result of 
contamination and images are not shown. Malcolm B Will 2010    Chapter 3, 118 
 
Figure 3-18 Telomere shortening was observed in most MSC cultures after prolonged 
expansion 
The telomere lengths of eight MSC’s cultures at passage two and nine were 
determined using the TeloTAGGG telomere length assay and displayed on a 
single southern blot.  Telomere lengths were calculated from the blot by 
densitometry following the manufacturer’s protocol.  Undigested low and high 
molecular weight DNA and ladders are shown. Malcolm B Will 2010    Chapter 3, 119 
3.2.8 Expression of Senescence Associated β-Galactosidase in 
MSC’s 
The activity of the enzyme SA β Gal was assessed at pH 6 using the Senescent 
Cells Staining Kit (Sigma) and calculating the percentage of MSC’s staining blue 
from eight donors (Figure 3 19).  The mean percentage of SA β Gal positive cells 
at passage two was 1.5 ± 3.3 % although this reached 10% in cells from donor 28.  
In contrast, 47.2 ± 12.1 % MSC’s stained positive for SA β Gal at passage nine and 
cells displayed a senescent morphology.  SA β Gal staining was most intense in 
the peri nuclear region of MSC’s viewed at high magnification (Figure 3 19D). 
3.3 Discussion 
The ease with which MSC’s can be isolated and expanded in vitro has enhanced 
the clinical application of these cells for the treatment MI (9;10).  However, 
MSC’s used in these studies have not been extensively characterised and the 
characteristics of cells from patients with IHD is poorly understood.  In our donor 
population the frequency of MSC’s was approximately 1 in 1 x 10
5 MNC’s and 
similar to the findings of previous studies (1 in 3.4 x 10
4 to 1 in 3 x 10
5 
)(11;17;91;156;157).  The effect of ageing on the frequency of MSC’s in the BM is 
not clear because Baxter et al reported a decrease in MSC’s with increasing age 
and Stenderup et al could not demonstrate a difference.  MSC’s in our study 
displayed a fibroblast like morphology and were heterogeneous in size and 
shape.  Colter et al have described that MSC’s cultures are composed of rare 
small round cells, spindle shaped cells and large flat cells and that each 
population has different proliferative and differentiation potential (32).  Our 
study identified similar small rapidly self renewing (RS) cells although these 
were rare and not the focus of further experiments.  These cells are recognised 
as MSC progenitors and enriched when cultures are plated low density (<3 cells 
per cm
2) (59). Malcolm B Will 2010    Chapter 3, 120 
 
Figure 3-19 Senescence Associated β-Galactosidase (SA β-Gal) staining increased in late 
passage MSC’s 
The activity of the enzyme SA β Gal was assessed at pH 6 using the Senescent 
Cells Staining Kit (Sigma).  Representative photographs of MSC’s at passage two 
(A) and nine are shown (B) (4x magnification).  At least 300 cells were counted 
in random fields to determine the percentage of SA β Gal (blue) cells (C).  Bars 
represent the mean and error bars the standard deviation.  MSC’s displayed a 
senescent morphology and intense peri nuclear staining with SA β Gal (40x 
magnification). Malcolm B Will 2010    Chapter 3, 121 
When viewed under a microscope, early passage MSC’s contained mostly spindle 
shaped cells and less frequently, large flat cells.  In contrast, the study by 
Baxter et al demonstrated that MSC’s from aged donors contained predominantly 
large flat cells that proliferated poorly (11).  The difference in comparison to 
our results may be explained by differences in culture methods used and the 
characteristics of the donors.  Our study used more serum (20% compared to 
10%), a lower plating density and low glucose media containing Glutamax and all 
have been shown to enhance the proliferation of MSC’s (58). 
The surface marker profiles of MSC’s have been extensively investigated by 
different groups and a minimal criteria for characterisation has been agreed 
(33).  In our study the majority of MSC’s (>90%) expressed the surface markers 
CD13, CD29, CD44, CD49e, CD73, CD90, CD105, CD166 and MHC Class I.  This 
profile is remarkably similar to that described in the original study by Pittenger 
et al (17).  Many of these proteins have diverse roles although their exact 
functions in MSC’s remain poorly understood.  CD73 (ecto 5’ nucleotidase) is 
important for cell cell integrity as defects in vascular permeability have been 
demonstrated in CD73 knockout mice (158).  Distinct epitopes on CD73 are 
recognised by the monoclonal antibodies, SH3 and SH4 that were initially 
thought to be specific markers of MSC’s but later shown to be widely expressed 
(159).  CD90 (Thy1) has been recognised on other stem cell populations and 
somatic cells including fibroblasts so cannot prospectively identify MSC’s.  
Similarly, the monoclonal antibody SH2 which was developed for the 
identification of MSC’s in fact recognises an epitope of CD105 (endoglin) and is 
expressed in other cell types (160). 
The surface markers CD49d, 71, 106 and MHC Class II were found expressed on a 
moderate number (5 90%) of MSC’s in our culture conditions.  CD106 (vascular 
cell adhesion molecule 1, VCAM 1) expression can vary with the source of MSC’s 
used.  MSC’s derived from cord blood do not express CD106 (161), a small 
percentage of BM MSC’s express this marker (162) and significantly higher levels 
are seen in MSC’s derived from adipose tissue (163).  Furthermore, Gronthos et 
al have described a method to isolate almost all of the CFU F population from 
the BM MNC using magnetic selection and the combination of markers CD106 and 
Stro 1 (34).  We identified a higher percentage of MSC’s expressing MHC Class II 
(mean 11.2%) in comparison to earlier studies although the antibody we used Malcolm B Will 2010    Chapter 3, 122 
detected all class II subtypes (HLA DR, DP and DQ) and HLA DR expression is 
typically described.  In fact, it has been suggested that HLA DR expression 
should be less than 2% in MSC’s cultured in standard conditions (33).  HLA DR 
expression can be induced in MSC’s in response to cytokines such as interferon γ 
(164) and also growth factors such as basic fibroblast growth factor (b FGF) 
(165).  A further study to determine HLA DR expression alone in our MSC’s is 
required to ensure the immune profile is similar to that reported in earlier 
studies. 
In our study a small percentage of MSC’s at passage two (<3%) expressed the 
markers CD14, CD31, CD34, CD45, CD133 and Stro 1.  Cultures at passage one 
contained small populations of endothelial and haematopoietic cells and is a 
recognised problem when using the plastic adherence technique for isolation of 
MSC’s.  Tondreau et al have described immunodepletion (Rosette step) and 
magnetic activated cell sorting (MACS) using the stem cell marker CD133 as a 
method to purify MSC’s from the MNC fraction (166).  Both methods produce 
homogenous cultures from initial isolation although at later passages the 
cultures are similar to those isolated by plastic adherence so the benefits, 
particularly for clinical application remain uncertain.  The surface marker Stro 1 
was present on 3% of MSC’s at passage two and it is recognised that Stro 1 can 
isolate a subset of MSC progenitors with enhanced proliferative and osteogenic 
differentiation capacity (167).  As discussed earlier, together with CD106 this 
combination has shown the most promise in identifying the most primitive MSC’s 
to date.  However, with long term culture the expression of these markers is not 
sustained and further research is required to identify culture conditions that 
maintain the self renewal of this population. 
MSC’s derived from our donors achieved almost thirty population doublings 
before the onset of growth arrest.  The results are similar to other studies that 
have derived MSC’s from aged donors (11;12;91).  SA β Gal was detected in 
almost 50% of MSC’s at passage nine and two studies have reported similar levels 
of expression (12;68) .  In contrast, Wagner et al reported that 80% of MSC’s 
expressed SA β Gal at passage ten and differences in the culture protocols used 
and interpretation of the assays may explain these differences (40).  Similar to 
the studies by Heo and Wagner et al, we did not detect SA β Gal activity in early Malcolm B Will 2010    Chapter 3, 123 
passage MSC’s confirming that expression is a late event and questioning the 
utility of this marker in identifying senescence of MSC’s during expansion. 
The telomere length of MSC’s used in our study was determined as an additional 
marker of cell ageing and senescence.  The mean telomere length of MSC’s at 
passage two was 7.3kB and almost 2 3kB shorter than reported by earlier studies 
(11;12).  The rate of telomere shortening was 64bp per PD (excluding donor 30) 
which is similar to that reported in these studies (mean 88 and 100bp per PD 
respectively) and suggests telomere shortening is a characteristic feature of 
MSC’s during expansion.  Baxter et al also showed that the rate of telomere loss 
in vitro was independent of donor age and estimated that MSC’s lost 17bp of 
telomeric DNA per year in vivo (11).  The telomere lengths in MSC’s at early and 
late passage are variable and inconsistent amongst some of these studies 
although donor characteristics, culture protocols and interpretation of the assays 
may be contributing factors.  Telomere dysfunction can also initiate a 
senescence response and in other cell types, oxidative stress has been shown to 
significantly increase telomere loss (168).  In mesothelial cells, oxidative stress 
can initiate senescence by damaging non telomeric DNA and therefore telomere 
shortening is not a pre requisite for the intiation of senescence (169). A recent 
study has confirmed that late passage MSC’s show high levels of oxidative stress 
during expansion and senescence in vitro and therefore it appears likely that 
telomere shortening and dysfunction together contribute to the senescence of 
MSC’s cultured in standard conditions (40;68). 
Similar to other reports, we did not detect telomerase activity in MSC’s which is 
required for telomere maintenance during cell division (72;76;81).  However, 
recent evidence has suggested that MSC’s may regulate telomerase expression in 
a cell cycle dependent manner and at levels below the sensitivity of the TRAP 
assay (78).  This could explain our own results and those from earlier studies.  
Collaborative research from our group has demonstrated that telomerase is 
actively repressed in MSC’s at the chromatin level and can be detected using the 
TRAP assay if MSC’s are exposed to de methylation agents or histone deacetylase 
inhibitors (79;80).  The role of telomerase in MSC’s is of interest because hTERT 
over expression has been shown to extend the proliferative and differentiation 
capacity of MSC’s (81).  In addition to its critical role in senescence and ageing 
of MSC’s, active repression of telomerase may function as a tumour suppressor Malcolm B Will 2010    Chapter 3, 124 
and barrier to transformation.  MSC’s transduced with hTERT show genetic 
instability and transformation after extended culture periods and generated 
sarcoma like tumours in immunodeficient animals (83). 
Lastly, we determined the effects of prolonged culture on the typical 
characteristics of MSC’s.  In comparison to MSC’s at passage two, late passage 
cells displayed a significant reduction in adipogenic and osteogenic 
differentiation capacity.  In particular, two of the cultures lost the capacity for 
osteogenic differentiation altogether.  There is conflicting results in the 
literature regarding the effects of prolonged culture on the differentiation 
ability of MSC’s.  MSC’s derived from young donors appear to maintain 
osteogenic differentiation (19;37;38) or have increased osteogenic differentiaion 
capacity at late passage in comparison to early passage cells (40).  The study by 
Muraglia et al supports these findings because it was shown that at the clonal 
level MSC’s with adipogenic differentiation capacity were lost earliest during 
expansion (38).  Furthermore, it was shown that MSC’s from aged donors 
contained fewer multi potent clones suggesting a critical role of donor age on 
the frequency and properties of MSC’s. 
Similar to our own results, MSC’s from aged donors show a similar decline in 
adipogenic and osteogenic differentiation capacity at late passage (12;91) while 
in another study osteogenic differentiation decreased to a much greater extent 
(71).  Therefore, prolonged culture and senescence of MSC’s is associated with a 
reduced capacity for differentiation although the exact restriction in lineage 
fate appears strongly influenced by the characteristics of the donor.  During 
ageing, the bone marrow is gradually replaced with fat and the capacity for 
bone formation is reduced.  It would be interesting to speculate that MSC’s 
contribute to these pathological changes and research in this area may lead to 
the development of new treatments for patients with age related conditions 
such as osteoporosis. 
3.4 Conclusion 
The results confirm that MSC’s derived from CABG patients meet the minimal 
criteria proposed by the International Society for Cellular Therapy in 2006 (33).  
MSC’s could be expanded for almost thirty population doublings and achieved Malcolm B Will 2010    Chapter 3, 125 
levels of expansion similar to that previously reported.  Late passage MSC’s 
showed evidence of cell ageing and displayed a senescent morphology, increased 
expression of SA β Gal and a reduction in telomere length.  Furthermore, late 
passage MSC’s showed a decline in adipogenic and osteogenic differentiation 
capacity confirming loss of their normal stem cell characteristics.  Our results 
support the findings of previous studies which gave us confidence that the 
transcriptional profiles generated by SAGE could identify genes associated with 
MSC ageing and senescence in vitro. 
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4  Serial Analysis of Gene Expression Profiles of 
Mesenchymal Stem Cells 
4.1 Introduction 
Serial analysis of gene expression (SAGE) is based on three main principles: 
1.  A short sequence tag (10 27bp) obtained from a defined position within the 
cDNA is sufficiently unique to identify a transcript. 
2.  Tags can be formed into long DNA fragments (concatamers), which can be 
cloned and sequenced to improve efficiency of the transcriptome analysis. 
3.  The expression level of each transcript is quantified by the number of times a 
tag is observed within a SAGE library. 
We used the long SAGE technique for this research in which the tag length 
generated is approximately 17bp long, each representing a single mRNA (110).  
This short nucleotide sequence should, in theory, contain sufficient information 
to identify the transcript uniquely, providing the tag is from a defined position 
within the transcript.  For example, a 17bp tag should be able to distinguish 
17,179,869,184 (4
17 = 4 possible nucleotides in 17 possible positions) transcripts, 
assuming that the distribution of nucleotides at the tag site is random.  When 
these tags are concatenated and cloned, each clone insert should contain up to 
35 tags joined serially, although in practice the inserts were usually shorter.  
The boundaries between each tag are recognised by a 4bp nucleotide sequence 
(CATG) corresponding to the recognition site of the NlaIII restriction enzyme 
used during SAGE.  The mRNA transcript corresponding to the long SAGE tag is 
identified using publicly available databases and analysed using described 
methods (108;109). 
Figure 4 1 provides a schematic of how SAGE is put into practice.  Double 
stranded cDNA is synthesized from mRNA captured using magnetic oligo (dT) 
beads.  The cDNA is then cleaved using the anchoring enzyme NlaIII, which is a 
restriction endonuclease with a 4bp recognition and cleavage site (CATG).  On 
average, NlaIII would be expected to cleave every 256bp (4
4 = 4 possible Malcolm B Will 2010     Chapter 4, 127 
nucleotides at 4 possible positions).  Most mRNA transcripts are considerably 
longer than this and are therefore cleaved at least once.  This process creates a 
unique site on each mRNA transcript that corresponds to the NlaIII restriction 
site which is the most 3’ and located closest to the polyA tail. 
The cleaved cDNA is then divided in half and ligated via the anchoring restriction 
site to one of two oligonucleotide adapters containing a recognition site for the 
tagging enzyme MmeI, a type IIS restriction enzyme.  The oligonucleotide 
adapters are designed so that cleavage of the ligation products with MmeI 
releases the adapter plus a short piece of the original cDNA, which is the SAGE 
tag from the oligo (dT) beads.  The two adapter tag pools are ligated to each 
other and amplified by PCR using adapter specific primers.  As well as amplifying 
the tag sequences, this process allows orientation of the tag sequences as two 
tags (ditags) that are linked tail to tail (3’ end to 3’ end) and flanked by CATG, 
the recognition site for NlaIII.  It also enables repeated ditags, potentially 
produced by PCR bias to be identified after sequencing and excluded from the 
final analysis. 
Cleavage of the PCR product with NlaIII releases the 34bp ditags which are then 
isolated and concatenated (linked) by ligation.  The concatamers are cloned and 
sequenced and individual sequences analysed using SAGE 2000 software.  
Interesting tags can be further investigated using bio informatics software 
available online.  The laboratory work, characteristics of the SAGE libraries 
generated and the results are now discussed. 
4.2 SAGE Method and Data Analysis 
4.2.1 SAGE Protocol 
Within our research group their was considerable experience of the SAGE 
technique (123).  Since first described, refinement to the protocol and the 
development of a kit to generate either short or long SAGE libraries has 
simplified the process.  Reagents and buffers are quality controlled and provided 
ready to use. Malcolm B Will 2010     Chapter 4, 128 
 
Figure 4-1 Schematic diagram of serial analysis of gene expression (SAGE) 
This diagram provides a simplified explanation of the SAGE method. Malcolm B Will 2010     Chapter 4, 129 
We were able to generate SAGE libraries (from mRNA to concatamer formation) 
in ten days with colony PCR and clean up prior to sequencing requiring two 
weeks.  The SAGE libraries were fully sequenced within four months.  All 
sequencing was provided by the Molecular Services Unit, Beatson Institute, 
Glasgow. 
The SAGE method requires sufficient amounts of high quality RNA.  We extracted 
RNA from snap frozen MSC’s using TRIzol
® reagent as recommended by the 
manufacturer.  For each SAGE library, the amount of total RNA used was 10 g.  
Within the protocol, a number of steps are recommended to ensure the reaction 
processes have occurred efficiently.  Demonstrating robust cDNA formation, 
cDNA digestion and linkage of the adapter’s usually guaranteed successful 
generation of the 130bp ditags (Figure 4 2 and Figure 4 3).  It was important to 
use silicon tubes and careful pipette technique in order to prevent loss of the 
magnetic beads that are the template for subsequent reactions. 
The amount of LS adapters A and B recommended by the protocol was sufficient 
for the generation of the 130bp ditags.  Stronger 130bp bands (ditags) than 
100bp bands (adapter dimers) were found when analysed by gel electrophoresis 
(Figure 4 3).  If using RNA in amounts out with the recommended range (5 50 g), 
further optimisation would be required. 
It is essential avoid PCR cross contamination of the template with positive and 
negative controls.  PCR reactions were always performed in two hoods in two 
different locations using fresh reagents, disposable PCR tips and specific 
pipettes.  The PCR optimisation step was always carried out with serial dilution 
of the template as recommended by the protocol in order to confirm the 
reactions worked.  During scale up PCR, the master mix was calculated based on 
600 PCR reactions using the entire template in order to generate large amounts 
of 130bp ditags.  The entire PCR was performed using 28 cycles.  During gel 
purification, smearing of the 130bp ditags and 100bp bands resulted from 
overloading the wells with DNA (Figure 4 4).  In retrospect, it would have been 
better to use multiple large format gels to avoid this. Malcolm B Will 2010     Chapter 4, 130 
 
Figure 4-2 Gel electrophoresis of PCR-based verification steps in the SAGE protocol 
The long SAGE™ kit recommends a number of PCR based verification steps to 
validate the initial stages in the protocol.  cDNA synthesis and efficient digestion 
by NlaIII was confirmed by PCR using GAPDH primers (Lanes 2 + 3).  Despite NlaIII 
digestion, the EF primer sites are maintained (Lanes 4 + 5).  Ligation of adapters 
(A + B) are confirmed by PCR using adapter specific primers (Lanes 6 + 9) and no 
product is produced using the opposite adapter (lane 7 + 8).  100bp DNA ladders 
were loaded at the ends of the gel (Lanes 1 + 10). Malcolm B Will 2010     Chapter 4, 131 
 
 
Figure 4-3 Gel electrophoresis of optimisation PCR for generation of 130bp ditags 
A serial dilution of the ditag template (1/20, 1/40 and 1/80) for use in an 
optimisation PCR reaction confirms the presence 130bp ditags and a lower 100bp 
band of ligated adapters without transcripts (Lanes 2 – 4).  Absence of 
contamination of the PCR reagents and a strong band with the LS control 
template provided in the kit aid in optimisation of PCR conditions (Lanes 5 + 6).  
25bp DNA ladders were loaded at either end of the gel (Lanes 1 + 7). Malcolm B Will 2010     Chapter 4, 132 
 
Figure 4-4 Gel purification of 130bp ditags 
The 130bp ditags from 600 scale up PCR reactions were purified by 
electrophoresis of the precipitated DNA on a large format 12% polyacrylamide 
gel (Lanes 2 12).  The large amount of DNA loaded in each well resulted in poor 
separation of the 130bp (ditags) and 100bp (adapters without transcript) bands.  
The 130bp region was excised as shown, the DNA recovered from the gel and 
used for the remaining SAGE protocol.  Lower molecular weight species including 
primers can be seen further down the gel.  A 25bp DNA ladder is shown (Lane 1). Malcolm B Will 2010     Chapter 4, 133 
In fact, cutting out the approximate 130bp region from the gel did not appear to 
cause any problems in downstream reactions.  The 130bp ditags were shown to 
be efficiently digested using NlaIII releasing the 34bp ditags (Figure 4 5).  It was 
important to the 34bp ditags on ice because they can degrade at higher 
temperatures.  The 34bp ditags were isolated and the incomplete digestion 
products and excess adapters removed by further gel purification (Figure 4 6). 
For the generation of concatamers, the ligation reaction was performed for 3 
hours.  After gel separation, the 300bp to 1.2kB region was excised using the 
molecular markers as guides and the region divided roughly into three before 
elution of the DNA (Figure 4 7).  The pZERO
® 1 vector was linearised by a 30 
minute digestion with SphI before ligation with each concatamer region.  It is 
important not to over digest the vector as this could disrupt the LacZα ccdB 
lethal gene and result in a large number of transformants that do not contain 
inserts.  Large concatamers (>900bp) were found to clone less efficiently than 
shorter ones (400 600bp) and a good example of gel electrophoresis of colony 
PCR’s is shown in Figure 4 8.  Altering the concatamer: vector ratio or 
alternatively, a brief digestion of the concatamer with NlaIII has been shown to 
improve cloning efficiency (170). 
4.2.2 SAGE Data Analysis 
After sequencing, the concatamer sequence files were analysed using SAGE 2000 
software, version 4.5.  A project file is generated and the following parameters 
specified: anchoring enzyme is NlaIII, with its CATG recognition site; the tag 
length is set to 17bp; and the maximum ditag length, over which any ditags are 
excluded from the analysis, is set to 36bp.  The SAGE software then builds a 
database of all possible tags (4
17) in order to perform the analysis of each 
individual sequence (Figure 4 9).  Thereafter, the sequence files are added and 
used to form a SAGE report: this includes number of sequences loaded; number 
of duplicate ditags which are usually excluded from any further analysis; and the 
list of tags and their absolute count.  The report can then be analysed by 
comparison with a downloadable reference sequence database such as SAGE map 
or on line using SAGE Genie. Malcolm B Will 2010     Chapter 4, 134 
 
Figure 4-5 Gel electrophoresis confirmed efficient digestion of the 130bp ditags 
The complete absence of a 130bp ditag band and generation of 34bp ditags 
confirmed efficient digestion by the anchoring enzyme NlaIII (Lane 2).  The large 
50bp band of released adapters occurred as a result of poor gel purification of 
the 130bp ditag as shown in the previous image.  25bp DNA ladders are shown 
either side (Lanes 1+3). Malcolm B Will 2010     Chapter 4, 135 
 
 
Figure 4-6 Gel purification of the 34bp ditags 
The 34bp ditags released by NlaIII were purified on an 8% polyacrylamide gel and 
the bands excised to recover the DNA.  The adapters and partially and 
completely undigested larger species are shown in the upper region of the gel.  
100bp and 25bp DNA ladders are shown at either end of the gel (Lanes 1+8). Malcolm B Will 2010     Chapter 4, 136 
 
Figure 4-7 Gel electrophoresis confirmed generation of concatamers 
The 34bp ditags are ligated to produce long concatamers that are then 
separated using an 8% polyacrylamide gel (Lane 2).  1kb and 100bp DNA ladders 
were used to visualise the 300bp to 1.2kB region which was excised and purified 
for subsequent cloning (Lanes 1+3). Malcolm B Will 2010     Chapter 4, 137 
 
Figure 4-8 Gel electrophoresis of colony PCR from cloned concatamers 
Single bacterial colonies containing the cloned concatamers are picked and 
subjected to PCR amplification with primers specific to the vector on either side 
of the polylinker.  The products were separated by electrophoresis on a 1% 
agarose gel as shown (Lanes 2  17).  The aim was to achieve PCR products of 
>500bp as these should contain at least 16 17 tags (around 200bp flanking vector 
plus 17bp per tag).  Although not displayed on this gel, some colonies lacked 
inserts or contained short concatamers which were not purified for sequencing.  
A 100bp DNA ladder and negative control (no template) are shown (Lanes 1+18). Malcolm B Will 2010     Chapter 4, 138 
NNCCTCTAGATGCATGTTCATACACCTATCCCCAATACTTATAAAGTACN  50 
NNNNNCGGCTGGCCAAGACTTAATACTGCCAGTCACATGCCTCAGGATAC  100 
TCCTCAAGAACTCAGCTCCTTACATGGAAAAATGGTTGATGGATACCCAG  150 
ATTTGATAACATGTATTGAAATACATATTGGGGTTTATGCCCAATCCATG  200 
TTTCCAATCTCTCTCTCCTTTATTTAATCCTCCCCATGCCTATTTACTGG   250 
AAACCTGGAGAACATAAAGGGCCATGGATTGCTGGAGGTCTTTTATACAG  300 
TCTTTGAACCATGGGTGGCACTCAGTCTCTCAAAAAGGCCAAATCCCATG  350 
GGCTTTGATTTTTTTCACTTTTGGTTTTTGGTCATGATGGCGCCTCCTGC  400 
CCGGTACTTTATTGATGGTACATGCTCACCTAAGCCACAGGGCCTCTGTC  450 
CTGGCTTCATGGCCCGCAGGGTCAAGGGGTTTTAGGGACGTTAACCATGG  500 
AAGCAGGACCAGTAAGGGGATAGGTGTATGAACATGGTGTGTTTGTAATA  550 
ATAAAAGTAGCTAATACTCACATGGGGCTGGGGTCCTCCTGTGGCTCTCT  600 
CCCTGGGACATGATCCGTGCCCTTGCTTCTGGGAGGGGGGTTGAGCATGG  650 
GCTTTACCCTTCCCTGCGATGGACGTGTTCCTCATGTTANNNNCNGTCTC  700 
TCANATCTAGTTTAGAAAACATGCTCGAGCGGCCGCCAGTGTGATGGATA  750 
TCTGCAGAATTCCAGCACACTGGCGGCCGNTACTAGTGGATCCGAGCTCG  800 
GTACCAAGCTTGATGCATAGCTTGAGTATTCTATAGTGTCACCTAAATAG  850 
CTTN                      854 
 
Figure 4-9 Sequence of cloned concatamer containing ditags separated by CATG’s 
This is an example of sequencing of the insert sequence.  The insert is 
delineated by the first and last CATG sites.  When this sequence is put into the 
SAGE program, the ditags are identified, extracted and split into tags (simply by 
dividing the ditags down the middle).  A catalogue of all tags is then assembled. Malcolm B Will 2010     Chapter 4, 139 
During this research, the SAGE map reference database underwent a prolonged 
up date which was not completed until the end of September 2007.  Therefore, 
SAGE Genie, developed by the Cancer Genome Anatomy Project (CGAP) was used 
instead (109).  The SAGE data is uploaded as a tab de limited text file and the 
analysis performed online using the Digital Gene Expression Display (DGED).  One 
advantage of this method is that the reference databases include single 
nucleotide polymorphism (SNP’s) associated alternative tags (171). 
4.2.3  Assessment of SAGE Library Quality 
By calculating the number of tags generated per clone and the number of clones 
per  l of ligation reaction, the total number of tags for each SAGE library can be 
estimated if all the ligation reaction were transformed.  The estimated total 
library sizes were more than 100,000 tags which was the recommended minimum 
in the protocol.  Most SAGE users generate libraries of over 40,000 tags with 
each sequenced clone producing between 25 and 30 tags.  We could never 
achieve this degree of efficiency and between 12 and 19 tags were generated 
per concatamer and each library required the sequencing of more than 2400 
clones (Table 4).  Rather than attempt optimisation of the whole process in 
order to improve efficiency we chose to perform additional colony PCR. 
The number of duplicate ditags that occurred (<5%) in the three SAGE libraries 
was similar to the findings of large scale SAGE datasets (172).  Duplicate ditags 
were originally thought to arise from PCR artefact and as a result it was common 
practice to exclude them from analysis (173;174).  However, a recent analysis of 
298 SAGE libraries by Kahttra et al demonstrated that duplicate ditags occur 
more frequently in long SAGE libraries that contain a small number of high 
abundance tags (172).  Other researchers have shown that removal of duplicate 
ditags can introduce error so it has been suggested to analyse the duplicate 
ditag population (174;175).  For the purposes of this research the duplicate 
ditags were excluded from further analysis. Malcolm B Will 2010     Chapter 4, 140 
 
Table 4 Characteristics of the three SAGE libraries Malcolm B Will 2010     Chapter 4, 141 
4.2.4  Problems with Tag to Gene Assignment 
Investigation of individual SAGE tags is relatively straight forward where a tag 
matches a single gene but is much more difficult if multiple or no matches exist.  
It has been demonstrated that up to two thirds of unique SAGE tags do not 
match the reference databases, limiting the information obtained by SAGE (118).  
Of the unmatched tags up to two thirds are estimated to be truly novel and the 
remaining third occur as a result of either alternative splicing, alternative 
polyadenylation, SNP’s and sequence error. 
Alternative splicing increases the complexity of the human transcriptome and 
may occur in up to two thirds of human transcripts (176).  Investigation of 
unmatched tags can be addressed by RT PCR using the SAGE tag as a primer in 
order to generate longer 3’ cDNA fragments that can be sequenced and analysed 
on line (177).  Alternatively, software tools such as SAGE2Splice have been 
shown to map up to 6% of unmatched SAGE tags to potential splice junctions 
within the genome (178). 
The use of alternative polyadenylation cleavage sites downstream of a 
polyadenylation signal may lead to more than one SAGE tag from what is in 
essence a single mRNA species.  One study calculated that this may affect 2.8% 
of human transcripts (179).  SNP’s create similar difficulties with tag to gene 
assignment as they can affect up to 9% of known human transcripts.  To enhance 
tag to gene assignment, databases such as SAGE Genie incorporate SNP 
prediction algorithms in order to improve tag mapping (171).  Sequence error is 
usually estimated to be in the range of 0.2 1.0% per base and therefore up to 
17% of tags in long SAGE libraries could have arisen due to error.  Erroneous tags 
have also been shown to occur more frequently with modifications of the SAGE 
technique that incorporate additional PCR steps (114).  The use of Phred scores 
or discarding ambiguous sequences using specific software tools can remove 
much of this error prior to data analysis (180 182).  In fact, Chen et al 
demonstrated that tags that arise due to sequence error are in fact less frequent 
than one would expect and account for less that 2% of the total tags in a SAGE 
library.  Most of the errors are single base substitutions with two or more base 
substitutions being extremely rare (118). Malcolm B Will 2010     Chapter 4, 142 
Tags match sequences derived from mRNA much more reliably than those from 
EST’s due to the nature of the SAGE technique.  In order to check the tag to 
gene matches using either SAGE map or SAGE Genie, we manually checked a 
number of original mRNA/cDNA sequences for a specific gene, usually via the 
UniGene or SAGE Genie database.  The last (3’ most) CATG tetranucleotide was 
identified and the immediately adjacent, downstream, SAGE tag was confirmed.  
To ensure the CATG site is truly the most 3’ requires the mRNA/cDNA sequence 
contains a polyadenylation site (AAU/TAAA) downstream.  The UniGene or SAGE 
Genie databases contain a wealth of other information on each gene, such as 
mRNA expression, chromosomal location and so on. 
4.2.5  Statistical Methods for Comparing SAGE Libraries 
Over the years, a number of computational tools and statistical methods have 
been developed to correctly perform the analysis of SAGE experiments.  Because 
SAGE determines absolute expression levels, comparisons between individual 
libraries are relatively easy to perform.  Five commonly used statistical methods 
for the analysis of SAGE data include the Madden test, Audic and Claverie test, 
SAGE300, Z test and Fisher’s Exact test (102;183 186).  A direct comparison of 
these methods in the evaluation of SAGE data has been published (187).  The 
authors have shown the Madden test can only be used reliably on libraries of 
equal size and tends to be more conservative due to the measure of variance in 
the statistical method.  The other methods give essentially the same result for 
libraries of equal or different sizes and the Z test has the advantage that it can 
be used for the analysis of more than two libraries. 
SAGE Genie performs comparisons of SAGE data using the Fishers Exact test.  As 
an alternative, I used SAGE Stat software that uses the Z test for comparison and 
is available for download upon request (185).  When comparing the SAGE 
libraries of donor 25 at passage two and nine using either method the number of 
differentially expressed tags was 332 and 317 tags respectively (with p value set 
to <0.05).  Tags not present in one library are assigned an arbitrary value of 1 
rather than 0 using SAGE Stat, which would account for the observed difference 
in number of differentially expressed tags.  SAGE Stat is useful not only for the 
testing of SAGE data but also in experimental design of SAGE experiments.  
Statistical inferences can be calculated based on fold differences for a given tag, Malcolm B Will 2010     Chapter 4, 143 
effects of p value, power of a test as well as estimation of subsequent SAGE 
library size.  The two examples generated from my own data are shown.  Figure 
4 10A demonstrates that low abundance tags require large differences in 
expression to reach significance if the SAGE libraries are of similar size.  
Secondly, if the abundance of a specific tag is known in one library the size of 
the subsequent SAGE library generated (for a set p value and power) can be 
calculated if one was looking to detect a specific enrichment of that tag (Figure 
4 10B). 
4.3 SAGE Profiles of Mesenchymal Stem Cells 
Having described how the SAGE method was performed and methods to analyse 
the data, the large scale mRNA profiles of MSC’s in short term (passage 2 – P2) 
and long term culture (Passage 9 – P9) are now discussed. 
4.3.1 Generation of MSC Long SAGE Libraries 
Three SAGE libraries were created from two patients – donor 12 and 25.  The 
first SAGE library generated was from donor 12 MSC’s at passage 2 (12 MSC P2) – 
the time point was chosen as most researchers characterise MSC’s at this culture 
point.  The original plan was to generate a further library at late passage and 
even during differentiation to a specific lineage.  However, due to loss of 
patient material when a cryostorage unit failed further MSC’s cultures had to be 
generated. 
Donor 25 demonstrated normal proliferative characteristics and was used to 
generate SAGE libraries at passage two and nine (25 MSC P2 and P9).  Due to 
time constraints it was not possible to generate a further SAGE library on 
differentiated MSC’s as initially planned.  After excluding the tags from 
duplicate ditags and the adapter sequences, a total of 123,990 tags were derived 
from 38,126 unique tags.  The libraries from 12 MSC P2, 25 MSC P2 and 25 MSC 
P9 contained 40,736, 40,580 and 42,674 tags respectively (Table 4). Malcolm B Will 2010     Chapter 4, 144 
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Figure 4-10 Statistical inferences from SAGE data 
Using SAGE Stat software, a matrix of critical values can be generated based on 
the size of the SAGE libraries (A). This demonstrates the difference in tag counts 
required to reach significance depending on the relative abundance of a specific 
tag.  SAGE can detect small differences in high abundance tags and large 
differences in low abundance tags based on set statistical thresholds.  If the 
abundance of a specific tag in a SAGE library is known the required size of a 
subsequent library to detect a specific fold difference in expression (for given 
power and p value) can be calculated (B). Malcolm B Will 2010     Chapter 4, 145 
4.3.2 Analysis of MSC SAGE Libraries 
The distribution of the unique tags and their abundance for each of the SAGE 
libraries is shown in Figure 4 11.  In the three SAGE libraries, an average of 
16,997 (78%) unique tags occurred only once and 18 (0.08%) tags occurred more 
than 100 times in each library.  Of the unique tags, 30% reliably matched a 
specific gene (UniGene), 7% a single deposited sequence (accession number) and 
the remainder were unmatched. 
2,960 unique tags were identified in the three SAGE libraries that accounted for 
57,003 of the total tags.  Of these, 77% matched a specific gene which confirms 
that high abundance tags are usually matched to known genes.  The twenty most 
abundant tags with their respective counts and abundance are shown in Table 5.  
The most abundant tag, TTCATACACCTATCCCC, occurred 866 times (0.7%) in all 
three libraries and was shown to be significantly increased in MSC’s after long 
term culture.  An online search using SAGE Genie anatomic viewer revealed that 
this tag occurs frequently (4,161,709 times in all online long SAGE libraries) and 
is highly expressed in a variety of normal and cancer tissues.  This tag can be 
matched to a single deposited sequence generated from human mitochondrial 
DNA.  The data was part of a larger study investigating the diversity of the 
human mitochondrial genome (188).  The tags TGATTTCACTTCCACTC and 
CACCTAATTGGAAGCGC were also differentially expressed and matched other 
sequences deposited in the same mitochondrial database.  Tags that matched 
known genes were found to be highly expressed in other profiling studies on 
MSC’s and will be discussed later. 
4.3.3 Comparison of MSC’s and Online SAGE Libraries 
The SAGE library of donor 25 MSC P2 was compared digitally to all publicly 
available long SAGE libraries using SAGE Genie (110 libraries containing a total of 
177,118,916 tags were available for comparison and were derived from a variety 
of cell lines, normal tissues and tumour samples).  For this comparison, a 
difference in tag ratio (Z) of five fold and a p value of 0.001 or less was used.  
144 tags that were found to be over expressed in MSC’s, included genes such as 
transgelin (TAGLN), fibronectin 1 (FN1) and myosin light polypeptide 9 (MYL9). Malcolm B Will 2010     Chapter 4, 146 
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Figure 4-11 Distribution of unique tags and tag frequency in the three SAGE Libraries 
Bars represent the number of unique tags in each MSC SAGE library. Malcolm B Will 2010     Chapter 4, 147 
 
Table 5 Twenty most abundant tags identified in the three MSC SAGE libraries Malcolm B Will 2010     Chapter 4, 148 
These genes were highly expressed in all three SAGE libraries.  Five tags 
(GGCCGCACCATAATGAG, CACAAGGCTCACATCTC, ACCCAAAAACCAAAAGT, 
TTAAAATAGCACCTTTA and ATGTGAANAGTTTCACA) were identified that were 
only present in MSC’s. 
A separate comparison was performed using the same statistical thresholds  
against SAGE libraries derived from haematopoietic stem cells (1), embryonic 
stem cells (11), monocyte depleted mono nuclear cells (2), rhabdomyosarcoma 
(1) and breast tissue stroma (1).  The numbers of differentially expressed tags 
were 466, 317, 326, 260 and 226 respectively demonstrating that MSC’s share 
more transcriptional similarity to tissues of mesenchymal origin. 
4.3.4 Comparison of Early and Late Passage MSC SAGE Libraries 
The effect of alteration of p value (P) on the number of differentially expressed 
tags between our SAGE libraries when a difference in level of expression of a tag 
(Z) is more or less than one is shown in Figure 4 12A.  The biggest difference in 
the number of differentially expressed tags was in the comparison of 12 MSC P2 
and 25 MSC P2.  Figure 4 12B demonstrates that the numbers of differentially 
expressed tags were similar to other publicly available SAGE comparisons.  As 
with our data, the number of differentially expressed tags is greatest when 
comparing tissues of different origins rather than a cell line under different 
experimental conditions. 
The direct comparison of 25 MSC P2 and P9 was the focus of most of our results 
in order to minimise donor and experimental differences.  When Z is more or less 
than 1 and the p value set to 0.05, 0.01 and 0.001 the numbers of differentially 
expressed tags were 332, 132 and 64 respectively.  Of the 332 differentially 
expressed tags, 234 (70%) tags matched a specific UniGene, 43 (13%) tags 
matched a single accession number only and 23 (7%) tags were unknown.  218 
(66%) differentially expressed tags were over expressed at passage nine and the 
remaining 114 (34%) tags under expressed.  The known chromosomal locations of 
258 tags were identified and shown in Figure 4 13.  Chromosomes two, one, 
eleven and nineteen contained the most differentially expressed tags 
respectively. 
 Malcolm B Will 2010     Chapter 4, 149 
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Figure 4-12 Pattern of differentially expressed tags in the MSC SAGE libraries matched 
online SAGE comparisons 
The numbers of differentially expressed tags in the three comparisons were 
determined using SAGE Genie for different p values (A).  The overall percentage 
of differentially expressed tags was determined from published comparisons 
available via the SAGE Genie website (B). Malcolm B Will 2010     Chapter 4, 150 
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Figure 4-13 Chromosomal location of differentially expressed tags in MSC’s at late passage 
The known chromosomal locations of 243 differentially expressed tags in the 
comparison of 25 MSC P2 and P9 are shown.  Bars represent the number of tags 
that matched an individual chromosome. Malcolm B Will 2010     Chapter 4, 151 
Fifteen genes were identified that matched forty seven differentially expressed 
tags demonstrating that within SAGE, multiple tags exist for some transcripts.  
Most of these tags matched genes that encode for cytoskeletal proteins that 
were highly abundant in the three MSC libraries.  For example, collagen type I, 
alpha 1 (COL1A1) matched seven differentially expressed tags 
(ACCAAAAACCAAAAGTG, GACCAGCAGACTGGCAA, TGGAAATGACCCAAACA, 
CCGGGGGAGCCACCAGC, GACTTTGGAAAATATTT, GGCCCCCCTGGATTGGC and 
GGAGGAGAGCGTGTGCG). 
In the comparison of 12 MSC P2 and 25 MSC P9, 111 (33%) differentially 
expressed tags were identified that were also found in the comparison of 25 MSC 
P2 and P9.  100 (90%) of the tags showed changes in expression in the same 
direction.  In the comparison of 12 MSC P2 and 25 MSC P2, 82 (25%) differentially 
expressed tags were identified that were found in the comparison of 25 MSC P2 
and P9.  All of these tags showed changes in expression in the same direction.  
The significance of these findings is that in addition to identifying genes altered 
with prolonged expansion of MSC’s, it would appear that differences are 
detectable between donor cultures as early as the second passage. 
4.3.5 Investigation of Differentially Expressed SAGE Tags 
Differentially expressed tags (Z more or less than 5 and p<0.001) in the 
comparison of 25 MSC P2 and 25 MSC P9 were analysed and twenty of the most 
over and under expressed tags shown in Table 6 and Table 7.  The genes marked 
in italics were those found in the comparison of 12 MSC P2 and 25 MSC P9.  Most 
of the over expressed tags at passage nine had very low counts at passage two 
and matched known genes.  These included transcription factors, genes involved 
in oxido reductase activity and proteolysis.  Conversely, the under expressed 
tags were either unknown or matched genes highly abundant in the three 
libraries. 
4.3.6 Analysis of Differentially Expressed Tags using MetaCore™ 
The differentially expressed tags from the comparison of 25 MSC P2 and P9 (Z 
<>1 and p <0.05) were analysed digitally using MetaCore™ systems biology 
software.Malcolm B Will 2010     Chapter 4, 152 
 
Table 6 Twenty most over-expressed tags in MSC’s at late passage Malcolm B Will 2010     Chapter 4, 153 
 
Table 7 Twenty most under-expressed tags in MSC’s at late passage Malcolm B Will 2010     Chapter 4, 154 
Less stringent statistical criteria were used to establish biological patterns that 
may be lost if the threshold were set too high.  243 UniGene identifiers were 
uploaded, and 234 (96%) matched genes within the MetaCore™ database.  The 
twenty most common canonical maps that matched the differentially expressed 
genes are shown in Figure 4 14.  These maps included chemokine, cell adhesion, 
cytoskeletal re modelling, glycolysis and MAPK signalling pathways.  The genes 
were assigned gene ontological descriptions using standard methods (GO 
processes) and the software’s own version (GeneGO processes) as shown in 
Figure 4 15 and Figure 4 16.  The gene list was matched to known metabolic 
pathways which demonstrated alteration in membrane lipid and glucose 
metabolism (Figure 4 17). 
The network building algorithm was used to build a network of direct 
gene/protein interactions around the up loaded gene list.  Genes with direct 
interactions clustered around the transcription factor, activator protein 1 (AP 1) 
(Figure 4 18).  AP 1 is a heterodimeric protein that can initiate a multitude of 
cellular processes in response to varying cellular stimuli.  When a network was 
built by auto expansion (interactions are predicted with genes not included in 
the analysed list) a cluster developed around the transcription factor, 
hepatocyte nuclear factor 4 alpha (HNF4A) (not shown).  The nuclear protein 
encoded by this gene is known to regulate the expression of genes involved in 
glucose transport and metabolism. 
4.4 Discussion 
SAGE is an excellent method of large scale mRNA expression profiling which 
produces comprehensive, quantitative and reproducible gene expression 
profiles.  We did not experience any technical difficulties in performing SAGE 
although the technique is labour intensive if performed individually.  Although 
some research groups have generated large numbers of SAGE libraries using 
automated devices, microarray technology has evolved rapidly and is now 
favoured by most researchers.  The rapid generation of results and analysis; the 
large coverage of known genes; and the versatility of the equipment that 
enables comparative genomic hybridization (CGH), SNP and microRNA (miRNA) 
profiles to be determined using the same platforms has further enhanced its 
application.Malcolm B Will 2010     Chapter 4, 155 
 
Figure 4-14 Twenty most significant canonical maps associated with differentially 
expressed genes in late passage MSC’s 
234 differentially expressed tags in the comparison of 25 MSC P2 and P9 that 
matched a Unigene identifier were analysed using Metacore™ systems biology 
software.  The statistical algorithm uses a z score equation to assign genes to 
specific sub networks and the significance can be determined by the network 
size (p value 0.05). Malcolm B Will 2010     Chapter 4, 156 
 
Figure 4-15 Twenty most significant gene ontology (GO) processes associated with 
differentially expressed genes in late passage MSC’s 
234 differentially expressed tags in the comparison of 25 MSC P2 and P9 that 
matched a Unigene identifier were analysed using Metacore™ systems biology 
software.  The statistical algorithm uses a z score equation to assign genes to 
specific sub networks and the significance can be determined by the network 
size (p value 0.05). Malcolm B Will 2010     Chapter 4, 157 
 
Figure 4-16 Twenty most significant GeneGO processes associated with differentially 
expressed genes in late passage MSC’s 
234 differentially expressed tags in the comparison of 25 MSC P2 and P9 that 
matched a Unigene identifier were analysed using Metacore™ systems biology 
software.  The statistical algorithm uses a z score equation to assign genes to 
specific sub networks and the significance can be determined by the network 
size (p value 0.05). Malcolm B Will 2010     Chapter 4, 158 
 
Figure 4-17 Twenty most significant metabolic maps associated with differentially 
expressed genes in late passage MSC’s 
234 differentially expressed tags in the comparison of 25 MSC P2 and P9 that 
matched a Unigene identifier were analysed using Metacore™ systems biology 
software.  The statistical algorithm uses a z score equation to assign genes to 
specific sub networks and the significance can be determined by the network 
size (p value 0.05). Malcolm B Will 2010     Chapter 4, 159 
 
Figure 4-18 A network of direct interactions built around the differentially expressed gene 
list showed a cluster around the transcription factor AP-1 
234 differentially expressed tags in the comparison of 25 MSC P2 and P9 that 
matched a Unigene identifier were analysed using Metacore™ systems biology 
software.  Network analysis was performed using the direct interactions network 
building algorithm within the software.  Green arrows represent positive, red 
negative and grey unspecified interactions on the network.  Red and blue circles 
represent the SAGE expression data.  Red: significantly overexpressed in MSC’s 
passage nine.  Blue: significantly underexpressed in MSC’s passage nine (p value 
0.05). Malcolm B Will 2010     Chapter 4, 160 
The investigation of unmatched tags in order to identify novel genes is one of 
the most attractive aspects of the SAGE technique although we did not have the 
opportunity to perform this.  The use of RT PCR, using the SAGE tag as a primer 
and generating longer, more specific 3’ cDNA sequences has already been 
described.  In fact, our research group has used this method in the discovery of 
gastrokine 1, a potential tumour suppressor gene highly expressed in normal 
stomach and absent in gastric cancer (189).  An additional advantage of SAGE is 
that repeat analysis of the data can be performed when the reference sequence 
databases are periodically up dated and therefore novel genes may be identified 
at a later date from the original dataset. 
Each of the SAGE libraries generated contained approximately 40,000 tags 
matching approximately 20,000 genes (Table 4).  From the three libraries, 18 
(0.08%) tags had counts of more than one hundred in each and 16,997 (78%) tags 
occurred only once.  The majority of tags in each library did not match known 
genes whilst 30% were reliably assigned a UniGene identity.  This pattern of tag 
distribution and gene assignment is in agreement with earlier SAGE publications 
(123;124). 
The most abundant genes found in all three MSC’s SAGE libraries were similar to 
other published expression profiles of MSC’s (45;105;141;142).  Silva et al and 
Panepucci et al produced short SAGE libraries on MSC’s derived from human BM 
and cord blood respectively.  Although the donors and culture protocols were 
different, seven of the twenty most abundant genes in our libraries were 
identified in these studies.  The genes included: cytoskeletal proteins such as 
collagen, type I, alpha 1 (COL1A1), transgelin (TAGLN), cofilin 1 (CFL1) and 
vimentin (VIM); eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) 
which functions in the delivery of aminoacyl t RNA’s to the ribosome; and extra 
cellular matrix proteins lectin, galactoside binding, soluble, 1 (LGALS1) and 
secreted protein, acidic, cysteine rich (SPARC).  These genes are considered the 
molecular foundation of MSC’s although are widely expressed in other tissues 
and cell types. 
We found three unmatched tags (TTCATACACCTATCCCC, TGATTTCACTTCCACTC 
and CACCTAATTGGAAGCGC) that were present in the SAGE libraries and 
significantly increased at late passage.  A search of SAGE Genie revealed that Malcolm B Will 2010     Chapter 4, 161 
these tags matched publicly available sequences derived from mitochondrial 
DNA.  The results suggest transcriptional alterations occur in the mitochondria 
during prolonged culture and ageing of MSC’s.  It is widely accepted that 
mitochondrial dysfunction and increased production of reactive oxygen species 
(ROS) can lead to DNA damage and initiate the onset of senescence.  In support 
of our findings, a recent study has shown that the senescence of MSC’s is stress 
induced and high levels of ROS are found in late passage cells (68). 
We identified a five unknown tags unique to MSC’s in the comparison of SAGE 
library 25 MSC P2 to 110 publicly available long SAGE libraries.  The tags were of 
low abundance in MSC’s (counts <10) and included GGCCGCACCATAATGAG, 
CACAAGGCTCACATCTC, ACCCAAAAACCAAAAGT, TTAAAATAGCACCTTTA and 
ATGTGAANAGTTTCACA.  Using SAGE Genie, GGCCGCACCATAATGAG was 
identified as an internal tag in an expressed sequence transcript (EST) similar to 
transforming growth factor beta induced protein ig h3 precursor (accession 
number: AK094055).  ACCCAAAAACCAAAAGT was identified as an internal tag in 
an unidentified EST (accession number: BE814198) and the remaining tags were 
unmatched. 
These tags are of interest because they could represent novel markers of MSC’s.  
Furthermore, one tag matched the gene for CD248, also known as endosialin.  
CD248 is found expressed on stromal fibroblasts and pericytes (190).  It has been 
suggested that MSC’s reside in a perivascular niche (20) and a recently adipose 
derived MSC’s and pericytes were shown to have a remarkably similar surface 
marker profile in vitro and express the markers Stro 1, CD146 and 3G5.  In 
addition, cells displaying these markers have been identified in the vicinity of 
blood vessel walls in vivo (191).  A further study of CD248 expression in our 
MSC’s would be of great interest. 
We uncovered a gene expression signature using SAGE that can distinguish 
between MSC’s at early and late passage.  332 tags matched 243 known genes 
and 100 of these genes were found in the comparison with early passage cells 
from a different donor.  This overlap would confirm that these transcripts could 
identify molecular changes of ageing in MSC’s.  Metacore™ analysis of the direct 
interactions within the gene signature highlighted a signalling network involved 
in repression of AP 1 in late passage cells.  AP 1 is a heterodimer composed of Malcolm B Will 2010     Chapter 4, 162 
DNA binding proteins that include Jun, FOS and ATF subgroups of transcription 
factors.  AP 1 can regulate gene expression in response to a variety of stimuli as 
well as control key cellular processes such as proliferation, apoptosis and 
differentiation (Reviewed by (192)).  Late passage MSC’s showed significantly 
decreased expression of both c Fos and Jun which would explain the reduction in 
proliferation seen in the cells.  In studies using fibroblasts, short term exposure 
to oxidants increased AP 1 expression but sustained activation eventually 
resulted in decreased expression (193).  The results would infer that oxidative 
stress may contribute to the senescence of MSC’s and indeed, Heo et al have 
recently demonstrated that MSC’s display high levels of ROS levels during 
prolonged expansion (68). 
Metacore™ analysis also revealed that late passage MSC’s display significant 
alterations in genes associated with cytoskeletal remodelling, inflammation, 
extra cellular matrix re modelling and glycolysis.  The results are remarkably 
similar to that seen in microarray studies of replicative senescence in fibroblasts 
(92;194).  It is well recognised that the senescent phenotype has the potential to 
cause detrimental effects on tissue function due to enhanced tissue re modelling 
and impaired wound healing.  This would be an undesirable feature of cells used 
in cell therapy approaches and would emphasise the need to characterise 
cultures at the molecular level prior to clinical use. 
The significance of altered glycolysis in late passage MSC’s is uncertain and 
requires further investigation.  Most normal cells generate ATP through 
mitochondrial oxidative phosphorylation although in cancer cells it has been 
recognised that aerobic glycolysis predominates (Warburg effect).  Although an 
inefficient method of energy production, it is thought to sustain the high levels 
of proliferation seen in cancer cells and enhance resistance to oxidative stress.  
In late passage MSC’s this would be a useful property in the face of ongoing 
culture stress or may simply be a consequence of mitochondrial dysfunction in 
the cell and a method of sustained ATP production.  Further studies of glucose 
uptake in the cells would be of interest, particularly as the media concentration 
can alter the proliferative ability of MSC’s with reduced proliferation seen with 
higher concentrations ofglucose (58). Malcolm B Will 2010     Chapter 4, 163 
Lastly, we found that differentially expressed genes in late passage MSC’s were 
more commonly associated with chromosome two which has been shown in a 
previous study to contain senescence initiating genes (195).  Tanaka et al 
performed chromosomal transfer experiments in human cervical carcinoma cells 
and showed that chromosome two could induce growth arrest and a senescent 
phenotype.  In addition, the cells still expressed telomerase suggesting the 
mechanism may be telomere independent.  The findings are in contrast to a 
recent study that demonstrated an over representation of genes on chromosome 
4 in MSC’s undergoing replicative senescence using microarray (40).  It remains 
unknown if these differences arise from the technique of gene expression 
profiling used or that MSC’s initiate senescence via entirely different molecular 
mechanisms in our own and this study. 
4.5 Conclusion 
We have identified a gene expression signature using SAGE capable of 
distinguishing MSC’s at early and late passage.  This signature contains a 
regulatory signalling network centred on AP 1 down regulation that determines 
the molecular phenotype of aged MSC’s.  We identified genes associated with 
senescence, cell cycle regulation, oxidative stress and apoptosis.  Importantly, 
late passage MSC’s display enhanced inflammatory and extra cellular matrix re 
modelling properties which may be detrimental on tissue function if used for 
cell based therapies.  The results provide us with candidate genes that may 
represent transcriptional markers of MSC ageing and senescence.  The validation 
studies and the individual genes that were identified in late passage MSC’s are 
discussed further in the next chapter. 
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5  Validation of SAGE Using Taqman
® Low Density 
Arrays 
5.1 Introduction 
Because SAGE is labour intensive and hence limited to a small number of  
experiments, the resulting candidate genes require validation in multiple 
samples (102;106).  Validation of RNA expression was traditionally performed by 
Northern blotting or conventional reverse transcription polymerase chain 
reaction (RT PCR), although this has largely been superseded by fluorescence 
based, real time RT PCR.  The technique is easy to use, accurate and highly 
reproducible and the results require minimal post processing.  Although this 
method was originally a single gene approach, developments in micro fluidics 
mean it is now possible to perform real time RT PCR on three hundred and 
eighty four genes simultaneously using Taqman
® low density arrays (TLDA’s) 
(Applied Biosystems).  In addition, TLDA’s are available in a choice of formats 
that allow the number of genes, replicates and samples to be determined by the 
researcher. 
The most critical aspect of real time RT PCR is the selection of a suitable 
control gene for normalisation of the results.  Commonly used controls in real 
time PCR include ‘housekeeping’ genes such as glyceraldehyde 3 phosphate 
dehydrogenase (GAPDH), β actin (ACTB) and the ribosomal RNA’s (rRNA) such as 
18S.  Often these genes are chosen on the assumption that they are expressed at 
constant levels across samples although it has been recognised that suitable 
control genes should be determined for individual experiments (196).  To 
address this, TLDA’s have been developed to assay potential control genes and 
approaches on selecting suitable candidates have been published (197). 
The results of SAGE had identified candidate genes differentially expressed in 
late passage MSC’s and many were assigned to a signalling network that 
clustered around the transcription factor, AP 1.  Using ninety six gene TLDA’s 
our aim was to validate the SAGE results in multiple donor samples and also 
identify genes that represent novel markers of MSC ageing and senescence 
during expansion in vitro. Malcolm B Will 2010     Chapter 5, 165 
5.2 Results 
5.2.1 Selection of Control Genes for Normalisation Using TLDA’s 
Comparison of the SAGE libraries had identified differential expression of tags 
that matched the housekeeping genes, ACTB and GAPDH.  Therefore, to identify 
the best candidate gene to use as a control for normalisation in our experiments, 
we used the TLDA endogenous control assay (Applied Biosystems).  The array 
contains sixteen pre determined control genes that are measured in triplicate in 
eight samples simultaneously.  Before using the TLDA, a small volume of cDNA 
reaction was used in a GAPDH PCR to confirm generation of cDNA and absence of 
genomic DNA.  This was performed whenever cDNA was created and a 
representative gel is shown in Figure 5 1. 
The average cycle thresholds (CT) of the sixteen control genes determined from 
seven samples are shown in Figure 5 2.  The results of the eighth, donor 12 
MSC’s at passage one was excluded because of greater variability in the average 
CT.  This was thought to have arisen from haematopoietic and endothelial cell 
contamination in passage one cultures as described in chapter 3.  The results 
demonstrate that 18S is expressed at high levels, and tyrosine 3 
monooxygenase/tryptophan 5 monooxygenase activation protein, zeta 
polypeptide (YWHAZ) at low levels in MSC’s.  The standard deviation of the CT 
was calculated and the results shown in Figure 5 3.  The results demonstrate 
that the genes with the lowest standard deviation, and therefore the lowest 
variation across samples were 18S (0.06), UBC (0.33), RPLP0 (0.41) and ACTB 
(0.43).  Although 18S had the lowest variability, it was noticed that some wells 
on the array had unusually low CT values and if included the overall results 
would have demonstrated that 18S had the greatest variability.  Therefore, 
ubiquitin C (UBC) was selected as the best control gene and as alternatives 
ribosomal protein, large, P0 (RPLP0), polymerase (RNA) II (DNA directed) 
polypeptide A (POLR2A), ACTB and GAPDH were also added to the array. Malcolm B Will 2010     Chapter 5, 166 
 
Figure 5-1 GAPDH PCR confirms cDNA synthesis and absence of genomic DNA 
contamination 
cDNA was generated from eight RNA samples using the High Capacity cDNA 
Archive Kit (Applied Biosystems).  1 l of each cDNA reaction was then used as a 
template for a GAPDH PCR and the reaction products analysed on a 1% agarose 
gel.  Strong DNA bands of similar intensity confirmed the production of cDNA 
from the RNA samples (lanes 3 – 10).  No template (Lane 2), no template no RT 
(Lane 11) and no RT controls (Lanes 12 – 19) demonstrated the absence of 
genomic DNA contamination in reagents and samples.  A 100bp molecular ladder 
is shown (Lane 1). Malcolm B Will 2010     Chapter 5, 167 
18S
ACTB
B2M
GAPDH
GUSB
HMBS
HPRT1
IPO8
PGK1
POLR2A
PPIA
RPLP0
TBP
TFRC
UBC
YWHAZ
0
5
10
15
20
25
30
12P2
23P2
23P9
24P2
24P9
25P2
25P9
C
y
c
l
e
 
T
h
r
e
s
h
o
l
d
 
(
C
T
)
 
Figure 5-2 Variable abundance of potential control genes for normalisation was 
demonstrated in MSC’s 
The expression of sixteen endogenous control genes was analysed in seven MSC 
samples at passage two and nine using the TLDA endogenous control panel 
(Applied Biosystems).  Each bar represents the average CT of each gene 
measured in triplicate; error bars show the standard deviation. Malcolm B Will 2010     Chapter 5, 168 
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Figure 5-3 Suitable controls for normalisation were identified that showed the least variation 
in expression in MSC’s 
The standard deviation of the average CT was determined for each gene from the 
seven samples.  Gene expression was measured in triplicate for each sample. Malcolm B Will 2010     Chapter 5, 169 
5.2.2 Selection of Candidate Genes for the Custom-Made TLDA’s 
TLDA format 96b was chosen to enable analysis of ninety six genes in duplicate 
in two samples simultaneously.  The process of selecting genes for the custom 
made TLDA in order to validate the SAGE results is shown in Figure 5 4.  Genes 
were selected to include: those most significantly different between MSC’s at 
passage two and nine; those on AP 1 regulatory network; endogenous controls; 
non significant genes of variable abundance by SAGE; cell cycle genes; and genes 
associated with the p38 pathway.  Further information on each gene and its 
function can be found in the appendix (Table 8).  With the exception of heat 
shock 70kDa protein 8 (HSPA8), assays were selected to include probes that 
spanned exon junctions and therefore minimise the chance of amplification from 
genomic DNA.  The differentially expressed SAGE tags were manually identified 
in the original sequences from which the assays were developed to ensure a 
match.  The abundance and differential expression of tags in the three SAGE 
libraries that matched genes on the TLDA are found in the appendix (Table 9). 
Seventy six genes on the array were chosen to match tags differentially 
expressed more that two fold in the comparison of SAGE libraries 25 MSC P2 and 
P9.  Of these, fifty six genes were identified that had more than two fold change 
in tag odds ratio and p <0.01 and were the focus of the validation studies.  The 
other nineteen genes were of lower significance (p<0.05) but included to 
validate the regulatory network involving the transcription factor, AP 1.  Of 
note, forty two differentially expressed tags in the comparison of SAGE libraries 
12 MSC P2 and 25 MSC P9, and thirty three in the comparison of libraries 25 MSC 
P2 and 12 MSC P2 matched genes included on the array. 
5.2.3 Confirmation of the Reproducibility of TLDA’s 
In this study, the number of TLDA’s provided with the order was limited and it 
was not possible to perform a dilution series and ensure consistent amplification 
when the amount of template varied.  For the experiments described here cDNA 
equivalent to 100ng RNA was loaded onto each lane of the array as 
recommended by the manufacturer’s protocol. Malcolm B Will 2010     Chapter 5, 170 
 
Figure 5-4 Process of selection of genes for validation using custom-made TLDA Malcolm B Will 2010     Chapter 5, 171 
cDNA from donor 30 cells at passage nine was analysed on two separate 
occasions on different arrays to determine variablility in amplification between 
arrays.  From both studies, the mean relative quantities (RQ) for each gene were 
calculated using the 2
 DDC
T method where DDCT = ((CT, Target – CT, Control) Time y – (CT, 
Target – CT. Control) Time x).  The standard error of the CT was used to calculate 95% 
confidence intervals, called the minimum RQ (RQ Min) and maximum RQ (RQ 
Max).  UBC was the control gene, time x defined as MSC’s at passage two and 
time y defined as MSC’s at passage five or nine, where stated.  Mean RQ values 
were plotted against each other and a line of best fit drawn using linear 
regression as shown in Figure 5 5.  The r
2 value of 0.98 confirmed a strong 
correlation and therefore the arrays appeared reproducible when using the same 
cDNA sample.  The assay for cytochrome c oxidase subunit Vb (COX5B) did not 
amplify and was excluded from the analysis. 
5.2.4 Validation of the SAGE Results Using TLDA’s 
In order to determine that the tag counts in SAGE library 25 MSC P2 were 
representative of mRNA abundance by RT PCR, the techniques were compared.  
The relative abundance was determined for the genes collagen, type I, alpha 1 
(COL1A1), connective tissue growth factor (CTGF), insulin like growth factor 
binding protein 4 (IGFBP4), RPLP0 and interleukin 6 signal transducer (IL6ST) by 
comparison with the gene forkhead box O3A (FOXO3A) which was expressed at 
low levels in MSC’s.  The abundance was calculated as ((CT FOXO3A  CT Gene)
 2) 
for RT PCR and (Tag count gene/Tag count FOXO3A) for SAGE, and the results 
are shown in Figure 5 6.  The two techniques were comparable although the 
higher abundance of COL1A1 in SAGE may be an artefact of the tag based 
approach and may have become less obvious if the SAGE library size was 
increased. 
In order to validate differentially expressed tags in the comparison of SAGE 
libraries 25 MSC P2 and P9, the expression of seventy six matching genes were 
determined in the same samples using the arrays.  Mean RQ values were 
determined by 2
 DDC
T method and a comparison made between donor 25 MSC’s at 
passage two and nine.  Genes were identified as differentially expressed if the 
mean RQ, including RQ Min and RQ Max did not overlap.  The results from this 
comparison can also be found in the appendix (Table 10). Malcolm B Will 2010     Chapter 5, 172 
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Figure 5-5 TaqMan
® low density arrays displayed excellent reproducibility 
cDNA from donor 30 MSC’s at passage nine was analysed on two occasions (day X 
and Y) and the relative quantity (RQ) of genes on the array calculated using the 
2
 DDC
T method.  Baseline expression was determined in cells at passage two and 
normalised to the control, UBC.  RQ values for each gene were plotted, and 
those less than 1 displayed as 1/RQ in order to determine a line of best fit by 
linear regression. Malcolm B Will 2010     Chapter 5, 173 
IL6ST
RPLP0
IGFBP4
CTGF
COL1A1
2
4
8
16
32
64
128
256
25 MSC P2 RT-PCR
25 MSC P2 SAGE
m
R
N
A
 
a
b
u
n
d
a
n
c
e
 
r
e
l
a
t
i
v
e
 
t
o
F
O
X
O
3
A
 
e
x
p
r
e
s
s
i
o
n
 
Figure 5-6 mRNA abundance detected by SAGE was comparable to that found by RT PCR 
Bars represent mRNA abundance relative to FOXO3A as determined by RT PCR 
((CT FOXO3A  CT GENE)
 2) or SAGE (Tag count gene/Tag count FOXO3A) in donor 
25 MSC’s at passage two.  CT for each gene was measured in duplicate.  The Y 
axis scale is set to log2 to aid visualisation of the results. Malcolm B Will 2010     Chapter 5, 174 
Forty one genes (54%) were confirmed as differentially expressed at passage nine 
and only the expression of cathepsin S (CTSS) was in the opposite direction to 
SAGE.  High mobility group AT hook 1 (HMGA1) showed increased expression that 
was not significant because of the large standard error in CT but it was decided 
not to exclude this gene from further analysis.  Eight genes were identified in 
MSC’s from donor 25 at passage five that were significantly different to MSC’s at 
passage two but not passage nine.  However, the mean RQ values were similar at 
both time points and these genes were considered for further analysis. 
To refine the gene list further, we identified thirty four genes (45% total 
validated) that were differentially expressed more than two fold i.e. mean RQ 
greater than two and less than half.  This was the fold difference chosen in the 
selection of SAGE tags for validation.  The expression of twenty one genes 
increased (Figure 5 7) in donor 25 MSC’s at passage nine and thirteen decreased 
(Figure 5 8).  The levels of expression by SAGE appeared greater than that by 
RT PCR, particular for genes whose expression increased in MSC’s at late 
passage.  It was noted that twenty two genes from the list of thirty four were 
also significantly different in MSC’s at passage five from the same donor. 
The results from the same TLDA’s were used to validate the differential 
expression of genes identified on the network clustered on AP 1.  Sixteen genes 
(50% of those validated on the network) were found to be differentially 
expressed between donor 25 MSC’s at passage two and nine (Figure 5 9).  The 
expression of the gene FOS showed a trend of decreased expression with 
increasing passage number although this was not significant (mean RQ of 0.85 
and 0.68 at passage five and nine respectively). 
5.2.5  Determining Transcriptional Markers of Late Passage 
MSC’s 
To determine if the transcriptional changes were a consistent feature of late 
passage cells, TLDA’s were used to analyse gene expression in seven other MSC 
cultures at passage two, five and nine.  All the results, including those from 
donor 25 were then used to determine the mean RQ for all genes on the array 
and comparisons made between groups using a paired student’s t test.  The 
results can be found in the appendix (Table 11). Malcolm B Will 2010     Chapter 5, 175 
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Figure 5-7 Genes that matched tags significantly increased by SAGE were confirmed by RT-
PCR 
RQ values were calculated in donor 25 MSC’s at passage nine using the 2
 DDC
T 
method with baseline expression determined in cells at passage two and 
normalised to the control, UBC.  Bars represent the mean RQ value for each 
gene measured in duplicate and the odds ratio for the same gene identified in 
the SAGE comparison 25 MSC P9:P2. Malcolm B Will 2010     Chapter 5, 176 
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Figure 5-8 Genes that matched tags significantly decreased by SAGE were confirmed by RT-
PCR 
RQ values were calculated in donor 25 MSC’s at passage nine using the 2
 DDC
T 
method with baseline expression determined in cells at passage two and 
normalised to the control, UBC.  Bars represent fold change in expression, 
equivalent to 1/mean RQ value for each gene measured in duplicate and the 
1/odds ratio for the same gene identified in the SAGE comparison 25 MSC P9:P2. Malcolm B Will 2010     Chapter 5, 177 
 
Figure 5-9 Validation studies supported the existence of a signalling network identified from 
differentially expressed SAGE tags 
Thirty two genes on the network of direct interactions built using Metacore
TM 
were validated by RT PCR in cells from donor 25 at passage two and nine.  Mean 
RQ values were calculated using the 2
 DDC
T method with baseline expression 
determined in MSC’s at passage two and normalised to the control, UBC.  Genes 
were considered significantly different if the 95% confidence intervals of the 
mean RQ did not overlap.  Green arrows represent positive, red negative and 
grey unspecified interactions on the network.  Red and blue circles represent the 
SAGE expression data and squares represent the expression of genes validated by 
RT PCR.  Red: significantly up in MSC’s at passage nine.  Blue: significantly down 
in MSC’s at passage nine.  Black: not significant.  Gene aliases are shown in black 
text. Malcolm B Will 2010     Chapter 5, 178 
Twenty four (71%) genes from the reduced list of thirty four were confirmed as 
differentially expressed in all cultures at passage nine and eighteen genes 
showed changes in expression of more than two fold.  From this list, sixteen 
genes showed increased expression (Figure 5 10 and Figure 5 11), and only two 
decreased in late passage MSC’s (Figure 5 12).  As shown in the figures, the 
genes CAV1, CCND1, PLAT and OLFML3 were differentially expressed in MSC’s at 
passage five and nine suggesting they could discriminate between cultures of 
different proliferative age in vitro. 
The overall results from the TLDA’s were used to validate the differential 
expression of genes identified on the network clustered on AP 1.  Eighteen (56%) 
genes validated on the network were found to be differentially expressed 
between eight donors MSC’s at passage two and nine (Figure 5 13).  Only eight 
were expressed at levels more than two fold as highlighted in the figure.  In 
contrast to the findings in donor 25, the mean expression of the gene FOS was 
significantly decreased in the eight donor samples. 
5.2.6 Determining the Expression of Cell Cycle Control Genes in 
Late Passage MSC’s 
Several important pathways control cell proliferation including the p16
INK4a
 – Rb 
pathway, the p53 – 21
CIP1/WAF1 pathway and PTEN – p27
Kip1.  The cyclin dependent 
kinase inhibitors (CDKN’s) 1A, 1B and 2A encode the proteins p21, 27 and 16 
respectively and were included on the array to assess activity of these pathways 
in MSC’s.  It was noted that SAGE had not identified differential expression of 
these genes in MSC’s from donor 25 at early and late passage.  The mean RQ 
values were determined for these genes as well as the gene FOS in eight MSC 
cultures at passage two, five and nine and the results are shown in Figure 5 14.  
The increased expression of CDKN1A and 2A would infer activation of both p53 
and Rb pathways, while CDKN1B was decreased and would suggest a decline in 
activity of the PTEN pathway during expansion of MSC’s in vitro. Malcolm B Will 2010     Chapter 5, 179 
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Figure 5-10 Genes with significantly increased expression in all MSC cultures during 
expansion 
RQ values were calculated using the 2
 DDC
T method with baseline expression 
determined in MSC’s at passage two and normalised to the control, UBC.  
Comparisons were made using a paired student’s t test, p value £ 0.05 *, 0.01 ** 
and 0.001 ***.  Bars represent the mean RQ value from eight cultures; each gene 
was measured in duplicate.  Error bars represent the standard deviation. Malcolm B Will 2010     Chapter 5, 180 
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Figure 5-11 Genes with significantly increased expression in all MSC cultures during 
expansion 
RQ values were calculated using the 2
 DDC
T method with baseline expression 
determined in MSC’s at passage two and normalised to the control, UBC.  
Comparisons were made using a paired student’s t test, p value £ 0.05 *, 0.01 ** 
and 0.001 ***.  Bars represent the mean RQ value from eight cultures; each gene 
was measured in duplicate.  Error bars represent the standard deviation.  RQ 
values significantly different at passage five and nine are highlighted. Malcolm B Will 2010     Chapter 5, 181 
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Figure 5-12 Genes with significantly decreased expression in all MSC cultures during 
expansion 
RQ values were calculated using the 2
 DDC
T method with baseline expression 
determined in MSC’s at passage two and normalised to the control, UBC.  
Comparisons were made using a paired student’s t test, p value £ 0.001 ***.  Bars 
represent the mean RQ value from eight cultures; each gene was measured in 
duplicate.  Error bars represent the standard deviation.  RQ values significantly 
different at passage five and nine are highlighted. Malcolm B Will 2010     Chapter 5, 182 
 
Figure 5-13 Altered expression of genes on the regulatory network were detected in eight 
MSC cultures at late passage 
Thirty two genes on the network of direct interactions built using Metacore
TM 
were validated by RT PCR in eight MSC cultures.  Green arrow’s represent 
positive, red negative and grey unspecified interactions on the network.  Red 
and blue circles represent the SAGE expression data while squares represent the 
expression of genes validated by RT PCR.  Red: significantly up in MSC’s at 
passage nine.  Blue: significantly down in MSC’s at passage nine.  Black: not 
significant.  Gene aliases are shown in black text.  Black stars: genes with 
altered expression more than two fold in comparison to MSC’s at passage two.  
Comparison of RQ values at passage two and nine performed using a paired 
student’s t test and p value £ 0.05. Malcolm B Will 2010     Chapter 5, 183 
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Figure 5-14 MSC’s show altered expression of cell cycle control genes during expansion 
The RQ values were calculated using the 2
 DDC
T method with baseline expression 
determined in MSC’s at passage two and normalised to the control, UBC.  
Comparisons were made using a paired student’s t test, p value £ 0.05 *, 0.01 ** 
and 0.001 ***.  Bars represent the mean RQ value from eight cultures; each gene 
was measured in duplicate.  Error bars represent the standard deviation. Malcolm B Will 2010     Chapter 5, 184 
5.2.7 Subjective Scoring of MSC Culture Age 
Four genes (CAV1, CCND1, PLAT and OLFML3) were found differentially 
expressed at passage five and nine and could potentially be used to discriminate 
the culture age of different MSC samples.  It was decided to retrospectively 
score all the cultures in order to highlight differences between donor cells.  
Therefore, the mean RQ value for each gene was reviewed in individual cultures 
at passage five and nine and a value of one assigned to the culture with the least 
expression and eight to the culture with the highest expression.  Total scores 
were calculated for each culture and the results shown in Figure 5 15.  MSC’s 
from donor 26 displayed the highest score at passage five and donor 23, the 
highest score at passage nine.  MSC’s from donor 24 had the lowest scores at 
passages five and nine.  The scores did correlate with proliferative ability 
because MSC’s from donor 26 proliferated slowly and together with cells from 
donor 23 could not be expanded beyond nine passages.  In contrast, MSC’s from 
donors 24 and 27 were able to proliferate until passage twelve before growth 
arrest.  Although the results are subjective, it would be of interest to determine 
if the expression of these genes can predict the proliferative potential of 
individual MSC cultures from initial isolation or first passage and a prospective 
study would be required to address this. 
5.3 Discussion 
One concern that arose from SAGE was that late passage MSC’s had altered 
expression of housekeeping genes commonly used for normalisation of RT PCR.  
The importance of determining the best gene for a control has been highlighted 
by other studies and we used a similar approach (196;197).  The gene UBC was 
identified as a suitable candidate in the initial study although on review of all 
the results, GAPDH, POLR2A and RPLP0 performed equally well.  Our results 
suggest ACTB is not suitable as a control because mean expression decreased in 
late passage MSC’s from the eight donors used in this study.  Therefore, our 
results provide insight for other researchers on the selection of appropriate 
control genes suitable for expression profiling experiments using MSC’s. Malcolm B Will 2010     Chapter 5, 185 
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Figure 5-15 Retrospective analysis identified differences in ageing of MSC cultures from 
different donors 
The mean RQ values of the genes CAV1, CCND1, PLAT and OLFML3 were used to 
identify differences in cultures by assigning a value of one to the culture with 
least expression of a gene to eight for the culture with the highest expression.  
The bars represent the total scores of the four genes in each sample measured 
at passage five and nine. Malcolm B Will 2010     Chapter 5, 186 
The validation studies have confirmed the validity of the SAGE results.  By 
determining tag counts in the SAGE libraries for selected genes and the relative 
abundance by RT PCR we have shown that both techniques correlate relatively 
well.  Therefore, we were confident that the SAGE libraries were representative 
of mRNA expression in MSC’s.  Furthermore, genes abundant in MSC’s, such as 
COL1A1, CTGF, TGFBI and VIM were confirmed by RT PCR and have been 
demonstrated in other studies of the MSC transcriptome (45;105;141;142).  To 
determine the differential expression of genes identified by SAGE, seventy six 
genes were validated by RT PCR using custom made TLDA’s.  The results on 
cDNA derived from the same RNA confirmed that forty one (54%) genes were 
differentially expressed and thirty four (45%) showed changes greater than two 
fold by RT PCR.  The differences in mRNA expression by SAGE were generally 
greater than those detected by RT PCR and may be due to differences between 
the techniques.  Reassuringly, the success of our SAGE validation was not 
dissimilar to that reported by earlier SAGE studies (102;123;198). 
In our study, we identified eighteen genes (23%) in passage nine cells with 
expression more than two fold different to those at passage two.  Of these, 
sixteen were increased and only two decreased.  Interestingly, the genes CAV1, 
CCND1, PLAT and OLFML3 were differentially expressed between passage five 
and nine and could potentially discriminate MSC’s of different culture age.  The 
results would suggest that the transcriptional alterations are part of a common 
molecular program that occurs beyond passage two and lends support to the 
findings of a recent study in which the expression of senescence associated 
genes was shown to increase with each subsequent passage (40). 
We identified genes that explain the decline in proliferation seen in late passage 
MSC’s.  Late passage cells showed increased expression of cyclin D1 (CCND1), a 
key regulator of G1/S transition in the cell cycle and increased levels have been 
found in fibroblasts undergoing replicative or stress induced senescence (199 
201).  In addition, the cyclin dependent kinase inhibitors 1A and 2A (CDKN1A and 
CDKN2A) were increased at passage nine and imply the activation of both the 
p53 and p16 pRB pathways.  In support, increased expression of SERPINE1 and 
HMGA1 was also demonstrated in late passage MSC’s and both have been 
identified as downstream targets of these pathways (202;203).  HMGA1 proteins 
are critical components of senescence associated heterochromatin foci (SAHF’s) Malcolm B Will 2010     Chapter 5, 187 
and function to maintain senescence by the silencing of genes critical for cell 
growth and proliferation (204).  These findings provide further evidence of an 
increased senescence response during the expansion of MSC’s in vitro. 
Our study identified genes that could enable late passage MSC’s to resist 
apoptosis and tolerate increased levels of oxidative stress.  The stanniocalcin, 
STC2 showed increased expression in late passage cells and is important for 
normal phosphate and calcium metabolism (205).  The expression of STC2 is 
increased in cells exposed to xenotoxins and reducing agents and knockdown 
studies reveal increased cell death upon exposure to the same agents (206).  
Similarly, caveolin proteins such as CAV1 can be induced in cells exposed to 
oxidising agents and knockdown studies also report an increase cell death (207).  
In addition, the overexpression of CAV1 can initiate senescence in fibroblasts 
(208) and increased expression has been demonstrated previously in senescent 
MSC’s (96).  In this study, forced over expression of CAV1 in MSC’s resulted in a 
loss of adipogenic differentiation capacity and the results are similar to that 
identified in this study when cells underwent prolonged culture.  Therefore, 
CAV1 plays an important role in both the senescence of MSC’s and in determining 
the restriction of lineage fate seen during prolonged expansion. 
The increased expression of superoxide dismutase 1 (SOD1) in MSC’s was also 
confirmed at late passage.  The protein encoded by this gene is critical for the 
removal of reactive oxygen species (ROS) and knockout mice display premature 
ageing and susceptibility to cancer formation due to increased level of ROS 
(209).  It has been demonstrated that MSC’s have a low tolerance of oxidative 
stress (210) and this is supported by a recent study showing that MSC’s culture in 
low oxygen conditions have enhanced proliferative and differentiation capacity 
(62).  These findings would suggest ROS levels are important in the initiation of 
senescence in MSC’s and that increased SOD1 expression may allow late passage 
cells to tolerate high levels of oxidative stress.  Providing further support, 
knockdown of SOD1 induces premature senescence of fibroblasts confirming a 
crucial role in reducing intra cellular ROS and preventing DNA damage that 
contributes to the initiation of a senescence response (211). 
Our study identified genes that would suggest late passage MSC’s have 
inflammatory properties and enhanced ability to remodel the extracellular Malcolm B Will 2010     Chapter 5, 188 
matrix.  The expression of signal transducer and activator of transcription 1 
(STAT1) increased, similar to the findings recently described by Wagner et al in 
a study of MSC’s undergoing replicative senescence (40).  STAT1 expression 
increases in response to interferon’s and sustained signalling has been 
demonstrated to initiate senescence in fibroblasts by the activation of p53 (212).  
High expression of STAT1 in synovial fibroblasts is thought to enhance tissue 
destruction in patients with active rheumatoid arthritis suggesting that such 
alterations of MSC properties could have detrimental effects on tissue 
homeostasis and repair (213).  In addition, late passage MSC’s were enriched for 
genes involved in proteolysis and turnover of the extra cellular matrix.  ADAM 
metallopeptidase with thrombospondin type 1 (ADAMTS1) and tissue plasminogen 
activator (PLAT) exhibit such properties and have been found at increased levels 
in patients with neurodegenerative disorders (214) as well as in senescent 
fibroblasts (215).  The role of serine protease 23 (PRSS23), also found at 
increased levels in late passage MSC’s is poorly understood although a proteomic 
study of ovarian function suggests a critical role in the breakdown of the extra 
cellular matrix during normal follicular development (216).  In contrast to the 
pattern of expression by SAGE, the protease cathepsin S (CTSS) was found at 
significantly decreased levels by RT PCR.  CTSS is important for the remodelling 
of the vasculature (217) and also the digestion of proteins required for intact 
MHC Class II immune responses (218).  Interestingly, CTSS deficient mice display 
decreased immune responsiveness and further studies would be required to 
establish if late passage MSC’s have similar changes in their immune 
characteristics.  This could be a mechanism by which senescent MSC’s evade 
immune detection and clearance that could enhance prolonged survival in vivo. 
Our results have identified other genes whose functions are not completely 
understood.  KIAA1199 was first identified in chromosome transfer experiments 
that induced senescence in renal cell carcinoma cell lines (219).  Further 
research demonstrated high expression in normal fibroblasts and low levels in 
the transformed counterparts and cancer cell lines implying this gene may 
function as a tumour suppressor (220).  The results of this study were in contrast 
to our findings because KIAA1199 expression did not differ in cells of different 
proliferative history.  We detected high levels of expression after passage two 
while the fibroblast cultures described by Michishita et al were assayed beyond 
thirty eight population doublings.  Interestingly, expression was not significantly Malcolm B Will 2010     Chapter 5, 189 
different between MSC’s at passage five and nine suggesting that this gene may 
be a marker of cell mortality as implied by the study. Decreased expression of 
olfactomedin like three (OLFML3) was found in late passage MSC’s and this was 
interesting because this family of secreted proteins are poorly understood.  They 
are typically found enriched in mucus linings, hence their name and are required 
to maintain the normal properties of the extra cellular matrix (221).  
Interestingly, mutations of myocilin which contains an olfactomedin domain 
results in the accumulation of intracellular proteins that have been implicated in 
the pathogenesis of age related glaucoma (222).  More recently, it has been 
suggested that olfactomedins may function as oncogenes because the family 
member OLFML4 was found highly expressed in pancreatic cancer cell lines.  In 
support, knockdown studies using siRNA were shown to initiate the onset of a 
senescent phenotype confirming a role of olfactomedins in cell proliferation 
(223).  The results of these studies suggest that decreased expression of OLFML3 
in late passage MSC’s may fundamentally alter the properties of the cells and 
maintain growth arrest. 
Finally, our results indicate that during the expansion of MSC’s a highly 
consistent pattern of gene expression emerges that can be detected in all 
cultures and before the onset of growth arrest.  The transcriptional alterations 
follow a common molecular program that would appear to be regulated by the 
decline in activity of the transcription factor AP 1.  Although we only validated 
one component of this transcription factor (the gene FOS), SAGE identified 
decreased expression of JUN and would support our findings.  AP 1 activity has 
been shown to increase in fibroblasts in response to physiological stimuli such as 
oxidative stress although sustained activation eventually results in a decline in 
activity (193).  As some evidence suggests that oxidative stress is a major 
component of routine MSC culture that can be overcome using media 
supplemented with selenium (210) or low oxygen conditions (62) it seems 
plausible that these factors have important effects on the regulation of AP 1 
activity.  Only recently, Heo et al demonstrated that late passage MSC’s exposed 
to oxidants displayed a similar phenotype to those undergoing proliferative 
stress providing further evidence that ROS and oxidative stress are important 
factors in the onset of senescence in MSC’s during routine culure (68).  
Therefore, we would speculate that the alterations in gene expression we 
detected represent a response to culture stress and together with telomere Malcolm B Will 2010     Chapter 5, 190 
erosion leads to a decline in the functional properties of MSC’s and the onset of 
senescence. 
5.4  Conclusion 
Our study has identified a regulatory pathway that controls the transcriptional 
changes observed during the expansion and senescence of MSC’s in vitro.  We 
have identified eighteen genes that could be used as markers of senescence or 
an enhanced senescence response seen during extended culture 
Four genes were identified that discriminate the proliferative history of 
individual MSC cultures and further validation is required in a prospective study.  
The results enhance our understanding of the molecular mechanisms that 
regulate proliferation and senescence of MSC’s and these markers could be used 
to ensure quality control of MSC’s prior to use in clinical trials or laboratory 
research.  In addition, these markers may be used to optimise existing culture 
protocols as well as in the development of novel culture techniques. 
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6  Investigating the Effects of p38 MAPK Mitogen-
Activated Protein Kinase Inhibition in MSC’s 
6.1 Introduction 
Pharmacological manipulation of stem cells using small molecules is an 
attractive approach to investigate the exact function of specific molecular 
pathways in these cells.  In recent years, the Wingless (Wnt) and p38 MAPK 
mitogen activated protein kinase (MAPK) pathways have been shown to be 
important in the regulation of self renewal and senescence. 
Wnt proteins are secreted lipid modified signalling molecules that regulate cell 
proliferation and cell fate during embryological development.  The proliferative 
effects are largely mediated through the canonical pathway by the binding of 
extra cellular Wnt proteins to their cognate receptors, Frizzled (Fzd).  This 
causes inactivation of glycogen synthase kinase 3 (GSK3) which prevents 
phosphorylation and degradation of the transcription factor, β catenin.  
Subsequently, β catenin relocates to the nucleus and drives the expression of 
proliferative genes such as cyclin D1 or c Myc.  The small molecule (2′Z, 3′E) 6 
Bromoindirubin 3′ oxime (BIO) has been identified as a specific inhibitor of GSK3 
and shown to mimic Wnt signalling in Xenopus embryo’s (224).  In a recent 
study, BIO was used to maintain self renewal and prevent spontaneous 
differentiation of mouse and human ESC’s in vitro (132).  In addition, BIO has 
been shown to enhance proliferation of human CSC’s (26) and even rodent 
cardiomyocytes (225).  At the time of this research, the effect of BIO on MSC’s 
had not been reported although the Wnt signalling pathway has been defined in 
MSC’s (226) and is recognised to influence MSC fate (227).  Therefore, we 
wanted to investigate the effect of GSK3 inhibition in MSC’s. 
The p38 MAPK pathway plays an essential role in the cellular response to 
inflammatory cytokines and environmental stress.  Like other MAPK pathways, 
the p38 MAPK signalling cascade involves sequential activation of MAPK kinase 
kinases (MAP3Ks) and MAPK kinases (MKKs).  Numerous substrates of p38 MAPK 
have been identified including other protein kinases, transcription factors and 
key regulators of the cell cycle (228).  A further role of p38 MAPK as a tumour Malcolm B Will 2010     Chapter 6, 192 
suppressor has been demonstrated recently.  Mice deficient in the downstream 
gene, p38 MAPK regulated/activated protein kinase (PRAK) show increased skin 
carcinogenesis in response to the mutagen, dimethlybezanthracene (DMBA) 
(229).  It was demonstrated that PRAK is essential for the initiation of 
senescence by the activation of the tumour suppressor, p53.  In support, other 
studies have demonstrated that p38 MAPK is activated in senescent cells in vitro 
in response to telomere shortening, oncogenes and oxidative stress (230).  
Therefore, it appears p38 MAPK activation is a common pathway to senescence 
regardless of the initiating mechanism. 
The exact insults that result in the activation of p38 MAPK remain poorly 
understood although reactive oxygen species (ROS) appear increasingly 
important.  HSC’s from mice deficient in the ataxia telangiectasia mutated 
(ATM) gene lose functional capacity with age and demonstrate high levels of 
intra cellular ROS (231).  It was shown that anti oxidants or the small molecule 
inhibitor of p38 MAPK, 4 (4 Fluorophenyl) 2 (4 methylsulfinylphenyl) 5 (4 
pyridyl) 1H imidazole (SB203580) could prevent this and HSC’s maintained the 
ability to reconstitute haematopoiesis in vivo.  The contribution of p38 MAPK 
activation to the premature ageing of other cell types has been demonstrated.  
In fibroblasts from patients with Werner’ syndrome (a premature ageing disease) 
it was shown that SB203580 could restore proliferation to levels seen in 
fibroblasts from healthy donors (232).  Therefore, it would appear that ROS and 
the resulting DNA damage may contribute to ageing as a general phenomenon.  
The results of these studies led us to speculate that p38 MAPK activation could 
contribute to the decline in stem cell properties of MSC’s. 
Therefore, we set out to investigate the effects of both drugs on the 
proliferative capacity of MSC’s during prolonged expansion in vitro.  The results 
are discussed and contributions from colleagues are acknowledged where 
appropriate. 
6.2 Results 
For the experiments described in this chapter, cultures were established from 
cryopreserved MSC’s at passage two recovered overnight and grown in medium 
containing drug or an equivalent volume of dimethyl sulfoxide (DMSO) as a Malcolm B Will 2010     Chapter 6, 193 
control.  Medium was replaced twice a week and contained fresh drug or DMSO.  
The final concentration of DMSO was 0.005% and would not be expected to cause 
significant cell toxicity. 
6.2.1 Dose Titration of SB203580 and BIO in MSC’s 
To obtain data on drug sensitivity, MSC’s were treated with SB203580 or BIO in a 
dilution series and viable cell counts determined after seven days (Figure 6 1).  
MSC’s cultured in SB203580 displayed a proliferative advantage at the 
concentrations tested although this was not significant in comparison to the 
controls.  MSC’s cultured in 1 M of SB203580 underwent more population 
doublings (PD) in comparison to the controls at seven days although this was not 
significant (4.36 versus 3.85 PD; p value 0.06).  Viability of cultures was always 
greater than 95% suggesting the concentration of SB203580 used was not toxic to 
the cells. 
A greater range of concentrations of BIO was tested based on the amounts 
described in previous studies (26;132;225).  MSC’s cultured in 3nM to 1 M BIO 
showed similar proliferation to the controls whereas 3 M and 10 M BIO 
significantly inhibited MSC proliferation (Figure 6 1B).  At these concentrations, 
MSC’s altered cell morphology with some cells long and tubular, and others large 
and flat.  The appearances raised the possibility of differentiation or the onset 
of senescence although further studies were not performed. 
Due to time constraints and the variable effect of BIO on MSC’s it was decided to 
focus our research on the effect of SB203580 in detail.  Five MSC cultures 
(donors 23, 25, 27, 28 and 29) with average proliferation were cultured 
continuously in either 1 m SB203580 or an equivalent volume of DMSO (control).  
The concentration was selected based on the manufacturers suggested IC50 
(50nM to 600nM) as well as the slight proliferative advantage seen at this 
concentration.  Research on Werner’s syndrome fibroblasts and HSC’s used much 
higher concentrations (10 M) of SB203580 although this increases the possibility 
of off target effects which have not been considered in these studies 
(207;231;232). Malcolm B Will 2010     Chapter 6, 194 
 
Figure 6-1 Dose titration of a p38 MAPK and GSK3 inhibitor in MSC’s 
MSC’s at passage two were cultured in medium containing varying concentrations 
of SB203580 or BIO.  Bars represent the mean viable cell counts obtained from 
three donor MSC cultures in either drug.  Error bars represent the standard 
deviation.  Comparisons were made to controls using a paired student’s t test; p 
value £ 0.05 *. Malcolm B Will 2010     Chapter 6, 195 
6.2.2 SB203580 Does Not Alter Cell Cycle Rate of MSC’s 
To determine if SB203580 altered the rate of cell division in MSC’s we used the 
CellTrace™ CFSE Cell Proliferation Kit (Molecular Probes, Invitrogen).  This was a 
gift from Heather Jorgensen, post doctorate within the research group of 
Professor T. Holyoake.  Carboxy fluorescein diacetate succinimidyl diester 
(CFSE) is a colourless dye that passively diffuses into cells and remains non 
fluorescent until the acetate groups are removed by intracellular esterases.  The 
resulting carboxyfluorescein succinimidyl ester is highly fluorescent and reacts 
with intracellular amines to form fluorescent conjugates that are retained by the 
cell.  CFSE is partitioned equally between daughter cells during cell division and 
as a result high resolution tracking of cell division can be monitored by the 
reduction in fluorescence seen using flow cytometry. 
Early passage MSC’s were labelled with CFSE and cultured in MSC medium 
containing either SB203580 or DMSO for five days.  In some flasks, mitomycin C 
was used to inhibit cell proliferation and determine the maximum level of 
fluorescence known as CFSEmax.  The remaining flasks were analysed on day one, 
three and five and the results shown in Figure 6 2.  There was increased uptake 
of CFSE in SB203580 treated cells compared to controls despite similar 
incubation times (Geometric mean CFSEmax (FL1) 480.2 ± 195.7 and 284.5 ± 106.8 
respectively; p value 0.09).  Representative overlay histograms for the controls 
(Figure 6 2A) and SB203580 treated cells (Figure 6 2B) demonstrate this finding.  
It was noted that the fluorescence curves were spread out unlike the distinct 
peaks seen during cell division of HSC’s.  This was thought to reflect the 
heterogeneity in MSC size and granularity (FSC and SSC properties) as well as 
variation in the rate of dividing cells and the absolute number of cells that 
entered or exited the cell cycle. 
The number of PD’s was determined using the formula: PD = (log (Geometric mean CFSE 
max   Geometric mean unstained cells) – log (Geometric mean CFSE Day x – Geometric mean unstained cells)) / log 
2.  The results showed that SB203580 treatment did not alter the cell cycle rate 
of MSC’s (Figure 6 2C).  In fact, the control cells had proliferated to a greater 
extent than drug treated cells at day three (3.5 ± 0.5 versus 2.7 ± 0.6; p value 
0.06) although at day five the results were similar (5.0 ± 0.3 versus 4.8 ± 0.5; p 
value 0.40). Malcolm B Will 2010     Chapter 6, 196 
 
Figure 6-2 SB203580 does not alter cell cycle properties of early passage MSC’s 
The rate of cell division in MSC’s was determined by flow cytometry using the 
CellTrace™ CFSE Cell Proliferation Kit (Molecular Probes, Invitrogen).  
Representative overlay histograms of control (A) and SB203580 treated (B) cells 
are shown.  The mean population doublings were calculated at each time point 
using the formula PD = log (Geometric mean CFSE max   Geometric mean unstained cells) – log 
(Geometric mean CFSE Day x – Geometric mean unstained cells)) / log 2 (C).  The coefficient of 
variation of fluorescence was calculated at each time point (D).  Bars represent 
the overall mean from five donor MSC cultures.  Error bars represent the 
standard deviation.  Comparisons were made to controls using a paired student’s 
t test. Malcolm B Will 2010     Chapter 6, 197 
It was noted that by CFSE, MSC’s achieved one additional PD compared to that 
calculated using viable cell counts (PD = (log (no. MSC’s harvested) – log (no. MSC’s plated)) / 
log 2).  This would support the findings in chapter 3 where it was shown that by 
CFE F less than 50% of MSC’s retain progenitor potential and therefore only half 
the plated cells undergo further cell division. 
To ensure that SB203580 did not alter the characteristics of the dividing 
population the coefficient of variation (CV) of the mean fluorescence was 
determined for drug treated cells and their respective controls (Figure 6 2D).  
There was no significant difference between drug treated MSC’s or the controls 
which confirmed that SB203580 does not alter cell cycle properties or number of 
dividing MSC’s during short term exposure. 
6.2.3 SB203580 Increases the Proliferative Capacity of MSC’s 
If p38 MAPK activation is important for senescence in MSC’s, we predicted that 
MSC’s cultured in SB203580 should proliferate to a greater extent than those in 
control media.  MSC’s from five donors underwent serial passage in the presence 
or absence of SB203580 until the control cells reached the ninth passage.  In this 
experiment, it was not possible to expand MSC’s from donor 23 beyond passage 
eight.  Drug treated cells were expanded beyond nine passages to determine the 
onset of growth arrest which was defined as a failure to reach near confluence 
after thirty days.  The growth curves for donors 23, 25, 27 and 28 (Figure 6 3 A 
D) and donor 29 (Figure 6 4A) are shown separately to aid visualisation of the 
results.  SB203580 increased the proliferation of all cultures in comparison to the 
controls although the drug was less effective in donor 27. 
The overall mean results from the experiments are summarised in Figure 6 4 B + 
C.  Between passage two and six, drug treated MSC’s proliferated at a similar 
rate to the controls although at passage nine, drug treated cells maintained 
their proliferation.  As a consequence, MSC’s treated with the drug were 
cultured for a shorter period before reaching passage nine (56 ± 7 days versus 71 
± 14 days; p value 0.09) and underwent significantly more PD’s (23.9 ± 2.3 versus 
18.2 ± 3.5; p value 0.02). Malcolm B Will 2010     Chapter 6, 198 
 
Figure 6-3 SB203580 enhances the long term proliferative capacity of MSC’s 
MSC’s from donors 23 (A), 25 (B), 27 (C) and 28 (D) were cultured in medium 
containing either 1 M SB203580 or an equivalent volume of DMSO.  Population 
doublings were determined from viable cell counts at each passage.  PD = (log 
(no. MSC’s harvested) – log (no. MSC’s plated)) / log 2. Malcolm B Will 2010     Chapter 6, 199 
 
Figure 6-4 SB203580 enhances the proliferative capacity of MSC’s  
MSC’s from donor 29 (A) were cultured in medium containing either 1 M 
SB203580 or an equivalent volume of DMSO.  Population doublings were 
determined from viable cell counts at each passage.  PD = (log (no. MSC’s harvested) – 
log (no. MSC’s plated)) / log 2.  Cumulative population doublings (B) and time in 
culture at different passages (C) are shown.  Bars represent the overall mean 
from five donor MSC cultures.  Error bars represent the standard deviation.  
Comparisons were made to the controls using a paired student’s t test; p value £ 
0.05 *. Malcolm B Will 2010     Chapter 6, 200 
This was equivalent to a 32% increase in proliferation at passage nine and a 43% 
increase when drug treated cells were compared to controls at the onset of 
growth arrest (26.5 ± 3.3 versus 18.5 ± 4.2; p value 0.01).  By our estimations, 
cultures treated with 1 M SB203580 from isolation could potentially achieve 50 
PD’s before growth arrest.  The proliferative lifespan would therefore be similar 
to that described in studies on MSC’s derived from from young donors (11;12) 
6.2.4 SB203580 Preserves Progenitors and Osteogenic 
Differentiation in Late Passage MSC’s 
To investigate if SB203580 altered the number of MSC progenitors in long term 
cultures, the CFE F assay was performed at passages three, six and nine (Figure 
6 5).  At passage three, the mean percentage of cells forming colonies was 
similar between drug treated cells and the controls (36.9 ± 6.1 % versus 36.6 ± 
6.2 %; p value 0.90).  At passage six, significantly more colonies were observed 
in drug treated cells from two donors (23 and 25) although the overall results 
from the five cultures were similar to the controls (18.9 ± 3.0 % versus 16.7 ± 3.9 
% respectively; p value 0.1).  However, at passage nine drug treated cells from 
donors 23, 25, 28 and 29 contained significantly more colonies and the overall 
results were significantly different to the controls (7.1 ± 3.5 % versus 3.7 ± 3.0 % 
respectively; p value 0.01).  The results demonstrate that SB203580 maintains 
MSC progenitors with colony forming potential during expansion. 
In chapter three, it was demonstrated that MSC’s display a reduction in 
differentiation capacity at late passage.  Therefore, late passage MSC’s cultured 
in the presence or absence of SB203580 were tested for their ability to undergo 
adipogenic and osteogenic differentiation.  During differentiation, the drug was 
not added to the medium and after three weeks cells were stained using either 
Oil Red O or Alizarin Red S.   Representative images from the adipogenic 
differentiation experiment are shown in Figure 6 6.  Drug treated cells from 
donors 25 and 29 maintained the ability to undergo adipogenic differentiation 
compared to their respective controls (Figure 6 6 F+B, I+J)).  However, this 
effect was not observed in the other donor cultures which lost adipogenic 
differentiation ability to a similar extent than the controls. Malcolm B Will 2010     Chapter 6, 201 
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Figure 6-5 SB203580 preserves the progenitor potential of MSC cultures during expansion 
MSC’s were cultured in medium containing either SB203580 or an equivalent 
volume of DMSO.  The CFE F assay was performed in triplicate on MSC’s at 
passage three, six and nine.  Colonies were stained with Giemsa and those 
containing at least twenty cells counted.  Bars represent the mean percentage 
MSC’s forming colonies.  Error bars represent the standard deviation.  
Comparisons were made to the controls at each passage using a paired student’s 
t test; p value £ 0.05 *. Malcolm B Will 2010     Chapter 6, 202 
 
Figure 6-6 SB203580 had variable effects on the adipogenic differentiation capacity of 
MSC’s at late passage 
MSC’s were cultured in medium containing either SB203580 or an equivalent 
volume of DMSO until late passage.  Cells were then re plated at 100% 
confluence and cultured for three weeks in adipogenic differentiation medium 
without the drug.  Representative images are shown of MSC’s from donors 23, 
25, 27, 28 and 29 treated with DMSO (A D, I) or SB203580 (E H, J).  Lipid is 
stained red using Oil Red O (4x magnification). Malcolm B Will 2010     Chapter 6, 203 
In contrast, four of the SB203580 treated cultures showed increased amounts of 
staining with Alizarin Red S in comparison to the controls and confirmed that 
osteogenic differentiation capacity was maintained during expansion (Figure 
6 7).  The best examples were MSC’s from donors 25 and 29 (Figure 6 7 F+J) and 
similar to the previous experiment, SB203580 appeared ineffective on cells from 
donor 27.  Together with the CFE F assay, the results suggest that SB203580 
could potentially preserve an osteogenic progenitor population during expansion 
and a modified version of the CFU F could be used to investigate this further 
(167). 
6.2.5 SB203580 Does Not Prevent Telomere Erosion but 
Decreases the Expression of SA β-Gal at Late Passage  
In chapter three it was demonstrated that telomere erosion and the expression 
of senescence associated β galactosidase (SA β Gal) was a characteristic feature 
of late passage MSC’s.  Therefore, both methods were used to investigate the 
effects of SB203580 during prolonged expansion of MSC’s.  Genomic DNA was 
extracted from late passage cells and used in the mTRF length assay.  Telomere 
lengths were determined from a single Southern blot by densitometry (Figure 
6 8).  There was insufficient material from the control cells of donor 25 and 
therefore excluded from further analysis.  The method and results were 
produced by Sharon Burns, research assistant within the group of Professor W.N 
Keith. 
First, we compared the telomere lengths of the controls to their counterparts 
not subject to a freeze thaw cycle as described in chapter three.  The results 
were almost identical which confirmed our MSC’s undergo growth arrest at a 
critical telomere length (6.2 ± 1.2 kB versus 6.0 ± 0.8 kB; p value 0.82). 
Furthermore, drug treated cells at late passage had similar mean telomere 
lengths to controls providing further evidence that 6kB is the critical telomere 
length of MSC’s used in our study (5.9 ± 1.1 versus 6.2 ± 1.2 kB; p value 0.73).  
To account for differences in the proliferative history of SB203580 treated and 
control MSC’s, the rate of telomere loss was calculated for each group and the 
results were similar (70.5 ± 67.8 bp/PD versus 73.3 ± 73.2 bp/PD; p value 0.96). Malcolm B Will 2010     Chapter 6, 204 
 
Figure 6-7 SB203580 maintained the osteogenic differentiation capacity of MSC’s at late 
passage 
MSC’s were cultured in medium containing either SB203580 or an equivalent 
volume of DMSO until late passage.  Cells were then re plated at 70% confluence 
and cultured for three weeks in osteogenic differentiation medium without the 
drug.  Representative images are shown of MSC’s from donors 23, 25, 27, 28 and 
29 treated with DMSO (A D, I) or SB203580 (E H, J).  Calcium is stained red using 
Alizarin Red S (4x magnification). Malcolm B Will 2010     Chapter 6, 205 
 
Figure 6-8 SB203580 does not prevent telomere erosion in MSC’s during expansion 
Genomic DNA was extracted from late passage MSC’s cultured in medium 
containing either SB203580 or an equivalent volume of DMSO and telomere 
lengths determined using the TeloTAGGG telomere length assay (Roche 
Diagnostics Ltd) and displayed on a single blot.  Telomere lengths were 
calculated from the blot by densitometry following the manufacturer’s protocol.  
Undigested high and low molecular weight DNA and molecular ladders are 
shown. Malcolm B Will 2010     Chapter 6, 206 
The large standard deviation can be explained by heterogeneity in the rate of 
telomere loss between different donor MSC’s.  Donor 27 displayed the lowest 
and donor 29 the highest rate of telomere shortening in this study (mean 12.7 ± 
12.8 and 161.9 ± 4.0 bp/PD respectively). 
MSC’s at late passage were stained for SA β Gal expression at pH 6.0 using the 
Senescent Cells Staining Kit (Sigma) and the percentage of cells determined 
using the same methods described in chapter three (Figure 6 9).  MSC’s treated 
with SB203580 showed significantly decreased expression of SA β Gal at late 
passage in comparison to the controls (19.4 ± 11.9 % versus 54.2 ± 13.4 %; p 
value <0.001). 
6.2.6 Assessment of DNA Damage in MSC’s 
Histone H2AX is phosphorylated rapidly and extensively to form γ H2AX in 
response to agents that cause DNA double strand breaks (233).  In addition, the 
detection of γ H2AX in the nuclei of senescent human fibroblasts has confirmed 
that telomere shortening or dysfunction can initiate a DNA damage response 
(DDR) (234).  MSC’s displayed significant telomere losses during expansion and it 
was decided to determine the expression of γ H2AX as a surrogate marker of 
DNA damage. 
In the first study, the expression of γ H2AX was determined by flow cytometry 
using the H2A.X Phosphorylation Assay Kit (Upstate, Millipore).  Drug treated 
cells from donor 25 were treated with mitomycin C and hydrogen peroxide to 
generate positive controls.  In addition, the human promyelocytic leukemia cell 
line (HL 60) was used as a positive control because it was known to display high 
rates of apoptosis and therefore, γ H2AX.  The cell line was a gift from the 
research group of Professor T. Holyoake.  Representative histograms of the 
results are shown for control and SB203580 treated MSC’s (Figure 6 10 A+B).  The 
signal from the nuclear expression of γ H2AX was low as demonstrated by the 
small shift in mean fluorescence between isotype and γ H2AX stained cells.  
Therefore, we determined the mean cell fluorescence using the formula: 
geometric mean γ H2AX stained cells   geometric mean isotype stained cells. Malcolm B Will 2010     Chapter 6, 207 
 
Figure 6-9 SB203580 decreased expression of SA β-Gal in late passage MSC’s 
MSC’s were cultured in medium containing either SB203580 or an equivalent 
volume of DMSO until late passage.  The activity of the enzyme SA β Gal was 
assessed at pH 6 using the Senescent Cells Staining Kit (Sigma).  At least 300 
cells were counted in random fields in order to determine the mean percentage 
of SA β Gal (blue) positive cells (A).  Error bars represent the standard deviation.  
Comparisons were made to the controls using a paired student’s t test; p value £ 
0.001 ***.  Representative images from control (B) and SB203580 treated (C) 
cultures are shown (4x magnification). Malcolm B Will 2010     Chapter 6, 208 
 
Figure 6-10 SB203580 treated MSC’s show increased DNA damage using the marker γ-H2AX 
MSC’s were cultured in medium containing either SB203580 or an equivalent 
volume of DMSO until late passage.  Expression of γ H2AX was determined by 
flow cytometry using the H2AX Phosphorylation Assay Kit (Upstate, Millipore).  
Representative overlay histograms are shown of control (A) and SB203580 
treated MSC’s including those treated with mitomycin C and hydrogen peroxide 
(B).  The expression of γ H2AX is represented as the change in mean 
fluorescence (geometric mean γ H2AX stained cells   geometric mean isotype 
stained cells) (C).  Bars represent the mean of five control and drug treated MSC 
cultures.  Positive controls and the HL 60 cell line were obtained from a single 
experiment.  Error bars represent the standard deviation.  Comparisons were 
made between drug treated and control MSC’s using a paired student’s t test (p 
value £ 0.05 *) Malcolm B Will 2010     Chapter 6, 209 
This method was previously described in a study to detect intra nuclear hTERT 
by flow cytometry where the returning fluorescence signal was noted to be weak 
(235).  The results are summarised in Figure 6 10 C.  SB203580 treated MSC’s 
expressed significantly more γ H2AX compared to controls cells (mean cell 
fluorescence 2.31 ± 1.24 versus 0.57 ± 0.40; p value 0.02).  Much higher levels of 
γ H2AX were detected in MSC’s exposed to DNA damaging agents and in the HL 
60 cell line.  The results suggest that SB203580 treated MSC’s exhibit higher 
levels of DNA damage during expansion than the controls. 
Because this method appeared to have a low sensitivity the expression of γ H2AX 
was also determined using immunofluorescence.  This experiment had to be 
performed using cryopreserved cells because it was performed when the long 
term cultures had finished and time constraints meant it was impossible to 
repeat the whole experiment.  Early passage cells were used as negative 
controls and positive controls were obtained by inducing DNA damage with 
hydrogen peroxide or ultra violet (U.V) irradiation.  In this experiment, to 
improve detection we used an unconjugated γ H2AX monoclonal antibody 
detected with a FITC conjugated secondary (Figure 6 11).  γ H2AX was detected 
in the nuclei of 4.7 ± 1.4 % MSC’s at passage two and 15.1 ± 5.8 % and 13.8 ± 5.0 
% of at late passage cultured with or without SB203580, respectively.  The 
results were not significantly different and did not support the findings by flow 
cytometry although this experiment has obvious limitations. 
It was noted that most nuclei contained only one or two γ H2AX foci which 
would account for the low signal detected by flow cytometry.  In contrast, MSC’s 
exposed to either hydrogen peroxide or U.V irradiation had multiple γ H2AX foci 
and some cells appeared to have initiated DNA fragmentation and apoptosis.  
Together, the results demonstrate that MSC’s show increased levels of DNA 
damage during their expansion compared to early passage cultures.  The flow 
cytometry experiment revealed that SB230580 allowed the accumulation of DNA 
damage and inhibited normal DNA damage responses allowing the cultures to 
proliferate to a much greater extent than the controls. Malcolm B Will 2010     Chapter 6, 210 
 
Figure 6-11 γ-H2AX was expressed as discrete nuclear foci in MSC’s 
The expression of γ H2AX was determined by immunofluorescence in MSC’s at: 
early passage (A); late passage controls (B); late passage treated with SB203580 
(C); passage two exposed to ultra violet irradiation (D); and passage two 
exposed to hydrogen peroxide (E).  On average, more than 200 cells were 
counted in random fields to determine the mean percentage of γ H2AX positive 
cells (F).  Bars represent the mean results from five donor cultures.  The results 
for MSC’s at passage two were obtained from a single experiment.  Error bars 
represent the standard deviation.  Comparisons were made between drug 
treated and control MSC’s using a paired student’s t test (not significant).  White 
arrows show discrete γ H2AX foci stained green (FITC) and nuclei are blue (DAPI) 
(100x magnification). Malcolm B Will 2010     Chapter 6, 211 
6.2.7 SB203580 Treatment Does Not Alter the Expression of 
Genes Associated with MSC Ageing  
The gene expression profile of late passage MSC’s cultured with or without 
SB203580 were determined using the same TLDA’s as described in chapter five.  
The results can be found in the appendix (Table 12).  The standard deviation of 
the cycle thresholds of ACTB, GAPDH, POLR2A, RPLP0 and UBC were calculated 
(1.2, 1.1, 0.6, 0.7 and 0.6, respectively) from all samples to ensure UBC 
remained a suitable control.  The RQ of gene expression was calculated using the 
formula 2
 DDC
T with baseline expression determined in MSC’s at passage two.   
To determine if cryopreservation altered the expression profile of late passage 
MSC’s the TLDA results were compared to cells from the same donors cultured 
from initial isolation and not subjected to a freeze thaw cycle (data not shown).  
Using a paired student’s t test, only GAPDH showed a significant decrease in 
expression in cultures established from cryopreserved cells (mean RQ 0.5 ± 0.3 
versus 1.0 ± 0.4; p value 0.05).  By linear regression, the r
2 value was 0.7 (95% 
confidence intervals) which gave us confidence that MSC’s in this experiment 
displayed similar transcriptional alterations to those identified in chapter five 
The genes identified in chapter five as differentially expressed in late passage 
MSC’s were compared in SB203580 treated cells and their respective controls.  
The levels of expression were not significantly different and the sixteen genes 
with increased expression at late passage are shown in Figure 6 12 and Figure 
6 13 and the two that decreased expression shown in Figure 6 14.  There was a 
non significant increase in expression of HMGA1 (RQ 10.4 ± 9.3 versus 4.6 ± 5.4), 
KIAA1199 (RQ 12.2 ± 11.0 versus 7.8 ± 6.6) and desmoplakin (DSP) (RQ 7.9 ± 4.7 
versus 4.5 ± 2.9) in drug treated MSC’s.  There was a non significant decrease in 
expression of PLAT (RQ 17.0 ± 10.7 versus 27.0 ± 31.4), CAV1 (RQ 3.6 ± 1.1 
versus 5.6 ± 5.1), PRSS23 (RQ 2.4 ± 1.2 versus 3.7 ± 1.7) and STAT1 (RQ 3.6 ± 1.9 
versus 6.3 ± 5.2). 
Previous studies have identified both CAV1 (207) and STAT1 (236) as 
transcriptional targets of p38 MAPK and the slight reduction of expression in drug 
treated MSC’s suggested some inhibition of this pathway. Malcolm B Will 2010     Chapter 6, 212 
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Figure 6-12 SB203580 does not alter the expression of genes associated with MSC ageing 
RQ values were calculated using the 2
 DDC
T method with baseline expression 
determined in MSC’s at passage two and normalised to the control, UBC.  
Comparisons were made between SB203580 treated and control cells using a 
paired student’s t test (not significant).  Bars represent the mean RQ value from 
five donor cultures; each gene was measured in duplicate.  Error bars represent 
the standard deviation. Malcolm B Will 2010     Chapter 6, 213 
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Figure 6-13 SB203580 does not alter the expression of genes associated with MSC ageing 
RQ values were calculated using the 2
 DDC
T method with baseline expression 
determined in MSC’s at passage two and normalised to the control, UBC.  
Comparisons were made between SB203580 treated and control cells using a 
paired student’s t test (not significant).  Bars represent the mean RQ value from 
five donor cultures; each gene was measured in duplicate.  Error bars represent 
the standard deviation. Malcolm B Will 2010     Chapter 6, 214 
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Figure 6-14 SB203580 does not alter the expression of genes associated with MSC ageing 
RQ values were calculated using the 2
 DDC
T method with baseline expression 
determined in MSC’s at passage two and normalised to the control, UBC.  
Comparisons were made between SB203580 treated and control cells using a 
paired student’s t test (not significant).  Bars represent the mean RQ value from 
five donor cultures; each gene was measured in duplicate.  Error bars represent 
the standard deviation. Malcolm B Will 2010     Chapter 6, 215 
On the TLDA were genes described as targets of p38 MAPK from earlier studies 
including connective tissue growth factor (CTGF), heat shock 70kDa protein 8 
(HSPA8), interleukin 6 signal transducer (IL6ST), prostaglandin endoperoxide 
synthase 2 (PTGS2) and transglutaminase 2 (TGM2) (237 239).  It was 
disappointing that none were expressed at levels significantly different to the 
controls (Figure 6 15).  TGM2 was expressed at increased levels in drug treated 
cells compared to the controls (5.0 ± 4.8 versus 2.4 ± 2.0), in contrast to the 
decreased expression seen in the study by Zer et al using rodent fibroblasts 
(237). 
We also determined the expression of the cell cycle genes CDKN1A, CDKN1B, 
CDKN2A and FOS because the drug treated MSC’s showed a proliferative 
advantage when compared to controls (Figure 6 16).  The results were similar in 
both groups although CDKN2A was expressed at lower levels in the SB203580 
treated MSC’s.  A similar effect of SB203580 was demonstrated in HSC’s from 
ATM deficient mice suggesting that p38 MAPK can regulate the p16
INK4a
 – Rb 
pathway although the exact mechanisms have not been determined (231). 
To account for the fact that drug treated MSC’s had proliferated to a much 
greater extent, the RQ of gene expression per population doubling was 
calculated and compared to that of the controls (data not shown).  Only the 
expression of PRSS23 significantly decreased in SB203580 treated MSC’s 
compared to the controls (mean RQ/PD 0.10 ± 0.09 versus 0.20 ± 0.05, p value 
0.04).  The results confirmed that SB203580 treated MSC’s expressed a similar 
transcriptional signature to the controls at late passage and highlight the need 
to determine the exact transcriptional targets of SB203580 and the p38 MAPK 
pathway in MSC’s. 
Another issue is that our results are based on mRNA analysis and many of these 
proteins are known to be regulated by post translational modifications so it 
remains entirely possible that the function of many of these proteins was 
dramatically altered by SB203580 treatment despite similar levels of mRNA 
expression.  Therefore, further study of the protein levels of the genes we 
validated is essential to support or refute the results obtained by TLDA. Malcolm B Will 2010     Chapter 6, 216 
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Figure 6-15 SB203580 does not alter the expression of putative p38 MAPK target genes in 
MSC’s at late passage 
RQ values were calculated using the 2
 DDC
T method with baseline expression 
determined in MSC’s at passage two and normalised to the control, UBC.  
Comparisons were made between SB203580 treated and control cells using a 
paired student’s t test (not significant).  Bars represent the mean RQ value from 
five donor cultures; each gene was measured in duplicate.  Error bars represent 
the standard deviation. Malcolm B Will 2010     Chapter 6, 217 
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Figure 6-16 SB203580 does not alter the expression of cell cycle genes in MSC’s at late 
passage 
RQ values were calculated using the 2
 DDC
T method with baseline expression 
determined in MSC’s at passage two and normalised to the control, UBC.  
Comparisons were made between SB203580 treated and control cells using a 
paired student’s t test (not significant).  Bars represent the mean RQ value from 
five donor cultures; each gene was measured in duplicate.  Error bars represent 
the standard deviation. Malcolm B Will 2010     Chapter 6, 218 
6.2.8 SB203580 Suppresses p38 Kinase Activity in Late Passage 
MSC’s 
The protein studies were kindly performed by Alan Bilsland, a post doctorate 
within the research group of Professor W.N. Keith as described in an earlier 
publication (240).  To assess the status of the p38 MAPK pathway, protein was 
extracted from MSC’s grown in the presence or absence of SB203580 and probed 
with antibodies specific for p38 MAPK and its activating phosphorylation (Figure 
6 17).  Interestingly, the levels of phosphorylated p38 MAPK were highest in 
SB203580 treated cells from donors 23 and 27 which would suggest that the drug 
concentration used was insufficient to prevent p38 MAPK activation or 
alternative activating pathways exist.  This finding is in agreement with a study 
on fibroblasts derived from Werner’s syndrome patients treated with the same 
drug (232).  Much lower levels were detected in the controls although we have 
not analysed protein levels in early passage cells to confirm that p38 MAPK 
activation increases during prolonged expansion of MSC’s.  This is a major 
limitation to the interpretation of the results from this experiment. 
The protein, v akt murine thymoma viral oncogene homolog 1 (AKT) is a target 
of both the phosphoinositide 3 kinase (PI 3 kinase) and p38 MAPK pathway 
(241;242).  As shown in Figure 6 17, the phosphorylation of AKT was suppressed 
by SB203580 in MSC’s from donor 28.  However, levels were similar to the 
controls in other cultures.  The protein levels of macrophage stimulating 1 
(MST1), which is known to be upstream of p38 MAPK were also determined as 
shown in the blot (243).  The findings were similar in that phosphorylation of 
MST1 was suppressed in SB203580 treated cells from donors 23 and 29, but not 
those from donor 28. 
Together, our results demonstrate that SB203580 can inhibit kinases upstream 
and down stream of p38 MAPK but does not prevent its activation.  The variable 
targeting of the p38 MAPK appeared dependent on the donor cells themselves 
suggesting different susceptibility to the drug.  Off target effects have also been 
considered and in MSC’s from donor 28 we have identified that SB203580 can 
inhibit the c Jun N terminal kinase (JNK) pathway as well (data not shown).  
More detailed experiments are required to determine the exact effects of 
SB203580 on the MAPK pathways in MSC’s.Malcolm B Will 2010     Chapter 6, 219 
 
Figure 6-17 SB203580 has variable effects on the p38 MAPK pathway in MSC’s 
MSC’s were cultured in medium containing either SB203580 or an equivalent 
volume of DMSO until late passage.  Protein was extracted and western blotting 
performed using phospho specific antibodies to detect AKT phosphorylation on 
Serine
473 [(p AKT (pS473)], p38 MAPK phosphorylation on Threonine
180 and 
Tryosine
182 [(p p38 MAPK (pT180/pY182)] and MST1 phosphorylation on 
Threonine
183 [p MST1 (pT183)].  Blots for total protein are also shown (AKT, p38 
MAPK and MST1).  Each blot is representative of a single experiment. Malcolm B Will 2010     Chapter 6, 220 
6.2.9 SB203580 Treatment Causes Genomic Alterations in Late 
Passage MSC’s 
By inhibiting a normal senescence response, we speculated that SB203580 
treatment may increase genomic instability in MSC’s.  Therefore, array 
comparative genomic hybridization (aCGH) was used to detect chromosomal 
deletions or duplications in the genome of MSC’s.  The technique was performed 
by Stacey Hoare, research assistant within the research group of Professor W.N. 
Keith.  Genomic DNA was extracted from late passage cells cultured with or 
without the drug and labelled with cyanine using the Genomic DNA Enzymatic 
Labelling Kit (Agilent Technologies).  1 g of labelled DNA was then analysed 
using the Human Genome CGH Microarray Kit 244A (Agilent Technologies) 
following the manufacturer’s protocol (www.agilent.com/chem/goCGH).  In 
addition, reference DNA (Promega) was used as sex matched controls.  Each 
microarray contains over 236,000 biological probes sourced from UCSC hg 18 
(NCBI Build 36) allowing a resolution of approximately 8.9 kB.  The results were 
generated using CGH Analytics software (Agilent Technologies). 
The samples for this study included cells from four donors (23, 27, 28 and 29) 
treated in the presence or absence of SB203580.  When the control cells were 
compared to reference DNA, very few duplications or deletions were identified 
(Figure 6 18).  This would suggest that MSC’s retain a high degree of genomic 
stability during expansion in keeping with the results of a previous study that 
used aCGH and chromosomal analysis on late passage MSC’s (85).  However, on 
review of the sex chromosomes a loss of the Y chromosome in control cells from 
donor 28 was identified (data not shown).  We were confident that this was not 
a mix up with cells from female donor 29 because a complete duplication of the 
X chromosome would have been observed when compared to sex matched 
reference DNA. 
In the comparison of SB203580 treated cells and the controls the results raised 
some concern (Figure 6 19).  The drug treated cells displayed high levels of 
genomic instability with predominantly chromosomal duplications rather than 
deletions.  The exact significance is uncertain because none of these cultures 
showed evidence of transformation when cultured for two weeks after growth 
arrest.Malcolm B Will 2010     Chapter 6, 221 
 
Figure 6-18 Control MSC’s maintain genomic stability at late passage 
Genomic DNA was extracted and labelled from control MSC’s at late passage 
(donors 23, 27, 28 and 29).  1 g was analysed using the Human Genome CGH 
Microarray Kit 244A (Agilent Technologies).  The results were compared to sex 
matched reference DNA (Promega) using CGH Analytics software (Agilent 
Technologies).  Chromosomal regions containing duplications (red) and deletions 
(green) are highlighted. Malcolm B Will 2010     Chapter 6, 222 
 
Figure 6-19 MSC’s treated with SB203580 show increased genomic instability at late 
passage 
Genomic DNA was extracted and labelled from SB203580 treated MSC’s at late 
passage (donors 23, 27, 28 and 29).  1 g was analysed using the Human Genome 
CGH Microarray Kit 244A (Agilent Technologies).  The results were compared to 
control MSC’s using CGH Analytics software (Agilent Technologies).  
Chromosomal regions containing duplications (red) and deletions (green) are 
highlighted. Malcolm B Will 2010     Chapter 6, 223 
Unfortunately, it was not possible to to commit additional time to analyse these 
results in depth.  It would be of interest to examine the chromosomal regions of 
tumour suppressor genes and also the genes identified as markers of aged MSC’s.  
However, these genes were not differentially expressed when compared to the 
controls by TLDA which would make it unlikely that duplications or deletions 
occurred in their respective chromosomal regions. 
6.3 Discussion 
In contrast to results seen in other cell types BIO did not enhance the 
proliferation of MSC’s cultured short term in the presence of the drug 
(26;132;225).  Tateishi et al treated CSC’s with 10nM BIO and demonstrated a 
50% increase in the number of Ki67 positive cells when grown as cardio spheres.  
CSC’s in this study had similar surface marker and gene expression profile to that 
described for MSC’s so it was surprising the drug did not produce a similar 
effect.  In fact,  BIO appeared toxic at high concentrations and significantly 
inhibited MSC proliferation and our results are similar to the effects recently 
described in adipose derived MSC’s (244).  The morphological changes suggested 
BIO may have induced differentiation or senescence of MSC’s and recent 
evidence confirms a role of Wnt proteins in the onset of senescence.  The 
knockdown of Wnt2 by siRNA can induce SAHF formation and senescence of 
human fibroblasts (245) and MEF’s grown in Wnt3a conditioned media have been 
shown to senesce prematurely (246).  Therefore, the extent and duration of Wnt 
signals may be the most important factor in determining the effect of this 
pathway in different cell types. 
The studies using SB203580 provide preliminary evidence that the p38 MAPK 
pathway can contribute to the decline in proliferation and differentiation 
capacity of MSC’s during expansion in vitro.  The growth rate and replicative 
lifespan of the cells were significantly increased when cultured in the presence 
of SB203580 and at levels seen in MSC’s derived from young donors (11;12).  In 
effect, SB203580 maintains the proliferative rates seen in early passage cells and 
the growth curves are shifted up.  By CFSE, we determined that the proliferative 
advantage was not due to an increase in cell cycle rate.  In the study by Davis et 
al using Werner’s syndrome fibroblasts, SB203580 was shown to decrease the 
number of fibroblasts that exited the cell cycle during expansion measured by Malcolm B Will 2010     Chapter 6, 224 
the incorporation of bromodeoxyuridine as a marker of DNA synthesis (232).  We 
suspect the drug has a similar effect on MSC’s and performing an identical 
experiment is required to confirm this.  In keeping with the results of the same 
study, SB203580 treated MSC’s appeared smaller than their controls and 
fibroblast growth factor 2 (FGF 2) has been shown to have a similar effect on 
the morphology of MSC’s (64;247).  Therefore, the increase in proliferation seen 
in drug treated cells could be explained by an increase in cell density at 
confluence because of the smaller size or even loss of contact inhibition.  The 
smaller size of drug treated cells would also explain the increased brightness 
seen when SB203580 treated MSC’s were incubated for a similar time in CFSE as 
the controls.  Alternatively, SB203580 may alter the properties of the cell 
membrane and therefore alter the penetration of the dye. 
It was demonstrated that SB203580 treated cells retained progenitor potential at 
late passage and would suggest that p38 MAPK contributes to the loss of 
functional capacity of MSC’s.  The results are supported by studies on HSC’s from 
ATM deficient mice and Werner’s syndrome fibroblasts where SB203580 was 
shown to maintain both function and proliferative lifespan of these cell types 
(231;232).  Earlier studies on MSC’s have identified small rapidly self renewing 
(RS) cells in culture that have the greatest proliferative potential which leads us 
to speculate that these cells are exhausted during expansion in vitro (32).  The 
lack of specific markers to identify and isolate such cells is a major limitation in 
the field although the combination of Stro 1 and CD106, or the marker CD271 
(LNGFR) have shown the most promise in studies to date (191;248).  Using flow 
cytometry and cell sorting based on cell size or these surface markers could 
enable the effects of SB203580 to be determined on MSC subsets in an attempt 
to explain our findings in greater depth. 
In addition to maintaining the number of colony forming cells at late passage, 
SB203580 treated MSC’s maintained the ability to undergo osteogenic 
differentiation which typically decreased during expansion.  If this effect 
resulted from the increase in progenitors in drug treated cultures, these cells 
appear similar to a subset of MSC’s expressing the marker Stro 1 that display 
enhanced osteogenic differentiation capacity (167).  Further experiments 
whereby a modified version of the CFU F assay is used to assess adipogenic or 
osteogenic progenitors would enable us to determine the exact effects of Malcolm B Will 2010     Chapter 6, 225 
SB203580 on the pluripotency and maintenance of MSC progenitors during 
expansion.  Another possibility is that SB203580 maintained MSC’s in an 
undifferentiated state and prevented the lineage restriction that typically occurs 
during expansion.  In support, genes associated with the p38 MAPK pathway are 
found enriched in differentiated MSC’s when compared to their undifferentiated 
counterparts using microarray (144).  Furthermore, another study has shown that 
the JNK inhibitor SP600125 can prevent osteogenic differentiation of MSC’s when 
cultured in osteogenic media confirming that other MAPK pathways are 
important in regulating MSC differentiation (249).  This is particularly relevant 
because we found some evidence that SB203580 had activity on this pathway 
despite the low concentrations used in our attempt to minimise off target 
effects.  The ability to preserve the osteogenic differentiation capacity of MSC’s 
either through maintenance of the undifferentiated state or preservation of 
osteogenic progenitors has relevance in the application of MSC’s for the 
treatment of bone diseases and would merit further research (3). 
SB203580 treated cells showed similar rates of telomere shortening which was 
initially surprising given the increased proliferation of these cultures.  The rate 
of telomere shortening in other cell types has been shown to vary depending on 
ambient oxygen levels, with the lowest rates observed in low oxygen conditions 
(168).  One possibility is that SB203580 maintained the telomere length of a 
progenitor population within MSC cultures.  This population may be so small that 
it is not possible to detect differences in telomere length using the TeloTAGG 
mean telomere length assay.  Using flow cytometry and cell sorting based on 
specific surface markers or cell size as described earlier could enable telomere 
lengths to be determined in single cells using specialised techniques methods 
previously reported (250). 
Of some concern was that drug treated cells continued to proliferate despite a 
similar critical telomere length as the controls.  The results infer that SB230580 
inhibited a normal telomere initiated senescence response.  We noted that in 
this experiment the controls had a mean telomere length of 6kB which was 
similar to our earlier studies.  In a previous study, MSC’s were shown to undergo 
senescence at a critical telomere length of approximately 10kB (11).  This 
discrepancy is hard to explain although it does question the relevance of 
telomere length in determining the proliferative capacity of MSC’s.  It would Malcolm B Will 2010     Chapter 6, 226 
also suggest telomere dysfunction itself may be more important.  Further 
support that SB203580 treatment may enable MSC’s to inhibit a normal 
senescence response was provided by the gene expression studies.  Using 
TLDA’s, SB023580 did not prevent the characterisitic gene expression changes 
seen in late passage MSC’s cultured without the drug.  It is difficult to interpret 
the exact significance of this result as it would have been better to compare the 
expression profiles of drug treated cells and controls after an equivalent number 
of population doublings.  This may have confirmed that SB203580 prevented the 
expression of ageing associated genes in MSC’s and that the assay time point 
missed this difference.  If a similar result was obtained from this experiment it 
would confirm that SB203580 does not prevent the onset of a senescence 
phenotype at the transcriptional level.  A detailed analysis of global gene 
expression of MSC’s treated with SB203580 compared to controls using SAGE or 
microarray is required to confirm the exact targets of this drug in MSC’s.  
Although known p38 MAPK targets, CAV1 and STAT1 showed decreased 
expression this provides only indirect evidence that SB203580 was targeting this 
pathway (207;236).  Given that our analysis was based on mRNA expression and 
many of these proteins are regulated by post translational modifications, further 
experiments are required to determine protein levels of some of these genes in 
SB203580 treated MSC’s. 
The limited protein studies peformed did provide some evidence that SB203580 
was targeting the p38 MAPK pathway in MSC’s although the results were not 
clear cut.  Depending on the donor cells used, SB203580 was shown to inhibit the 
upstream kinase MST1 and downstream substrate AKT.  However, activation of 
p38 MAPK itself was not inhibited and actually increased in some cultures.  A 
similar effect of SB203580 has been observed in Werner’s syndrome fibroblasts 
although the effects on upstream kinases were not investigated in this study 
(232).  The time point chosen to assay p38 MAPK activity also appears crucial 
because a study using fibroblasts treated with powerful oxidants showed that 
SB203580 prevented premature senescence by the inhibition of p38 MAPK 
phosphorylation when assayed 48 hours after exposure (207).  Few studies have 
determined the effects of this drug in cells during continous exposure and 
expansion in vitro.  Therefore, our results provide the basis for further studies to 
unravel MAPK signalling pathways and establish their exact role in the 
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experiments are required to consolidate these findings.  Firstly, it needs to be 
demonstrated by protein studies that p38 MAPK activation is a feature of long 
term culture of MSC’s.  The variable sensitivity of different MSC cultures to the 
drug suggests that studies to determine the IC50 for each different donor MSC’s 
are also required.  It seems likely that individual donor cells require specific 
concentrations of SB203580 to ensure a consistent effect.  It would then be 
easier to determine the effects of SB203580 on proteins involved in the p38 and 
other MAPK pathways using moderate throughput techniques such as powerblots.  
Together with gene expression profiling studies and identifying transcriptional 
targets of SB203580 for validation it would be possible to confirm or refute our 
findings with greater confidence. 
By flow cytometry we demonstrated that MSC’s treated with SB203580 showed 
increased levels of DNA damage in comparison to the controls and therefore, p38 
MAPK activation may be critical for normal DNA damage responses in MSC’s.  It 
was concerning that these cells were still proliferating in the context of 
increased accumulation of DNA damage and shortened telomeres.  The results 
provide further evidence that p38 MAPK inhibition may prevent a normal 
senescence response and is supported by both in vitro (230) and in vivo studies 
(229).  The flow cytometry method appeared to have poor sensitivity and it was 
unfortunate that the immunofluorescence studies were not performed at the 
same time.  This would have provided additional confirmation of our results 
although another possibility is that protein studies could be performed 
retrospectively to detect γ H2AX on archived cell pellets that were generated 
from SB203580 treated and control MSC’s. 
The array CGH study provided further evidence that intact p38 MAPK signalling is 
required to maintain genomic stability in MSC’s.  The controls showed minimal 
chromosomal alterations in comparison to the reference DNA and would support 
the findings of a previous study using aCGH and chromosomal analysis on late 
passage cells (85).  The loss of chromosome Y in donor 28 was unexpected and 
we believed this may have arisen in vitro because a similar change was not seen 
in the drug treated counterparts.  Interestingly, the loss of chromosome Y is a 
common finding in the bone marrow compartment with advanced age and in 
patients with myelodysplastic syndrome although the exact clinical significance 
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marked genomic instability with predominantly chromosomal duplications.  We 
suspected that these changes may have arisen in a progenitor cell population 
and the potential risk would be that SB203580 could increase susceptibility to 
further genetic events that could result in cell transformation.  It has been 
recognised that human (13;14) and mouse (253;254) MSC’s can undergo 
transformation in vitro.  Furthermore, MSC’s transduced with hTERT have been 
shown to undergo transformation after prolonged culture due to both 
chromosomal losses and epigenetic events (83).  Together with our results this 
highlights that the tight regulation of proliferation in MSC’s and senescence is 
critical for the maintenance of genomic stability in conditions of cellular stress.  
Of note, p38 MAPK inhibitors are currently under development for the treatment 
of inflammatory conditions such as rheumatoid arthritis and we would speculate 
that such agents could in fact increase susceptibility to the development of 
cancer itself (255).  The identification of side population cells in mesenchymal 
tumours such as sarcomas provide further evidence that these cancers may 
originate in MSC’s and our results highlight the importance of p38 MAPK 
activation in the initiation of a senescence response in vitro.  Comparison of 
publicly available aCGH data derived from mesenchymal tumours would be of 
interest to determine if a pattern of chromosomal changes can be identified 
with similarities to those seen in SB203580 treated MSC’s. 
6.4 Conclusion 
We have identified that inhibition of p38 MAPK using the small molecule 
SB203580 can prevent the decline in proliferation and differentiation of MSC’s 
during expansion.  Confirming a potential tumour suppressor role of p38 MAPK 
treatment with SB203580 allowed the accumulation of genomic instability in MSC 
cultures possibly as a consequence of impaired DNA damage responses in a 
progenitor cell population.  Our results provide some evidence that MSC’s are 
aged prematurely in response to undefined cellular stress that activate the p38 
MAPK pathway and identifying these insults should improve understanding of MSC 
ageing and enhance the ability to use MSC’s in cell therapy approaches. 
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7  Summary and Conclusions  
Mesenchymal stem cells (MSC’s) are stroma derived adult stem cells that have 
shown promise in animal models of tissue repair which has encouraged use in 
clinical trials.  MSC’s are rare and require significant expansion in vitro to 
generate sufficient cells for such approaches.  The expansion process itself 
induces rapid ageing of MSC’s as shown by a decline in proliferative and 
differentiation capacity (11;12).  It has been recognised that there is a need for 
human models of adult stem cell ageing in addition to transgenic animal studies 
that have provided important insights into stem cell ageing to date (Reviewed in 
(95)).  Therefore, understanding the molecular mechanisms that control MSC 
ageing in vitro should not only enhance our ability to use MSC’s for cell therapy 
but also give insight into mechanisms of tissue and organ ageing. 
First, we have established the isolation and characterisation of MSC’s from the 
sternal BM of patients undergoing CABG and demonstrated that these cells meet 
the defining criteria set out by the International Society for Cellular Therapy 
(33).  MSC’s could be expanded for almost thirty population doublings and 
achieved levels of expansion similar to that previously reported (11;12).  Late 
passage MSC’s showed evidence of cell ageing with the development of a 
senescent morphology, expression of the marker SA β Gal and a reduction in 
telomere length.  In addition, the cells showed a decline in adipogenic and 
osteogenic differentiation capacity confirming loss of their stem cell properties.  
The findings were confirmed in multiple cultures which gave us confidence that 
our model of MSC ageing in vitro was reproducible and not entirely influenced by 
the donor characteristics themselves.  Our studies confirmed that sternal BM is a 
reliable source of MSC’s and this approach for harvesting autologous cells may be 
suitable for clinical application. 
The next part of our study used SAGE to determine the expression profile of 
MSC’s during expansion.  Three libraries, two at passage two and one at passage 
nine were generated containing 123,990 tags of which 38,126 were unique.  Less 
than 1% of the tags were differentially expressed matching 243 known genes.  
This pattern of differential expression was similar to that reported by other 
SAGE studies.  We confirmed genes abundant in our libraries matched those 
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direct interactions between genes revealed a regulatory signaling network 
centered on down regulation of activator protein 1 (AP 1) in late passage MSC’s.  
This network highlights the importance of global analysis of gene expression and 
also demonstrates that small changes in a combination of genes in a signalling 
pathway are responsible for defining a cell phenotype. By investigating signaling 
networks we can enhance understanding of the biology of senescence and its 
regulation in MSC’s.  Transcriptional changes in MSC’s at passage nine included 
genes associated with inflammation, regulation of cell cycle, metabolism and 
extracellular matrix re modelling.  These characteristics are typical of other 
senescent cell types and thought to be detrimental on normal tissue function 
and homeostasis.  The effect of using aged MSC cell preparations for cell therapy 
has not been addressed in animal studies to date and it remains unclear if these 
cells are beneficial or even detrimental when used for tissue repair.  The results 
emphasise the need to characterise MSC’s at the molecular level prior to clinical 
use and when comparing MSC preparations from different researchers. 
TLDA’s were used to perform a comprehensive evaluation of gene expression in 
multiple MSC cultures at different passages and confirmed the SAGE findings.  
The success of the validation was similar to other SAGE studies and good 
considering the nature of primary cell culture work.  Eighteen genes were 
identified as differentially expressed in late passage MSC’s and CAV1, CCND1, 
PLAT and OLFML3 were able to discriminate between cultures at different 
passage number.  The results confirm that ageing and senescence of MSC’s 
cultures is detectable much earlier than the onset of growth arrest.  Our findings 
support the study by Wagner et al that demonstrated senescence of MSC’s occurs 
immediately from isolation and increases during expansion (40).  It remains to be 
determined if this reflects an accumulation of senescent cells in culture or an 
enhanced stress response.  Further studies using the four gene signature may 
address this although the detection of CAV1 (207), CCND1 (199)and PLAT (215) in 
senescent fibroblasts would infer senescent MSC’s do in fact accumulate during 
expansion.  These markers are likely to outperform current methods of detection 
of senescence in MSC’s such as SA β Gal expression, lipofuscin accumulation and 
telomere shortening although prospective studies are required to confirm this.  
The validation study confirmed that genes on the AP 1 regulatory network were 
differentially expressed in all cultures.  This is a stress response transcription 
factor and a recent study has shown that MSC’s senesce prematurely in response Malcolm B Will 2010     Chapter 7, 231 
to increased levels of oxidative stress (68).  The regulatory network that defines 
the senescent phenotype remains a novel finding and has not been reported.  
Our results also provide molecular markers that could be used to ensure quality 
control of MSC’s in clinical trials and enhance optimisation of existing culture 
protocols. 
Lastly, we have provided further evidence that MSC’s senesce prematurely in 
response to undefined stresses because inhibition of p38 MAPK signalling 
prevented the decline in proliferation and differentiation of MSC’s during 
expansion.  Interestingly, similar findings have been demonstrated in HSC’s (231) 
and Werner’s syndrome fibroblasts (232).  However, these studies did not assess 
genomic integrity and in MSC’s the use of SB230580 allowed the accumulation of 
genomic instability.  Although the cultures could not be transformed there was 
evidence of impaired DNA damage responses.  Therefore, intact p38 MAPK 
signalling appears to have a tumour suppressor role in MSC’s as it does in other 
cell types. 
Overall, the conclusions can be summarised: 
·  The sternal BM of patients undergoing CABG is a reliable source of MSC’s 
that could be used for cell based therapies.  The expansion of MSC’s is 
associated with a decline in stem cell properties and the onset of 
senescence.  This may ultimately limit the applicability of autologous 
cells derived from IHD patients although further studies in animal models 
of tissue repair are required. 
·  MSC ageing is associated with an increased resistance to oxidative stress 
and apoptosis, enhanced extra cellular matrix re modelling and an 
inflammatory phenotype at the transcriptional level. 
·  The molecular phenotype appears to be regulated by decreased 
expression of the transcription factor, activator protein 1 (AP 1). 
·  Eighteen genes have been identified that represent markers of MSC ageing 
and senescence in vitro and the expression of CAV1, CCND1, PLAT and 
OLFML3 can be used to discriminate cultures of different proliferative 
history. Malcolm B Will 2010     Chapter 7, 232 
·  Activation of p38 MAPK signalling pathway contributes to the loss of 
progenitors, decline in proliferation and loss of osteogenic differentiation 
capacity in late passage cultures.  The p38 MAPK pathway appears critical 
for the maintenance of genomic stability in MSC’s by regulating normal 
DNA damage responses. 
Overall, this study has provided an excellent platform towards understanding the 
molecular mechanisms that regulate ageing and senescence of MSC’s in vitro.  
This study also raises several important questions: 
·  Can CAV1, CCND1, PLAT and OLFML3 be used prospectively as molecular 
markers of MSC senescence? 
·  What stresses activate the p38 MAPK pathway in MSC’s? 
·  What are the transcriptional targets of p38 MAPK signalling in MSC’s? 
·  Can anti oxidant treatments produce similar effects to SB203580 in MSC’s 
without detrimental effects on genomic stability? 
·  Does genomic instability arise in a progenitor cell population within MSC 
cultures?  
The ideal culture protocol for MSC’s is yet to be defined but our results suggest 
that strategies to minimise oxidative stress by culturing cells in low ambient 
oxygen levels and in the presence of anti oxidants are likely to have beneficial 
effects on preserving the stem cell properties of MSC’s.  Grayson et al recently 
reported that MSC’s cultured in 2% oxygen had a thirty fold greater expansion 
than cells grown in standard conditions and maintained differentiation capacity  
(62).  Furthermore, anti oxidants have beneficial effects in other cell types 
although their effects in MSC’s have not been extensively researched.  Applying 
such strategies immediately upon isolation of the cells is likely to significantly 
increase the proliferative capacity of the cells and maintain their stem cell 
characteristics in vitro. 
Therefore, autologous cells appear the way forward for clinical application to 
minimise immune responses and optimised culture protocols may overcome the Malcolm B Will 2010     Chapter 7, 233 
perceived limitations of this approach.  This is a very exciting area of research 
for the future and there is no doubt that understanding stem cell ageing will 
inform on new treatments for age related conditions including IHD and cancer. Malcolm B Will 2010     Chapter 7, 234 
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Symbol  Gene Name  Function  Process  Cytoband 
ACTB  actin, beta  Cytoskeletal protein, Actin 
family cytoskeletal protein, 
Actin and actin related 
protein 
Intracellular protein traffic, 
Exocytosis, Endocytosis, Cell cycle, 
Mitosis, Cytokinesis, Cell structure 
and motility 
7p15 p12 
ADAMTS1  ADAM metallopeptidase with 
thrombospondin type 1 motif, 
1 
Signalling molecule, 
Protease, Metalloprotease 
Protein metabolism and 
modification, Proteolysis, Signal 
transduction, 
Cell communication 
21q21.2 
AKRC1,2  aldo keto reductase family 1, 
member C1 (dihydrodiol 
dehydrogenase 1; 20 alpha (3 
alpha) hydroxysteroid 
dehydrogenase) 
Oxido reductase  Other metabolism  10p15 
p14 
ANXA2  annexin A2  Select calcium binding 
protein, Annexin, 
Transfer/carrier protein 
Intracellular protein traffic, 
Mesoderm development, Cell 
structure and motility 
15q21 
q22 
APLP2  amyloid beta (A4) precursor 
like protein 2 
Receptor  Cell surface receptor mediated 
signal transduction, Neuronal 
activities 
11q23 
q25; 
11q24 
ARPC2  actin related protein 2/3 
complex, subunit 2, 34kDa 
Actin family cytoskeletal 
protein 
Cell structure and motility  2q36.1 
ATP5G3  ATP synthase, H+ 
transporting, mitochondrial F0 
complex, subunit C3 (subunit 
9) 
Hydrogen transporter, 
Synthase and synthetase, 
ATP synthase 
Nucleotide and nucleic acid 
metabolism, 
Ion transport 
2q31.1 
BLVRB  biliverdin reductase B (flavin 
reductase (NADPH)) 
Oxido reductase  Electron transport, Coenzyme and 
prosthetic group metabolism 
19q13.1 
q13.2 
BSCL2, 
HNRPUL2 
Bernardinelli Seip congenital 
lipodystrophy 2 
(seipin),heterogeneous 
nuclear ribonucleoprotein U 
like 2 
Molecular function 
unclassified 
Biological process unclassified  11q12.3 
CALM1,2  calmodulin 1 (phosphorylase 
kinase, delta),calmodulin 2 
(phosphorylase kinase, delta) 
Select calcium binding 
protein 
Intracellular signalling cascade, 
Calcium mediated signalling, Cell 
cycle, 
Cell proliferation and 
differentiation 
2p21 
CAV1  caveolin 1, caveolae protein, 
22kDa 
Membrane traffic protein  Intracellular protein traffic  7q31.1 
CCND1  cyclin D1  Select regulatory molecule, 
Kinase modulator, Kinase 
activator 
Cell cycle control, Cell proliferation 
and differentiation 
11q13 
CCT7  chaperonin containing TCP1, 
subunit 7 (eta) 
Chaperone  Protein metabolism and 
modification 
2p13.2 
CD44  CD44 molecule (Indian blood 
group) 
Receptor, Cell adhesion 
molecule, Cell junction 
protein 
Intracellular signalling cascade, 
MAPKKK cascade, Cell 
communication, Cell adhesion 
mediated signalling, Immunity and 
defence, Oncogenesis, Inhibition of 
apoptosis, Cell structure and 
motility, Cell adhesion 
11p13 
CD63  CD63 molecule  Signalling molecule  Signal transduction, Cell 
communication, Cell adhesion 
mediated signalling, Immunity and 
defence 
12q12 
q13 
CDKN1A  cyclin dependent kinase 
inhibitor 1A (p21, Cip1) 
Select regulatory molecule, 
Kinase inhibitor 
Oncogenesis, Tumour suppressor, 
Cell cycle control, Cell proliferation 
and differentiation 
6p21.2 
CDKN1B  cyclin dependent kinase 
inhibitor 1B (p27, Kip1) 
Select regulatory molecule, 
Kinase inhibitor 
Oncogenesis, Tumour suppressor, 
Cell cycle control, Cell proliferation 
and differentiation 
12p13.1 
p12 
CDKN2A  cyclin dependent kinase 
inhibitor 2A (melanoma, p16, 
inhibits CDK4) 
Select regulatory molecule, 
Kinase inhibitor, Molecular 
function unclassified 
Oncogenesis, Tumour suppressor, 
Cell cycle control, Biological 
process unclassified 
9p21 
CEECAM1  cerebral endothelial cell 
adhesion molecule 1 
Cell adhesion molecule, 
Other cell adhesion 
molecule 
Cell adhesion  9q34.11 
CLIC1  chloride intracellular channel 
1 
Ion channel, Voltage gated 
ion channel 
Biological process unclassified  6p22.1 
p21.2 
COL1A1  collagen, type I, alpha 1  Extracellular matrix 
structural protein 
Mesoderm development, Skeletal 
development, Cell structure and 
motility, 
Cell adhesion 
17q21.33 
COL1A2  collagen, type I, alpha 2  Extracellular matrix 
structural protein 
Mesoderm development, Skeletal 
development, Cell structure and 
motility, 
Cell adhesion 
7q22.1 
COL3A1  collagen, type III, alpha 1 
(Ehlers Danlos syndrome type 
IV, autosomal dominant) 
Extracellular matrix 
structural protein 
Cell structure and motility  2q31 
COL5A1  collagen, type V, alpha 1  Extracellular matrix 
structural protein 
Cell structure and motility  9q34.2 
q34.3 
COTL1  coactosin like 1  Molecular function  Biological process unclassified  16q24.1 255 
(Dictyostelium)  unclassified 
COX5B  cytochrome c oxidase subunit 
Vb 
Oxido reductase  Electron transport, 
Oxidative phosphorylation 
2cen q13 
CST3  cystatin C (amyloid 
angiopathy and cerebral 
haemorrhage) 
Select regulatory molecule, 
Cysteine protease inhibitor 
Protein metabolism and 
modification, 
Proteolysis 
20p11.21 
CTGF  connective tissue growth 
factor, Gene hCG22108 Celera 
Annotation 
Signalling molecule, 
Growth factor, Cell 
adhesion molecule 
Cell surface receptor mediated 
signal transduction, Cell 
communication, 
Ligand mediated signalling, 
Immunity and defence, Stress 
response, Oncogenesis, Mesoderm 
development, Angiogenesis, 
Cell structure and motility 
6q23.1 
CTSS  Cathepsin S  Protease, Cysteine protease  Protein metabolism and 
modification, Proteolysis 
1q21 
DEGS1  degenerative spermatocyte 
homolog 1, lipid desaturase 
(Drosophila) 
Oxido reductase  Other metabolism  1q42.11 
DPYSL3  dihydropyrimidinase like 3  Hydrolase,   Nucleotide and nucleic acid 
metabolism 
5q32 
DSP  desmoplakin  Cytoskeletal protein, 
Intermediate filament, 
Cell structure and motility,  
Cell adhesion 
6p24 
DUSP6  dual specificity phosphatase 6  Protein phosphatase, 
Kinase inhibitor 
Protein metabolism and 
modification, Intracellular signalling 
cascade, MAPKKK cascade, 
Immunity and defence, Stress 
response, Antioxidation and free 
radical removal 
12q22 
q23 
DVL1  dishevelled, dsh homolog 1 
(Drosophila) 
Select regulatory molecule  Ectoderm development, 
Neurogenesis, Mesoderm 
development, Heart development 
1p36 
ELN  elastin (supravalvular aortic 
stenosis, Williams Beuren 
syndrome) 
Extracellular matrix 
protein, Structural protein 
Blood circulation and gas exchange, 
Cell structure and motility, Cell 
proliferation and differentiation 
7q11.23 
FBXO18  F box protein, helicase, 18  Nucleic acid binding, 
Helicase 
Biological process unclassified  10p15.1 
FOS  v fos FBJ murine 
osteosarcoma viral oncogene 
homolog 
Transcription factor  Nucleotide and nucleic acid 
metabolism, mRNA transcription, 
Immunity and defence, 
Oncogenesis, Mesoderm 
development, Skeletal 
development, Cell cycle control, 
Cell proliferation and 
differentiation 
14q24.3 
FOXO3A  forkhead box O3A  Transcription factor  Nucleotide and nucleic acid 
metabolism, mRNA transcription, 
Cell cycle control, Induction of 
apoptosis 
6q21 
GAPDH  glyceraldehyde 3 phosphate 
dehydrogenase 
Molecular function 
unclassified 
Biological process unclassified  12p13.3 
GARS  glycyl tRNA synthetase  Synthase and synthetase, 
Aminoacyl tRNA 
synthetase, Ligase 
Protein metabolism and 
modification, 
Amino acid activation 
7p15 
GPX4  glutathione peroxidase 4 
(phospholipid 
hydroperoxidase) 
Oxido reductase, 
Peroxidase 
Lipid, fatty acid and steroid 
metabolism, Immunity and defence, 
Stress response, Detoxification, 
Antioxidation and free radical 
removal 
19p13.3 
HMGA1  high mobility group AT hook 1  Molecular function 
unclassified 
Biological process unclassified  6p21 
HMOX1  heme oxygenase (decycling) 1  Oxido reductase  Coenzyme and prosthetic group 
metabolism, Porphyrin metabolism 
22q12; 
22q13.1 
HNF4A  hepatocyte nuclear factor 4  Receptor, Transcription 
factor, 
Nuclear hormone receptor, 
Nucleic acid binding 
Lipid, fatty acid and steroid 
metabolism, Nucleoside, nucleotide 
and nucleic acid metabolism, mRNA 
transcription, Signal transduction, 
Cell communication, Developmental 
processes 
20q12 
q13.1 
HSPA8  heat shock 70kDa protein 8  Hsp 70 family chaperone  Protein metabolism and 
modification, Immunity and 
defence, Stress response 
11q24.1 
HTRA1  HtrA serine peptidase 1  Serine protease  Protein metabolism and 
modification, Proteolysis, 
Intracellular signalling cascade, Cell 
communication 
10q26.3 
IFI30  interferon, gamma inducible 
protein 30 
Oxido reductase  Immunity and defence  19p13.1 
IGFBP4  insulin like growth factor 
binding protein 4 
Miscellaneous function  Signal transduction, Cell 
communication, Extracellular 
matrix protein mediated signalling, 
Homeostasis, Growth factor 
homeostasis 
17q12 
q21.1 
IL6ST  interleukin 6 signal transducer 
(gp130, oncostatin M 
receptor) 
Cytokine receptor, 
Interleukin receptor 
Cell surface receptor mediated 
signal transduction, Cytokine and 
chemokine mediated signalling 
pathway, Intracellular signalling 
cascade, MAPKKK cascade, JAK 
STAT cascade, Cell communication, 
Ligand mediated signalling, 
5q11 256 
Immunity and defence, Mesoderm 
development, Haematopoiesis 
ITGA1  integrin, alpha 11  Receptor, Cell adhesion 
molecule,  
Signal transduction, Cell surface 
receptor mediated signal 
transduction, Cell communication, 
Cell adhesion 
15q23 
KDELR2  KDEL (Lys Asp Glu Leu) 
endoplasmic reticulum protein 
retention receptor 2 
Receptor, Membrane traffic 
regulatory protein 
Intracellular protein traffic, 
Exocytosis 
7p22.1 
KIAA1199  KIAA1199  Molecular function 
unclassified 
Biological process unclassified  15q24 
KLF9  Kruppel like factor 9  Zinc finger transcription 
factor, KRAB box 
transcription factor 
Nucleoside, nucleotide and nucleic 
acid metabolism, mRNA 
transcription, 
9q13 
LMO7  LIM domain 7  Molecular function 
unclassified 
Biological process unclassified  13q22.2 
LOC401152  HCV F transactivated protein 
1 
Molecular function 
unclassified 
Biological process unclassified  4q26 
LOXL1  lysyl oxidase like 1  Extracellular matrix, Oxido 
reductase 
Oncogenesis, Tumour suppressor  15q24 
q25; 
15q22 
LUM  Lumican  Extracellular matrix  Signal transduction, Cell 
communication,  
Cell adhesion mediated signalling 
12q21.3 
q22 
MRC2  mannose receptor, C type 2  Receptor  Intracellular protein traffic, 
Endocytosis, Phagocytosis, 
17q23.2 
MVP  major vault protein  Nucleic acid binding, 
Ribonucleoprotein 
Biological process unclassified  16p13.1 
p11.2 
MYL9  myosin, light chain 9, 
regulatory 
Select calcium binding 
protein 
Muscle contraction, Mesoderm 
development, Muscle development, 
Cell structure and motility 
20q11.23 
MYO10  myosin X  Cytoskeletal protein  Cell structure and motility  5p15.1 
p14.3 
OAZ2  ornithine decarboxylase 
antizyme 2 
Select regulatory molecule, 
enzyme inhibitor, 
Miscellaneous function 
Protein metabolism and 
modification, Proteolysis, 
Oncogenesis, Gametogenesis, 
Spermatogenesis and motility, 
Apoptosis 
15q22.31 
OLFML3  olfactomedin like 3  Extracellular matrix 
glycoprotein 
Sensory perception, Olfaction  1p13.2 
PEA15  phosphoprotein enriched in 
astrocytes 15 
Molecular function 
unclassified 
Biological process unclassified  1q21.1 
PLAT  plasminogen activator, tissue  Tyrosine protein kinase 
receptor, Serine protease 
Protein metabolism and 
modification, Proteolysis, Cell 
surface receptor mediated signal 
transduction, Receptor protein 
tyrosine kinase signalling pathway, 
Immunity and defence, Blood 
clotting, Ectoderm development, 
Neurogenesis 
8p12 
POLR2A  polymerase (RNA) II (DNA 
directed) polypeptide A, 
220kDa 
Nucleic acid binding, DNA 
directed RNA polymerase, 
Nucleotidyltransferase 
Nucleoside, nucleotide and nucleic 
acid metabolism, mRNA 
transcription, 
17p13.1 
PRG1  proteoglycan 1, secretory 
granule 
    10q22.1 
PRSS23  protease, serine, 23  Serine protease, Hydrolase  Protein metabolism and 
modification, Proteolysis 
11q14.1 
PSAP  prosaposin (variant Gaucher 
disease and variant 
metachromatic 
leukodystrophy) 
Miscellaneous function  Lipid, fatty acid and steroid 
metabolism, Lipid and fatty acid 
transport 
10q21 
q22 
PTGS2  prostaglandin endoperoxide 
synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase) 
Synthase and synthetase, 
Oxido reductase, 
Peroxidase 
Lipid, fatty acid and steroid 
metabolism, Fatty acid biosynthesis, 
1q25.2 
q25.3 
ROR1  receptor tyrosine kinase like 
orphan receptor 1 
Tyrosine protein kinase 
receptor 
Protein metabolism and 
modification, Cell surface receptor 
mediated signal transduction, 
Receptor protein tyrosine kinase 
signalling pathway, Ectoderm 
development, Neurogenesis 
1p32 p31 
RPLP0  Ribosomal protein, large, P0  Nucleic acid binding, 
Ribosomal protein 
Protein metabolism and 
modification 
12q24.2 
RTN4  reticulon 4  Miscellaneous function, 
Transmembrane receptor 
regulatory/adaptor protein 
Intracellular protein traffic  2p16.3 
S100A6  S100 calcium binding protein 
A6 
Signalling molecule, 
Growth factor,  
Select calcium binding 
protein,  
Signal transduction, Cell cycle 
control, Cell proliferation and 
differentiation 
1q21 
SERPINE1  serpin peptidase inhibitor, 
clade E (nexin, plasminogen 
activator inhibitor type 1), 
member 1 
Select regulatory molecule, 
Serine protease inhibitor 
Protein metabolism and 
modification, Proteolysis, Immunity 
and defence 
7q21.3 
q22 
SERPINE2  serpin peptidase inhibitor, 
clade E (nexin, plasminogen 
activator inhibitor type 1), 
member 2 
Select regulatory molecule, 
Serine protease inhibitor 
Protein metabolism and 
modification, Proteolysis, Neuronal 
activities 
2q33 q35 
SHC1  SHC (Src homology 2 domain 
containing) transforming 
protein 1 
Signalling molecule  Signal transduction, Cell surface 
receptor mediated signal 
transduction, Receptor protein 
1q21 257 
tyrosine kinase signalling pathway, 
Intracellular signalling cascade, 
MAPKKK cascade, Oncogenesis, Cell 
cycle control 
SLC38A2  solute carrier family 38, 
member 2 
Transporter  Amino acid metabolism and 
transport 
12q 
SOD1  superoxide dismutase 1, 
soluble (amyotrophic lateral 
sclerosis 1 (adult)),Gene 
hCG1748590 Celera 
Annotation 
Oxido reductase  Immunity and defence  21q22.1; 
21q22.11 
SPARC  secreted protein, acidic, 
cysteine rich (osteonectin) 
Extracellular matrix 
glycoprotein 
Immunity and defence, Cell 
proliferation and differentiation 
5q31.3 
q32 
SRM  spermidine synthase  Synthase and synthetase, 
Transferase 
Other metabolism  1p36 p22 
STAT1  signal transducer and 
activator of transcription 1, 
91kDa 
Transcription factor,  
Nucleic acid binding 
Nucleoside, nucleotide and nucleic 
acid metabolism, mRNA 
transcription, mRNA transcription 
termination, Intracellular signalling 
cascade, JAK STAT cascade, 
Immunity and defence, Stress 
response, Oncogenesis, Mesoderm 
development, Haematopoiesis, Cell 
cycle control, Inhibition of 
apoptosis, Cell proliferation and 
differentiation 
2q32.2 
STC2  stanniocalcin 2  Signalling molecule, 
Peptide hormone 
Signal transduction, Cell surface 
receptor mediated signal 
transduction, Ion transport, Calcium 
ion homeostasis 
5q35.2 
TGFBI  transforming growth factor, 
beta induced, 68kDa 
Signalling molecule, 
Cell adhesion molecule 
Signal transduction, Cell 
communication, Extracellular 
matrix protein mediated signalling, 
Sensory perception, Vision, 
Mesoderm development, Skeletal 
development, Cell proliferation and 
differentiation, Cell adhesion 
5q31 
TGM2  transglutaminase 2 (C 
polypeptide, protein 
glutamine gamma 
glutamyltransferase) 
Select calcium binding 
protein, Annexin, 
Transferase, 
Acyltransferase 
Protein metabolism and 
modification 
20q12 
THY1  Thy 1 cell surface antigen  Membrane bound signalling 
molecule 
Signal transduction, Cell 
communication, Ligand mediated 
signalling 
11q22.3 
q23 
TM4SF1  transmembrane 4 L six family 
member 1 
Molecular function 
unclassified 
Oncogenesis  3q21 q25 
TMEM47  transmembrane protein 47  Miscellaneous function  Apoptosis  Xp11.4 
TRAM2  translocation associated 
membrane protein 2 
Molecular function 
unclassified 
Biological process unclassified  6p21.1 
p12 
TUBB6  tubulin, beta 6  Cytoskeletal protein, 
Microtubule family 
Intracellular protein traffic, Cell 
cycle, Mitosis, Chromosome 
segregation, Cell structure and 
motility 
18p11.21 
UBC  ubiquitin C  Molecular function 
unclassified 
Protein metabolism and 
modification 
12q24.3 
VCP  valosin containing protein  Hydrolase  Protein metabolism and 
modification, Intracellular protein 
traffic, Exocytosis, Protein targeting 
and localization 
9p13.3 
VIM  Vimentin  Cytoskeletal protein, 
Intermediate filament 
Cell structure and motility  10p13 
WBSCR1  Williams Beuren syndrome 
chromosome region 1 
Nucleic acid binding, 
Translation factor, 
Translation initiation factor 
Protein metabolism and 
modification, Protein biosynthesis 
7q11.23 
YIPF5  Yip1 domain family, member 5  Molecular function 
unclassified 
Biological process unclassified  5q32 
YWHAB  tyrosine 3 
monooxygenase/tryptophan 5 
monooxygenase activation 
protein, beta polypeptide 
Miscellaneous function  Non vertebrate process  20q13.1 
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Long Tag  Unigene  Gene  Tags    O.R  P  O.R  P  O.R  P 
      12P2  25P2  25P9 
25P9: 
25P2   
25P9: 
12P2   
25P2: 
12P2   
GCTTTATTTGTTTTTTT  Hs.520640  ACTB
4,11  13  189  179  0.98  n.s  14.39  ***  15.11  *** 
TACTTTATAAGTATTGG  Hs.643357  ADAMTS1
1,15  7  2  28  14.44  ***  4.18  ***  0.30  n.s 
AGGTCTGCCAGAAGGCC  Hs.567256  AKR1C2
1  1  1  14  14.44  ***  14.63  ***  1.04  n.s 
CTTCCAGCTAACAGGTC  Hs.511605  ANXA2
2,15  123  61  137  2.32  ***  1.16  n.s  0.52  *** 
AATAGGGTCAAAGGGGA  Hs.370247  APLP2
1,15  4  2  18  9.28  ***  4.70  ***  0.52  n.s 
CAGGAGTTCAAAGAAGG  Hs.529303  ARPC2
2  29  9  39  4.47  ***  1.41  n.s  0.32  *** 
GGAATGTACGTTATTTC  Hs.429  ATP5G3
  17  4  23  5.93  ***  1.41  n.s  0.24  ** 
AGGAGCAAAGGAAGGGG  Hs.515785  BLVRB
1  3  4  25  6.44  ***  8.71  ***  1.39  n.s 
AAGCTGAATCTCTGGGG  Hs.533709  BSCL2
1  1  1  6  6.19  *  6.27  n.s  1.04  n.s 
TTGTTGTTGAAGTGTGG  Hs.643483  CALM2
2,15  46  14  35  2.58  ***  0.80  n.s  0.32  *** 
TCCTGTAAAGGTTACAA  Hs.74034  CAV1
2,9  14  2  12  6.19  **  0.90  n.s  0.15  ** 
AAAGTCTAGAAATAAAA  Hs.523852  CCND1
1,15  2  4  21  5.41  ***  10.97  ***  2.08  n.s 
GCTGGCTGGCTGCTGGG  Hs.368149  CCT7
2  14  5  19  3.92  ***  1.42  n.s  0.37  * 
ATATGTATATTGCTGAG  Hs.502328  CD44
1,15  4  3  12  4.12  *  3.14  *  0.78  n.s 
TCGAAGAACCGAGTCCC  Hs.445570  CD63
2  55  17  50  3.03  ***  0.95  n.s  0.32  *** 
TGTCCTGGTTCCCGTTT  Hs.370771     CDKN1A
10  1  1  1  1.03  n.s  1.05  n.s  1.04  n.s 
TTTTGTGCATTTGTAAA  Hs.238990  CDKN1B
10  1  1  1  1.03  n.s  1.05  n.s  1.04  n.s 
AAGAGAAGCAATTTTGG  Hs.238990  CDKN1B
10  1  2  1  0.52  n.s  1.05  n.s  2.08  n.s 
CCCGCATAGATGCCGCG  Hs.512599  CDKN2A
10  2  1  1  1.03  n.s  0.52  n.s  0.52  n.s 
GCCACTCTGCCCTCTGG  Hs.495230  CEECAM1
  1  2  12  6.19  **  12.54  ***  2.08  n.s 
GTACTGTGGCTCAAGGG  Hs.414565  CLIC1
2  39  5  25  5.16  ***  0.67  n.s  0.13  *** 
ACCAAAAACCAAAAGTG  Hs.172928  COL1A1
1,2,8,15  138  289  177  0.63  ***  1.34  **  2.18  *** 
CCGGGGGAGCCACCAGC  Hs.172928  COL1A1
2,8,15  7  40  14  0.36  ***  2.09  n.s  5.94  *** 
GACCAGCAGACTGGCAA  Hs.172928  COL1A1
3,8,15  17  21  10  0.49  *  0.61  n.s  1.25  n.s 
TGGAAATGACCCAAACA  Hs.172928  COL1A1
1,8,15  22  17  6  0.36  *  0.29  ***  0.80  n.s 
GGAGGAGAGCGTGTGCG  Hs.172928  COL1A1
1,8,15  8  14  1  0.07  ***  0.13  *  1.82  n.s 
GGCCCCCCTGGATTGGC  Hs.172928  COL1A1
3,8,15  4  9  1  0.11  *  0.26  n.s  2.28  n.s 
GACTTTGGAAAATATTT  Hs.172928  COL1A1
2,8,15  1  8  1  0.13  *  1.05  n.s  8.32  * 
GATGAGGAGACTGGCAA  Hs.489142  COL1A2
1,8,15  97  101  58  0.59  ***  0.62  ***  1.08  n.s 
TTTGGTTTTCCAAAAGA  Hs.489142  COL1A2
1,2,8,15  42  83  34  0.42  ***  0.85  n.s  2.05  *** 
TTTGGTTTTCCAAAAAA  Hs.489142  COL1A2
2,8,15  12  27  3  0.11  ***  0.26  *  2.34  ** 
CCGTGACTTGAGACTCA  Hs.489142  COL1A2
2,8,15  1  14  1  0.07  ***  1.05  n.s  14.55  *** 
GTTCCACAGAAGCTTTG  Hs.489142  COL1A2
1,8,15  17  17  1  0.06  ***  0.06  ***  1.04  n.s 
CCACAGGGGATTCTCCT  Hs.443625  COL3A1
1,2  29  47  4  0.09  ***  0.14  ***  1.68  * 
GATCAGGCCAGTGGAAA  Hs.443625  COL3A1
1  33  29  15  0.53  *  0.48  **  0.91  n.s 
CCAGGTCCTAGGGGAAG  Hs.443625  COL3A1
2  1  7  1  0.15  *  1.05  n.s  7.28  * 
CCTCCAGCCCCCCAGCT  Hs.210283  COL5A1
1  6  13  1  0.08  ***  0.17  *  2.25  n.s 
TGATTCTGTTTTCATTT  Hs.210283  COL5A1
2  4  16  4  0.26  **  1.05  n.s  4.16  ** 
AGCACATTTGATATAGC  Hs.289092  COTL1
3  17  9  23  2.64  **  1.41  n.s  0.55  n.s 
CTGGCTGCAAAGAAGGG  Hs.1342  COX5B
1  11  5  23  4.74  ***  2.19  *  0.47  n.s 
TGCCTGCACCAGGAGAC  Hs.304682  CST3
3,15  14  7  24  3.54  ***  1.79  n.s  0.52  n.s 
TTTGCACCTTTCTAGTT  Hs.591346  CTGF
2,8,15  101  141  89  0.65  ***  0.92  n.s  1.45  *** 
CCTGTAATCCCAGCTAC  Hs.181301  CTSS
3,15  12  6  18  3.09  **  1.57  n.s  0.52  n.s 
GGAGGCTGAGGTGGGAG  Hs.299878  DEGS1
2  12  3  16  5.50  ***  1.39  n.s  0.26  * 
GGCTGCCCTGGGCAGCC  Hs.519659  DPYSL3
1  11  10  2  0.21  *  0.19  *  0.95  n.s 
ACAGCGGCAATCTTTTC  Hs.519873  DSP
3  4  1  9  9.28  *  2.35  n.s  0.26  n.s 
GGTACCCATTTGATAAG  Hs.712581  DUSP6
3  1  1  6  6.19  *  6.27  n.s  1.04  n.s 
GCCCGCAGGGTCAAGGG  Hs.74375  DVL1
1  5  1  13  13.40  ***  2.72  *  0.21  n.s 259 
CAGTACTGTATACCCCC  Hs.647061  ELN
3,15  25  15  34  2.34  ***  1.42  n.s  0.62  n.s 
AGGCCCTGCTCTTCCTC  Hs.498543  FBXO18
7,14  1  1  1  1.03  n.s  1.05  n.s  1.04  n.s 
TGGAAAGTGAATTTGAA  Hs.25647  FOS
1,12,13,15  11  37  7  0.20  ***  0.67  n.s  3.50  *** 
TAAATAAAGCATCAGTG  Hs.220950  FOXO3A
7,12,14  3  2  2  1.03  n.s  0.70  n.s  0.69  n.s 
TACCATCAATAAAGTAC  Hs.544577  GAPDH
2,11  76  125  207  1.71  ***  2.85  n.s  1.71  *** 
GGCTGATGTGGAGGCCA  Hs.404321  GARS
1  17  14  3  0.22  **  0.18  ***  0.86  n.s 
GCCTGCTGGGCTTGGCT  Hs.433951  GPX4
1,15  17  9  1  0.11  *  0.06  ***  0.55  n.s 
ATTTGTCCCAGCCTGGG  Hs.518805  HMGA1
1,12,15  6  2  33  17.01  ***  5.75  ***  0.35  n.s 
CGTGGGTGGGGAGGGAG  Hs.517581  HMOX1
1,15  11  8  26  3.35  ***  2.47  **  0.76  n.s 
TGTATATAAAGCCTCAC  Hs.116462    HNF4A
7,12,14  1  1  1  1.03  n.s  1.05  n.s  1.04  n.s 
CCAGGAGGAATGCCTGG  Hs.180414  HSPA8
1,2  54  17  83  5.03  ***  1.61  ***  0.33  *** 
TTTCCCTCAAAGACTCT  Hs.501280  HTRA1
2  7  15  2  0.14  ***  0.30  n.s  2.23  * 
ATCAAGAATCCTGCTCC  Hs.14623  IFI30
3,15  4  2  10  5.16  *  2.61  n.s  0.52  n.s 
ATGTCTTTTCTTCTTTT  Hs.462998  IGFBP4
4,6  14  85  85  1.03  n.s  6.35  ***  6.31  *** 
TGCTAATTGTAACCACA  Hs.532082  IL6ST
6,9  12  11  8  0.75  n.s  0.70  n.s  0.95  n.s 
CCCGCCAGTGCACAGGG  Hs.436416  ITGA11
1  14  24  4  0.17  ***  0.30  *  1.78  n.s 
AAAGGCATCAGTCCCCC  Hs.436416  ITGA11
2  10  24  11  0.47  *  1.15  n.s  2.50  ** 
ATACCTTCCGAGTGGAG  Hs.654552  KDELR2
1,15  3  5  18  3.71  **  6.27  ***  1.73  n.s 
AACAAAGATATATTTTC  Hs.459088  KIAA1199
1  1  1  14  14.44  ***  14.63  ***  1.04  n.s 
CTTCTCTTGAGAATTCT  Hs.150557  KLF9
3,12  5  1  6  6.19  *  1.25  n.s  0.21  n.s 
GTTTGTATACTAGAAGT  Hs.207631  LMO7
1,3  8  6  18  3.09  **  2.35  *  0.78  n.s 
ACTTGTTCGCTGATATC  Hs.173705  LOC401152
2  11  1  8  8.25  *  0.76  n.s  0.09  *** 
CACCTCTCATACCCAGG  Hs.65436  LOXL1
2,15  45  17  38  2.30  ***  0.88  n.s  0.39  *** 
TTATGTTTAATAAGCTA  Hs.406475  LUM
2  4  17  2  0.12  ***  0.52  n.s  4.42  ** 
GCCCTTTCTCTGTAGTT  Hs.7835  MRC2
2  13  51  5  0.10  ***  0.40  n.s  4.08  *** 
GCCGTGGAGAGCACCGG  Hs.632177  MVP
3,15  5  1  12  12.37  ***  2.51  n.s  0.21  n.s 
GGAGTGTGCTCAGGAGT  Hs.504687  MYL9
5  108  118  104  0.91  n.s  1.01  n.s  1.14  n.s 
CAAAACTGTTTGTTGGC  Hs.481720  MYO10
1  1  1  11  11.34  ***  11.50  **  1.04  n.s 
GCCTGGAGGGCTGGTGG  Hs.74563  OAZ2
3,15  6  1  10  10.31  **  1.74  n.s  0.17  n.s 
TCAACAAATTTCAGGCT  Hs.9315  OLFML3
1  19  24  5  0.21  ***  0.28  **  1.31  n.s 
AACTGTCCTTCCATTTG  Hs.517216  PEA15
2,15  12  4  14  3.61  *  1.22  n.s  0.35  * 
TTAGTTTTTACTTTCTG  Hs.491582  PLAT
1,15  1  1  8  8.25  *  8.36  *  1.04  n.s 
TCTCCCAGCTACTCGCC  Hs.270017  POLR2A
7,11  1  2  1  0.52  n.s  1.05  n.s  2.08  n.s 
GCCATAAAATGGCTTTA  Hs.1908   PRG1
4,9  1  8  9  1.16  n.s  9.41  n.s  8.32  * 
TTCTTATTTTAGGAGAG  Hs.25338  PRSS23
1  4  4  30  7.73  ***  7.84  ***  1.04  n.s 
AAGTTGCTATTAAATGG  Hs.523004  PSAP
1,15  6  7  19  2.80  **  3.31  **  1.21  n.s 
CTGTTCCTTTTCTTTTC  Hs.196384  PTGS2
9  4  1  3  3.09  n.s  0.78  n.s  0.26  n.s 
GACACACCGAATCTATG  Hs.654491  ROR1
12,14  1  1  1  1.03  n.s  1.05  n.s  1.04  n.s 
CTCAACATCTCCCCCTT  Hs.546285  RPLP0
6,11  42  35  31  0.91  n.s  0.77  n.s  0.87  n.s 
TGTTCATCATCTTAAGT  Hs.645283  RTN4
1  2  2  10  5.16  *  5.23  *  1.04  n.s 
AAATGCCACACACATAG  Hs.645283  RTN4
3  2  1  7  7.22  *  3.66  n.s  0.51  n.s 
CCCCCTGGATCAGGCCA  Hs.275243  S100A6
1,2  48  13  29  2.30  **  0.63  *  0.28  *** 
GGTTATTTTGGAGTGTA  Hs.414795  SERPINE1
1,2,15  13  3  44  15.12  ***  3.54  ***  0.24  * 
TATTCACTAAAATAAAA  Hs.38449  SERPINE2
1,2,15  8  23  56  2.51  ***  7.32  ***  2.99  ** 
GAGGGGAAACGCAAAAC  Hs.433795  SHC1
3  4  1  9  9.28  ***  2.35  n.s  0.26  n.s 
CTTAATCCTGAAAAAAA  Hs.221847  SLC38A2
  8  10  1  0.10  *  0.13  *  1.30  n.s 
AAAAAGCAGATGACTTG  Hs.443914  SOD1
2  12  1  16  16.50  ***  1.39  n.s  0.09  *** 
ATGTGAAGAGTTTCACA  Hs.111779  SPARC
2,8,15  72  226  76  0.35  ***  1.10  n.s  3.26  *** 
TTAGTGTCGTATTTTGA  Hs.111779  SPARC
3,8,15  13  22  8  0.37  *  0.64  n.s  1.72  n.s 
GGTGGACACGGATCTGC  Hs.111779  SPARC
1,8,15  11  11  1  0.09  **  0.10  **  1.04  n.s 
GAGCATTGCACCACCCG  Hs.111779  SPARC
1,8,15  8  12  1  0.09  ***  0.13  *  1.56  n.s 260 
CTGTGCAGCAAGAACCC  Hs.76244  SRM
2  11  2  13  6.70  **  1.24  n.s  0.19  * 
CAAATGCTGTATTCTTC  Hs.655132  STAT1
2,9,12,15  8  1  14  14.44  ***  1.83  n.s  0.13  * 
CCCGAGGCAGAGTCGGG  Hs.233160  STC2
1,2  53  14  82  6.04  ***  1.62  ***  0.27  *** 
GTGTGTTTGTAATAATA  Hs.369397  TGFBI
2,8  34  143  72  0.52  ***  2.21  n.s  4.37  *** 
GGAAGTCCTGGCACAGT  Hs.369397  TGFBI
2,8  6  17  6  0.36  *  1.05  n.s  2.95  * 
GGCCGCACCATAATGAG  Hs.369397  TGFBI
1,8  1  10  1  0.10  **  1.05  **  10.40  n.s 
TATATTTTCTCTATACA  Hs.517033  TGM2
1,9  3  2  12  6.19  **  4.18  *  0.69  n.s 
GAGTGAGACCCAGGAGC  Hs.653181  THY1
2  42  24  53  2.28  ***  1.32  n.s  0.59  * 
GGGACGAGTGACGGCAG  Hs.715499  TM4SF1
3  14  5  17  3.51  **  1.27  n.s  0.37  n.s 
AAGTCATCTATGTGGAA  Hs.8769  TMEM47
1  1  1  10  10.31  **  10.45  **  1.04  n.s 
TAAAAAAGGGTTGGGGG  Hs.520182  TRAM2
1,15  3  2  11  5.67  *  3.83  *  0.69  n.s 
TCTGCAAATTAGGAGGG  Hs.193491  TUBB6
2,15  18  3  24  8.25  ***  1.39  n.s  0.17  *** 
GGGTCCCGGGTCCGCCT  Hs.520348  UBC
11  1  1  1  1.03  n.s  1.05  n.s  1.04  n.s 
TTGTAAAAGGACAATAA  Hs.529782  VCP
1  3  2  11  5.67  *  3.83  *  0.69  n.s 
TCCAAATCGATGTGGAT  Hs.642813  VIM
1,8,15  131  73  166  2.34  ***  1.32  **  0.58  n.s 
CATCTAAACTGCTGGGC  Hs.520943  WBSCR1
3  15  8  25  3.22  ***  1.74  n.s  0.55  n.s 
CAGAGTTGTATATAGCC  Hs.372050  YIPF5
1  3  4  17  4.38  **  5.92  ***  1.39  n.s 
CTTTTTGTGCCTGTCAC  Hs.651212  YWHAB
2  11  1  8  8.25  *  0.76  n.s  0.09  ** 
Table 9 SAGE results matching genes on the TLDA 
1Genes differentially expressed 25P2v25P9 and found in 12P2v25P9 (F=1, p<0.05) 
2Genes differentially expressed 25P2v25P9 and found in 25P2v12P2 (F=1, p<0.05) 
3Genes differentially expressed 25P2v25P9 (F=1, p<0.05) 
4Genes not differentially expressed 25P2v25P9 but significantly different 12P2 and 25P2 and P9 (F=1, p<0.05) 
5Gene matching a high abundance tag in SAGE 
6Gene matching moderate abundance tags in SAGE 
7Gene matching low abundance tags in SAGE 
8Gene abundant in MSC’s from other studies 
9Potential p38 target gene 
10Cell cycle control gene 
11Endogenous control gene  
12Trancription factor 
13Component of AP 1 transcription factor 
14Wild card gene 
15Gene identified on the regulatory network from Metacore
TM 
 
O.R   Odds Ratio 
P   P value, * £ 0.05, ** £0.01, *** £0.001 and n.s, not significant 261 
 
Gene  25 P2 
RQ 
25 P2 
RQ Min 
25 P2 
RQ Max 
25 P5 
RQ 
25 P5 
RQ Min 
25 P5 
RQ Max 
25 P9 
RQ 
25 P9 
RQ Min 
25 P9 
RQ Max 
GAPDH  1  0.832  1.202  1.119  0.798  1.570  1.024  0.783  1.340 
ACTB  1  0.825  1.211  0.804  0.779  0.831  0.687  0.512  0.920 
ADAMTS1  1  0.693  1.443  2.326  2.310  2.341  3.107  2.159  4.469 
AKR1C1,2  1  0.824  1.213  0.594  0.535  0.658  2.818  1.957  4.057 
ANXA2  1  0.826  1.211  1.351  1.040  1.756  1.482  1.054  2.083 
APLP2  1  0.793  1.261  1.466  0.998  2.154  2.369  1.872  3.000 
ARPC2  1  0.752  1.329  0.898  0.740  1.091  1.398  1.057  1.849 
ATP5G3  1  0.834  1.199  0.859  0.673  1.097  2.391  1.877  3.046 
BLVRB  1  0.853  1.172  0.970  0.808  1.165  1.791  1.421  2.258 
BSCL2  1  0.902  1.109  0.934  0.924  0.944  1.260  0.828  1.918 
CALM1,2  1  0.781  1.280  1.177  0.688  2.014  1.413  1.064  1.876 
CAV1  1  0.728  1.374  1.475  1.136  1.916  3.696  2.580  5.296 
CCND1  1  0.834  1.199  4.292  3.055  6.030  9.625  7.607  12.18 
CCT7  1  0.856  1.168  0.984  0.979  0.988  1.757  1.193  2.588 
CD44  1  0.871  1.148  2.931  2.448  3.509  4.547  3.473  5.953 
CD63  1  0.897  1.115  1.007  0.979  1.035  1.375  0.988  1.914 
CDKN1A  1  0.899  1.112  0.852  0.851  0.853  1.054  0.781  1.423 
CDKN1B  1  0.838  1.194  0.629  0.628  0.631  0.572  0.441  0.740 
CDKN2A  1  0.891  1.122  0.686  0.636  0.740  1.139  0.822  1.579 
CEECAM1  1  0.894  1.118  0.818  0.754  0.886  0.910  0.710  1.165 
CLIC1  1  0.852  1.174  1.202  1.157  1.249  1.465  1.087  1.975 
COL1A1  1  0.537  1.862  0.570  0.271  1.197  0.268  0.208  0.345 
COL1A2  1  0.850  1.177  0.535  0.195  1.467  0.312  0.239  0.406 
COL3A1  1  0.855  1.169  0.382  0.327  0.447  0.240  0.187  0.308 
COL5A1  1  0.899  1.113  0.442  0.367  0.533  0.405  0.304  0.541 
COTL1  1  0.836  1.196  1.257  1.218  1.297  1.764  1.319  2.359 
COX5B  1  0.902  1.109  0.889  0.778  1.016  1.466  1.159  1.854 
CST3  1  0.821  1.218  0.908  0.807  1.022  1.006  0.785  1.289 
CTGF  1  0.866  1.154  0.668  0.665  0.671  0.821  0.649  1.039 
CTSS  1  0.691  1.446  0.414  0.230  0.743  0.336  0.258  0.438 
DEGS1  1  0.901  1.110  1.283  1.039  1.584  1.401  1.103  1.780 
DPYSL3  1  0.902  1.108  0.429  0.362  0.508  0.292  0.194  0.440 
DSP  1  0.901  1.110  1.770  1.374  2.280  2.418  1.864  3.137 
DUSP6  1  0.728  1.373  1.611  1.071  2.423  2.554  1.873  3.484 
DVL1  1  0.485  2.063  1.081  0.896  1.305  1.475  1.103  1.973 
ELN  1  0.609  1.642  2.309  1.754  3.039  1.920  1.451  2.540 
FBXO  1  0.787  1.271  0.913  0.892  0.935  0.776  0.601  1.002 
FOS  1  0.838  1.193  0.850  0.769  0.940  0.683  0.534  0.874 
FOXO3A  1  0.762  1.313  0.604  0.469  0.776  0.492  0.219  1.109 
GARS  1  0.901  1.110  0.420  0.302  0.585  0.499  0.353  0.706 
GPX4  1  0.820  1.220  0.816  0.692  0.962  0.577  0.282  1.181 
HMGA1  1  0.155  6.465  2.037  1.116  3.716  6.245  4.291  9.087 
HMOX1  1  0.795  1.258  1.087  1.022  1.156  0.701  0.530  0.928 
HNF4A  Not detected after 40 cycles 
HSPA8  1  0.872  1.146  1.007  0.730  1.389  1.602  1.200  2.138 
HTRA1  1  0.89  1.124  0.302  0.297  0.306  0.255  0.166  0.391 
IFI30  1  0.817  1.223  1.127  1.072  1.185  1.624  1.050  2.511 
IGFBP4  1  0.896  1.116  1.174  1.085  1.269  1.167  0.907  1.501 
IL6ST  1  0.893  1.120  0.938  0.888  0.991  1.282  0.950  1.731 
ITGA11  1  0.896  1.116  0.627  0.549  0.718  0.170  0.127  0.226 
KDELR2  1  0.881  1.135  0.976  0.971  0.982  1.149  0.663  1.991 
KIAA1199  1  0.792  1.263  5.292  4.771  5.870  3.916  2.733  5.612 
KLF9  1  0.898  1.113  0.999  0.948  1.053  0.621  0.492  0.783 
LMO7  1  0.872  1.146  0.913  0.563  1.480  1.106  0.788  1.551 262 
LOC40115
2  1  0.765  1.307  0.708  0.678  0.739  0.703  0.557  0.888 
LOXL1  1  0.831  1.204  0.652  0.512  0.831  0.708  0.543  0.923 
LUM  1  0.509  1.965  0.736  0.716  0.757  0.233  0.182  0.299 
MRC2  1  0.899  1.112  0.578  0.521  0.642  0.340  0.242  0.477 
MVP  1  0.901  1.110  1.169  0.978  1.398  1.702  1.347  2.151 
MYL9  1  0.549  1.821  1.666  1.287  2.157  1.458  1.017  2.089 
MYO10  1  0.815  1.227  1.060  1.013  1.109  1.932  1.500  2.489 
OAZ2  1  0.820  1.220  0.855  0.833  0.877  1.004  0.759  1.327 
OLFML3  1  0.879  1.137  0.324  0.323  0.324  0.205  0.128  0.327 
PEA15  1  0.475  2.106  1.052  0.797  1.389  1.401  0.751  2.616 
PLAT  1  0.597  1.676  1.912  1.719  2.125  9.789  7.575  12.651 
POLR2A  1  0.638  1.566  0.872  0.480  1.584  0.913  0.723  1.154 
PRG1  1  0.740  1.351  2.622  2.554  2.691  4.392  3.393  5.687 
PRSS23  1  0.834  1.199  2.114  1.805  2.475  2.142  1.669  2.749 
PSAP  1  0.759  1.318  1.230  1.064  1.423  1.171  0.828  1.656 
PTGS2  1  0.629  1.590  1.808  1.674  1.952  1.924  1.365  2.712 
ROR1  1  0.884  1.131  1.460  1.334  1.599  1.777  1.323  2.387 
RPLP0  1  0.901  1.109  0.507  0.488  0.527  0.815  0.583  1.138 
RTN4  1  0.872  1.147  1.280  1.118  1.466  2.092  1.381  3.168 
S100A6  1  0.649  1.542  2.028  1.642  2.506  2.030  1.539  2.678 
SERPINE1  1  0.640  1.562  2.046  1.887  2.219  2.591  1.857  3.615 
SERPINE2  1  0.902  1.108  1.808  1.492  2.190  1.471  0.940  2.303 
SHC1  1  0.795  1.258  0.803  0.719  0.896  1.132  0.887  1.444 
SLC38A2  1  0.718  1.393  0.584  0.348  0.981  0.638  0.496  0.822 
SOD1  1  0.902  1.109  1.212  1.075  1.366  2.429  1.573  3.751 
SPARC  1  0.882  1.134  0.490  0.442  0.544  0.284  0.223  0.362 
SRM  1  0.727  1.376  1.179  0.799  1.739  1.761  1.281  2.421 
STAT1  1  0.659  1.519  1.891  0.969  3.692  3.348  2.342  4.786 
STC2  1  0.834  1.199  1.720  1.298  2.280  2.335  1.812  3.009 
TGFBI  1  0.901  1.109  0.615  0.553  0.684  0.675  0.254  1.795 
TGM2  1  0.877  1.141  1.224  1.125  1.331  1.302  0.923  1.836 
THY1  1  0.897  1.115  1.229  1.100  1.373  0.974  0.748  1.267 
TM4SF1  1  0.846  1.183  2.477  2.178  2.817  5.859  4.579  7.497 
TMEM47  1  0.808  1.237  0.818  0.544  1.229  0.890  0.568  1.396 
TRAM2  1  0.834  1.199  1.363  1.342  1.384  1.429  1.112  1.835 
TUBB6  1  0.830  1.204  1.340  0.983  1.826  1.170  0.404  3.386 
UBC  Control 
VCP  1  0.902  1.108  1.121  1.024  1.228  1.624  1.040  2.535 
VIM  1  0.889  1.125  0.877  0.795  0.966  0.839  0.635  1.107 
WBSCR1  1  0.886  1.128  2.613  2.381  2.868  3.323  2.629  4.201 
YIPF5  1  0.857  1.167  0.996  0.946  1.049  1.374  1.065  1.771 
YWHAB  1  0.879  1.138  1.099  0.805  1.500  1.300  0.911  1.855 
Table 10 TLDA results for donor 25 MSC’s 263 
 
Gene   Mean RQ P5 
(n=8)  Std Dev.  P value 
 
Mean RQ P9 
(n=8)  Std Dev.  P value 
 
P value RQ 
P5 v P9 
ACTB  0.781  0.092  ***  0.574  0.252  ***  * 
ADAMTS1  2.315  0.832  ***  2.643  0.799  ***  n.s 
AKR1C1,2  1.231  0.358  n.s  2.169  1.563  n.s  n.s 
ANXA2  1.049  0.486  n.s  0.866  0.359  n.s  n.s 
APLP2  1.942  0.956  *  2.131  0.992  **  n.s 
ARPC2  1.069  0.238  n.s  1.057  0.332  n.s  n.s 
ATP5G3  1.114  0.182  n.s  1.402  0.530  *  n.s 
BLVRB  0.972  0.133  n.s  0.999  0.415  n.s  n.s 
BSCL2  1.035  0.109  n.s  1.184  0.298  n.s  n.s 
CALM1,2  1.535  0.741  n.s  1.358  0.533  n.s  n.s 
CAV1  2.430  0.669  ***  4.026  1.759  ***  * 
CCND1  2.836  1.090  ***  4.889  2.308  ***  * 
CCT7  1.041  0.179  n.s  1.129  0.393  n.s  n.s 
CD44  2.605  0.870  ***  3.490  1.462  ***  n.s 
CD63  1.276  0.253  **  1.495  0.394  **  n.s 
CDKN1A  1.049  0.409  n.s  1.329  0.353  *  n.s 
CDKN1B  0.823  0.141  **  0.761  0.189  **  n.s 
CDKN2A  1.656  0.605  **  1.979  1.250  *  n.s 
CEECAM1  1.207  0.256  *  1.196  0.286  n.s  n.s 
CLIC1  1.149  0.264  n.s  1.123  0.230  n.s  n.s 
COL1A1  1.217  0.469  n.s  0.976  0.683  n.s  n.s 
COL1A2  1.551  0.627  *  1.287  0.951  n.s  n.s 
COL3A1  0.922  0.331  n.s  0.947  0.454  n.s  n.s 
COL5A1  1.246  0.548  n.s  1.620  2.033  n.s  n.s 
COTL1  0.969  0.376  n.s  0.961  0.559  n.s  n.s 
COX5B  0.969  0.118  n.s  1.034  0.290  n.s  n.s 
CST3  1.229  0.288  *  1.573  0.603  *  n.s 
CTGF  1.700  0.770  *  1.699  0.714  *  n.s 
CTSS  0.283  0.314  ***  0.356  0.293  ***  n.s 
DEGS1  1.179  0.156  **  1.197  0.384  n.s  n.s 
DPYSL3  0.982  0.370  n.s  0.592  0.492  *  n.s 
DSP  2.011  0.760  **  2.300  0.994  **  n.s 
DUSP6  1.201  0.784  n.s  1.579  0.979  n.s  n.s 
DVL1  1.376  0.327  **  1.445  0.445  *  n.s 
ELN  1.283  0.582  n.s  1.216  0.804  n.s  n.s 
FBXO18  1.037  0.190  n.s  0.957  0.165  n.s  n.s 
FOS  0.549  0.206  ***  0.582  0.229  ***  n.s 
FOXO3A  0.807  0.163  **  0.654  0.166  ***  n.s 
GAPDH  1.028  0.250  n.s  0.914  0.340  n.s  n.s 
GARS  0.988  0.291  n.s  1.123  0.721  n.s  n.s 
GPX4  1.016  0.173  n.s  0.836  0.194  *  n.s 
HMGA1  2.295  1.479  *  3.249  2.699  *  n.s 
HMOX1  0.743  0.371  n.s  0.502  0.107  ***  n.s 
HNF4A  Not detected after 40 cycles 
HSPA8  1.216  0.143  ***  1.318  0.419  *  n.s 
HTRA1  0.827  0.356  n.s  0.652  0.629  n.s  n.s 
IFI30  0.731  0.390  n.s  0.845  0.620  n.s  n.s 
IGFBP4  0.695  0.208  ***  0.649  0.241  **  n.s 264 
IL6ST  1.078  0.288  n.s  1.421  0.473  *  n.s 
ITGA11  0.841  0.323  n.s  0.506  0.361  **  n.s 
KDELR2  1.062  0.265  n.s  1.115  0.348  n.s  n.s 
KIAA1199  4.951  1.516  ***  4.621  2.534  **  n.s 
KLF9  0.954  0.235  n.s  0.844  0.282  n.s  n.s 
LMO7  1.395  0.406  *  1.400  0.428  *  n.s 
LOC401152  0.954  0.297  n.s  0.806  0.163  **  n.s 
LOXL1  1.025  0.292  n.s  1.102  0.694  n.s  n.s 
LUM  0.870  0.085  ***  0.900  0.576  n.s  n.s 
MRC2  0.716  0.167  ***  0.507  0.161  ***  * 
MVP  1.290  0.256  **  1.499  0.259  ***  n.s 
MYL9  1.727  0.712  *  1.625  0.528  **  n.s 
MYO10  1.323  0.185  ***  1.706  0.344  ***  * 
OAZ2  0.957  0.144  n.s  1.008  0.165  n.s  n.s 
OLFML3  0.480  0.173  ***  0.166  0.061  ***  *** 
PEA15  1.279  0.218  **  1.300  0.259  **  n.s 
PLAT  3.726  2.438  **  14.722  7.640  ***  ** 
POLR2A  0.871  0.120  **  0.955  0.147  n.s  n.s 
PRG1  1.818  0.536  **  2.812  1.076  ***  * 
PRSS23  1.944  0.579  **  3.223  2.110  *  n.s 
PSAP  1.339  0.248  **  1.520  0.550  *  n.s 
PTGS2  1.215  1.118  n.s  1.178  0.744  n.s  n.s 
ROR1  1.948  0.316  ***  2.161  0.576  ***  n.s 
RPLP0  1.178  0.429  n.s  1.054  0.469  n.s  n.s 
RTN4  1.392  0.240  ***  1.605  0.430  **  n.s 
S100A6  1.644  0.428  ***  2.005  1.063  *  n.s 
SERPINE1  2.060  0.426  ***  2.860  1.161  ***  n.s 
SERPINE2  2.274  0.773  ***  1.943  1.315  n.s  n.s 
SHC1  1.212  0.353  n.s  1.369  0.507  n.s  n.s 
SLC38A2  1.221  0.375  n.s  1.003  0.484  n.s  n.s 
SOD1  1.693  0.534  **  2.047  0.566  ***  n.s 
SPARC  1.030  0.505  n.s  0.773  0.332  n.s  n.s 
SRM  1.250  0.377  n.s  1.266  0.569  n.s  n.s 
STAT1  2.048  0.584  ***  3.378  1.743  **  n.s 
STC2  2.287  1.778  n.s  2.305  1.558  *  n.s 
TGFBI  0.904  0.470  n.s  0.967  0.473  n.s  n.s 
TGM2  0.919  0.553  n.s  1.303  1.262  n.s  n.s 
THY1  1.282  0.200  **  1.086  0.627  n.s  n.s 
TM4SF1  2.596  1.225  **  5.215  3.351  **  n.s 
TMEM47  1.769  0.660  **  2.047  0.850  **  n.s 
TRAM2  1.359  0.227  ***  1.593  0.437  **  n.s 
TUBB6  1.082  0.262  n.s  0.823  0.389  n.s  n.s 
UBC  Control 
VCP  1.216  0.334  n.s  1.323  0.317  *  n.s 
VIM  1.011  0.181  n.s  0.876  0.194  n.s  n.s 
WBSCR1  1.651  1.153  n.s  1.716  0.913  *  n.s 
YIPF5  1.319  0.389  *  1.334  0.496  n.s  n.s 
YWHAB  1.220  0.207  **  1.224  0.223  **  n.s 
Table 11 TLDA results for eight MSC cultures at passage five and nine 
P   P value, * £ 0.05, ** £0.01, *** £0.001 and n.s, not significant265 
 
Gene 
Mean RQ P9 
DMSO Control 
(n=5) 
Std Dev. 
Mean RQ P9 
SB203580 (1µM) 
(n=5) 
Std Dev.  P value 
ACTB  0.359  0.058  0.485  0.090  * 
ADAMTS1  2.753  1.776  2.785  0.876  n.s 
AKR1C1,2  1.249  0.498  1.067  0.787  n.s 
ANXA2  0.786  0.288  1.063  0.264  n.s 
APLP2  6.053  5.423  6.586  5.394  n.s 
ARPC2  1.168  0.599  1.426  0.414  n.s 
ATP5G3  1.225  0.540  1.568  0.615  n.s 
BLVRB  0.666  0.149  0.837  0.064  * 
BSCL2;HNRPUL2  1.084  0.214  0.887  0.168  n.s 
CALM1,2  1.908  1.325  2.298  1.243  n.s 
CAV1  5.619  5.076  3.646  1.054  n.s 
CCND1  9.607  10.316  7.501  3.348  n.s 
CCT7  1.105  0.423  1.294  0.316  n.s 
CD44  3.884  2.783  4.796  0.964  n.s 
CD63  1.895  0.704  1.786  0.431  n.s 
CDKN1A  2.610  2.185  2.238  1.721  n.s 
CDKN1B  0.967  0.598  1.305  0.783  n.s 
CDKN2A  6.808  6.163  4.496  4.384  n.s 
CEECAM1  1.811  1.106  1.860  1.036  n.s 
CLIC1  1.168  0.478  1.386  0.264  n.s 
COL1A1  1.553  1.436  1.336  0.986  n.s 
COL1A2  2.160  1.859  1.948  1.520  n.s 
COL3A1  1.104  0.938  0.869  0.626  n.s 
COL5A1  6.230  9.970  4.700  6.717  n.s 
COTL1  0.845  0.294  1.397  0.164  ** 
COX5B  0.676  0.230  0.763  0.420  n.s 
CST3  1.622  0.558  1.726  0.585  n.s 
CTGF  3.771  3.508  3.958  3.799  n.s 
CTSS  0.255  0.295  0.211  0.227  n.s 
DEGS1  1.414  0.669  1.365  0.420  n.s 
DPYSL3  1.289  1.301  1.299  0.968  n.s 
DSP  4.540  2.928  7.893  4.736  n.s 
DUSP6  1.324  0.617  1.423  1.065  n.s 
DVL1  2.377  1.487  2.908  1.722  n.s 
ELN  1.006  0.672  1.190  1.122  n.s 
FBXO18  1.006  0.247  1.096  0.309  n.s 
FOS  0.452  0.486  0.484  0.323  n.s 
FOXO3A  0.934  0.457  1.171  0.669  n.s 
GAPDH  0.508  0.287  0.677  0.368  n.s 
GARS  1.377  0.844  1.116  0.504  n.s 
GPX4  0.593  0.247  0.552  0.074  n.s 
HMGA1  4.638  5.436  10.445  9.350  n.s 
HMOX1  0.471  0.227  0.501  0.290  n.s 
HNF4A  Not detected after 40 cycles 
HSPA8  0.830  0.150  1.167  0.332  n.s 
HTRA1  1.583  1.735  1.577  1.270  n.s 
IFI30  0.692  0.489  0.786  0.375  n.s 
IGFBP4  0.793  0.370  0.826  0.336  n.s 
IL6ST  1.104  0.447  1.082  0.173  n.s 
ITGA11  1.040  0.536  0.635  0.348  n.s 
KDELR2  1.155  0.222  1.060  0.081  n.s 
KIAA1199  7.833  6.631  12.194  10.958  n.s 
KLF9  0.846  0.140  1.128  0.277  n.s 
LMO7  1.840  0.850  2.329  1.154  n.s 266 
LOC401152  0.971  0.480  1.214  0.404  n.s 
LOXL1  2.054  1.547  2.578  1.643  n.s 
LUM  1.032  0.391  0.549  0.109  * 
MRC2  0.638  0.258  0.663  0.168  n.s 
MVP  2.282  1.281  2.880  1.238  n.s 
MYL9  2.165  0.964  2.333  0.872  n.s 
MYO10  1.826  0.569  2.325  0.436  n.s 
OAZ2  0.843  0.225  0.845  0.314  n.s 
OLFML3  0.228  0.275  0.334  0.213  n.s 
PEA15  2.381  1.216  2.498  1.286  n.s 
PLAT  27.046  31.410  17.032  10.702  n.s 
POLR2A  1.060  0.153  1.045  0.101  n.s 
PRG1  3.313  2.194  2.698  0.807  n.s 
PRSS23  3.717  1.694  2.365  1.245  n.s 
PSAP  2.431  2.153  1.445  0.609  n.s 
PTGS2  0.832  0.446  1.407  0.928  n.s 
ROR1  2.324  1.109  2.534  1.142  n.s 
RPLP0  1.429  1.418  1.801  1.406  n.s 
RTN4  2.561  1.650  2.075  1.051  n.s 
S100A6  1.819  0.745  1.462  0.469  n.s 
SERPINE1  5.430  4.277  6.325  4.035  n.s 
SERPINE2  4.468  3.560  1.866  1.442  n.s 
SHC1  2.045  1.082  2.215  0.923  n.s 
SLC38A2  1.295  0.847  1.244  0.873  n.s 
SOD1  2.570  1.362  3.137  1.393  n.s 
SPARC  1.576  1.458  1.222  0.793  n.s 
SRM  1.303  0.758  1.560  0.636  n.s 
STAT1  6.286  5.243  3.649  1.944  n.s 
STC2  5.029  3.617  4.082  3.026  n.s 
TGFBI  1.850  1.453  1.788  0.831  n.s 
TGM2  2.398  1.990  5.029  4.798  n.s 
THY1  1.262  0.282  2.113  0.440  *** 
TM4SF1  3.903  2.728  3.856  1.600  n.s 
TMEM47  5.000  3.066  3.698  2.725  n.s 
TRAM2  1.543  0.492  1.669  0.502  n.s 
TUBB6  0.943  0.631  1.398  0.509  n.s 
UBC  Control         
VCP  1.567  0.723  1.625  0.515  n.s 
VIM  0.984  0.345  1.287  0.124  n.s 
WBSCR1  2.143  1.282  2.225  0.720  n.s 
YIPF5  1.300  0.434  1.331  0.282  n.s 
YWHAB  1.156  0.299  1.339  0.087  n.s 
Table 12 TLDA results for late passage MSC’s treated with DMSO or SB203580 
P   P value, * £ 0.05, ** £0.01, *** £0.001 and n.s, not significant 